

酸化チタン（ナノ粒子、アナターゼ型）の  
ラットを用いた吸入によるがん原性試験報告書

試験番号：0883

# TABLES

## TABLES

TABLE A	CONCENTRATIONS OF TITANIUM DIOXIDE IN THE INHALATION CHAMBER
TABLE B1	SURVIVAL ANIMAL NUMBERS : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE B2	SURVIVAL ANIMAL NUMBERS : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE B3	SURVIVAL ANIMAL NUMBERS : MALE (SATELLITE 52w)
TABLE B4	SURVIVAL ANIMAL NUMBERS : FEMALE (SATELLITE 52w)
TABLE B5	SURVIVAL ANIMAL NUMBERS : MALE (SATELLITE 52w+26w)
TABLE B6	SURVIVAL ANIMAL NUMBERS : FEMALE (SATELLITE 52w+26w)
TABLE B7	SURVIVAL ANIMAL NUMBERS : MALE (SATELLITE 52w+52w)
TABLE B8	SURVIVAL ANIMAL NUMBERS : FEMALE (SATELLITE 52w+52w)
TABLE C1	CLINICAL OBSERVATION : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE C2	CLINICAL OBSERVATION : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE C3	CLINICAL OBSERVATION : MALE (SATELLITE 52w)
TABLE C4	CLINICAL OBSERVATION : FEMALE (SATELLITE 52w)
TABLE C5	CLINICAL OBSERVATION : MALE (SATELLITE 52w+26w)
TABLE C6	CLINICAL OBSERVATION : FEMALE (SATELLITE 52w+26w)

## TABLES (CONTINUED)

TABLE C7	CLINICAL OBSERVATION : MALE (SATELLITE 52w+52w)
TABLE C8	CLINICAL OBSERVATION : FEMALE (SATELLITE 52w+52w)
TABLE D1	BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE D2	BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE D3	BODY WEIGHT CHANGES : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE D4	BODY WEIGHT CHANGES : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE D5	BODY WEIGHT CHANGES : MALE (SATELLITE 52w)
TABLE D6	BODY WEIGHT CHANGES : FEMALE (SATELLITE 52w)
TABLE D7	BODY WEIGHT CHANGES : MALE (SATELLITE 52w+26w)
TABLE D8	BODY WEIGHT CHANGES : FEMALE (SATELLITE 52w+26w)
TABLE D9	BODY WEIGHT CHANGES : MALE (SATELLITE 52w+52w)
TABLE D10	BODY WEIGHT CHANGES : FEMALE (SATELLITE 52w+52w)
TABLE E1	FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE E2	FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE (CARCINOGENICITY STUDY GROUPS)

**TABLES (CONTINUED)**

TABLE	E3	FOOD CONSUMPTION CHANGES : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE	E4	FOOD CONSUMPTION CHANGES : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE	E5	FOOD CONSUMPTION CHANGES : MALE (SATELLITE 52w)
TABLE	E6	FOOD CONSUMPTION CHANGES : FEMALE (SATELLITE 52w)
TABLE	E7	FOOD CONSUMPTION CHANGES : MALE (SATELLITE 52w+26w)
TABLE	E8	FOOD CONSUMPTION CHANGES : FEMALE (SATELLITE 52w+26w)
TABLE	E9	FOOD CONSUMPTION CHANGES : MALE (SATELLITE 52w+52w)
TABLE	E10	FOOD CONSUMPTION CHANGES : FEMALE (SATELLITE 52w+52w)
TABLE	F1	URINARYSIS : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE	F2	URINARYSIS : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE	G1	HEMATOLOGY : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE	G2	HEMATOLOGY : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE	H1	BIOCHEMISTRY : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE	H2	BIOCHEMISTRY : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE	I1	GROSS FINDINGS : MALE (CARCINOGENICITY STUDY GROUPS)

## TABLES (CONTINUED)

TABLE I2	GROSS FINDINGS : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE I3	GROSS FINDINGS : MALE (SATELLITE 52w)
TABLE I4	GROSS FINDINGS : FEMALE (SATELLITE 52w)
TABLE I5	GROSS FINDINGS : MALE (SATELLITE 52w+26w)
TABLE I6	GROSS FINDINGS : FEMALE (SATELLITE 52w+26w)
TABLE I7	GROSS FINDINGS : MALE (SATELLITE 52w+52w)
TABLE I8	GROSS FINDINGS : FEMALE (SATELLITE 52w+52w)
TABLE J1	ORGAN WEIGHT, ABSOLUTE : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE J2	ORGAN WEIGHT, ABSOLUTE : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE J3	ORGAN WEIGHT, ABSOLUTE : MALE (SATELLITE 52w)
TABLE J4	ORGAN WEIGHT, ABSOLUTE : FEMALE (SATELLITE 52w)
TABLE J5	ORGAN WEIGHT, ABSOLUTE : MALE (SATELLITE 52w+26w)
TABLE J6	ORGAN WEIGHT, ABSOLUTE : FEMALE (SATELLITE 52w+26w)
TABLE J7	ORGAN WEIGHT, ABSOLUTE : MALE (SATELLITE 52w+52w)
TABLE J8	ORGAN WEIGHT, ABSOLUTE : FEMALE (SATELLITE 52w+52w)

## TABLES (CONTINUED)

TABLE	K1	ORGAN WEIGHT, RELATIVE : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE	K2	ORGAN WEIGHT, RELATIVE : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE	K3	ORGAN WEIGHT, RELATIVE : MALE (SATELLITE 52w)
TABLE	K4	ORGAN WEIGHT, RELATIVE : FEMALE (SATELLITE 52w)
TABLE	K5	ORGAN WEIGHT, RELATIVE : MALE (SATELLITE 52w+26w)
TABLE	K6	ORGAN WEIGHT, RELATIVE : FEMALE (SATELLITE 52w+26w)
TABLE	K7	ORGAN WEIGHT, RELATIVE : MALE (SATELLITE 52w+52w)
TABLE	K8	ORGAN WEIGHT, RELATIVE : FEMALE (SATELLITE 52w+52w)
TABLE	L1	HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE	L2	HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE	L3	HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS : MALE (SATELLITE 52w)
TABLE	L4	HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS : MALE (SATELLITE 52w+26w)
TABLE	L5	HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS : FEMALE (SATELLITE 52w+26w)
TABLE	L6	HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS : MALE (SATELLITE 52w+52w)

## TABLES (CONTINUED)

TABLE L7	HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS : FEMALE (SATELLITE 52w+52w)
TABLE M1	NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE M2	NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE N	HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCr1Cr1j RATS
TABLE O1	HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMORS : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE O2	HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMORS : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE O3	HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMORS : MALE (SATELLITE 52w)
TABLE O4	HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMORS : MALE (SATELLITE 52w+52w)
TABLE O5	HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMORS : FEMALE (SATELLITE 52w+52w)
TABLE P1	HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE P2	HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS : FEMALE (CARCINOGENICITY STUDY GROUPS)

## TABLES (CONTINUED)

TABLE	P3	HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS : MALE (SATELLITE 52w)
TABLE	P4	HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS : FEMALE (SATELLITE 52w)
TABLE	P5	HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS : MALE (SATELLITE 52w+26w)
TABLE	P6	HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS : FEMALE (SATELLITE 52w+26w)
TABLE	P7	HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS : MALE (SATELLITE 52w+52w)
TABLE	P8	HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS : FEMALE (SATELLITE 52w+52w)
TABLE	Q	AMOUNT OF TITANIUM DIOXIDE IN THE LUNG
TABLE	R1	BALF : CYTOLOGICAL ANALYSIS : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE	R2	BALF : CYTOLOGICAL ANALYSIS : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE	S1	BALF : BIOCHEMICAL ANALYSIS : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE	S2	BALF : BIOCHEMICAL ANALYSIS : FEMALE (CARCINOGENICITY STUDY GROUPS)
TABLE	T1	CAUSE OF DEATH : MALE (CARCINOGENICITY STUDY GROUPS)
TABLE	T2	CAUSE OF DEATH : FEMALE (CARCINOGENICITY STUDY GROUPS)



## TABLES (CONTINUED)

TABLE	T3	CAUSE OF DEATH : MALE (SATELLITE 52w)
TABLE	T4	CAUSE OF DEATH : MALE (SATELLITE 52w+26w)
TABLE	T5	CAUSE OF DEATH : MALE (SATELLITE 52w+52w)
TABLE	T6	CAUSE OF DEATH : FEMALE (SATELLITE 52w+52w)

TABLE A

CONCENTRATIONS OF TITANIUM DIOXIDE  
IN THE INHALATION CHAMBER

## CONCENTRATIONS OF TITANIUM DIOXIDE IN THE INHALATION CHAMBER

Group Name	Concentration(mg/m <sup>3</sup> )	Mean ± S.D.
	(CARCINOGENICITY STUDY GROUPS)	(SATELLITE GROUPS)
Control	0.00 ± 0.00	0.00 ± 0.00
0.5 mg/m <sup>3</sup>	0.51 ± 0.02	0.51 ± 0.02
2 mg/m <sup>3</sup>	2.03 ± 0.06	2.04 ± 0.08
8 mg/m <sup>3</sup>	7.99 ± 0.21	7.99 ± 0.24

TABLE B1

SURVIVAL ANIMAL NUMBERS : MALE

(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : A4 104

SEX : MALE

Group Name	Animals At start	Administration (Weeks)													
		0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.5 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
8 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : A4 104

SEX : MALE

Group Name	Animals At start	Administration (Weeks)													
		14	15	16	17	18	19	20	21	22	23	24	25	26	27
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.5 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
8 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
Number of survival/ Number of effective animals															
Survival rate(%)															

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : A4 104

SEX : MALE

Group Name	Animals At start	Administration (Weeks)													
		28	29	30	31	32	33	34	35	36	37	38	39	40	41
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.5 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
8 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : A4 104

SEX : MALE

Group Name	Animals At start	Administration (Weeks)													
		42	43	44	45	46	47	48	49	50	51	52	53	54	55
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.5 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
8 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
		Number of survival/ Number of effective animals Survival rate(%)													



STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrIj[F344/DuCrj]

REPORT TYPE : A4 104

SEX : MALE

Group Name	Animals At start	Administration (Weeks)													
		56	57	58	59	60	61	62	63	64	65	66	67	68	69
Control	50	50/50 100.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	46/50 92.0
0.5 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0
2 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	49/50 98.0	48/50 96.0	48/50 96.0	48/50 96.0
8 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrIj[F344/DuCrj]

REPORT TYPE : A4 104

SEX : MALE

Group Name	Animals At start	Administration (Weeks)													
		70	71	72	73	74	75	76	77	78	79	80	81	82	83
Control	50	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	45/50 90.0	45/50 90.0	45/50 90.0	45/50 90.0	45/50 90.0	45/50 90.0	45/50 90.0
0.5 mg/m3	50	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	48/50 96.0	48/50 96.0	48/50 96.0	48/50 96.0	47/50 94.0	47/50 94.0	46/50 92.0	46/50 92.0	46/50 92.0
2 mg/m3	50	48/50 96.0	48/50 96.0	48/50 96.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	45/50 90.0	45/50 90.0	44/50 88.0
8 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	49/50 98.0	49/50 98.0	48/50 96.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	44/50 88.0	44/50 88.0	44/50 88.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : A4 104

SEX : MALE

Group Name	Animals At start	Administration (Weeks)													
		84	85	86	87	88	89	90	91	92	93	94	95	96	97
Control	50	45/50 90.0	44/50 88.0	44/50 88.0	44/50 88.0	43/50 86.0	42/50 84.0	42/50 84.0	42/50 84.0	41/50 82.0	41/50 82.0	39/50 78.0	39/50 78.0	39/50 78.0	39/50 78.0
0.5 mg/m3	50	46/50 92.0	46/50 92.0	45/50 90.0	44/50 88.0	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0	40/50 80.0	40/50 80.0	39/50 78.0	39/50 78.0
2 mg/m3	50	43/50 86.0	42/50 84.0	41/50 82.0	41/50 82.0	39/50 78.0	38/50 76.0	38/50 76.0	38/50 76.0	38/50 76.0	38/50 76.0	37/50 74.0	37/50 74.0	37/50 74.0	37/50 74.0
8 mg/m3	50	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0	43/50 86.0	42/50 84.0	42/50 84.0	41/50 82.0	41/50 82.0	41/50 82.0	41/50 82.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrIj[F344/DuCrj]

REPORT TYPE : A4 104

SEX : MALE

Group Name	Animals At start	Administration (Weeks)						
		98	99	100	101	102	103	104
Control	50	37/50	37/50	36/50	36/50	36/50	32/50	30/50
		74.0	74.0	72.0	72.0	72.0	64.0	60.0
0.5 mg/m3	50	39/50	38/50	36/50	36/50	34/50	32/50	32/50
		78.0	76.0	72.0	72.0	68.0	64.0	64.0
2 mg/m3	50	33/50	32/50	30/50	29/50	27/50	27/50	27/50
		66.0	64.0	60.0	58.0	54.0	54.0	54.0
8 mg/m3	50	41/50	41/50	41/50	40/50	39/50	38/50	37/50
		82.0	82.0	82.0	80.0	78.0	76.0	74.0
		Number of survival/ Number of effective animals						
		Survival rate(%)						

**TABLE B2**

**SURVIVAL ANIMAL NUMBERS : FEMALE**

**(CARCINOGENICITY STUDY GROUPS)**

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : A4 104

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)													
		0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.5 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
8 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : A4 104

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)													
		14	15	16	17	18	19	20	21	22	23	24	25	26	27
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.5 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
8 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
Number of survival/ Number of effective animals															
Survival rate(%)															

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : A4 104

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)													
		28	29	30	31	32	33	34	35	36	37	38	39	40	41
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.5 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
8 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
		Number of survival/ Number of effective animals Survival rate(%)													



STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : A4 104

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)													
		42	43	44	45	46	47	48	49	50	51	52	53	54	55
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.5 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0
8 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : A4 104

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)													
		56	57	58	59	60	61	62	63	64	65	66	67	68	69
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
0.5 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
2 mg/m3	50	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0
8 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrIj[F344/DuCrj]

REPORT TYPE : A4 104

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)													
		70	71	72	73	74	75	76	77	78	79	80	81	82	83
Control	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0
0.5 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	48/50 96.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0
2 mg/m3	50	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	48/50 96.0	48/50 96.0
8 mg/m3	50	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	50/50 100.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrIj[F344/DuCrj]

REPORT TYPE : A4 104

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)													
		84	85	86	87	88	89	90	91	92	93	94	95	96	97
Control	50	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	49/50 98.0	48/50 96.0	48/50 96.0	47/50 94.0	47/50 94.0	46/50 92.0	45/50 90.0	44/50 88.0	44/50 88.0
0.5 mg/m3	50	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	46/50 92.0
2 mg/m3	50	48/50 96.0	47/50 94.0	47/50 94.0	47/50 94.0	45/50 90.0	45/50 90.0	45/50 90.0	43/50 86.0	41/50 82.0	40/50 80.0	39/50 78.0	39/50 78.0	38/50 76.0	36/50 72.0
8 mg/m3	50	49/50 98.0	48/50 96.0	48/50 96.0	48/50 96.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	47/50 94.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0	46/50 92.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrIj[F344/DuCrj]

REPORT TYPE : A4 104

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)						
		98	99	100	101	102	103	104
Control	50	43/50	43/50	42/50	42/50	42/50	42/50	42/50
		86.0	86.0	84.0	84.0	84.0	84.0	84.0
0.5 mg/m3	50	46/50	45/50	45/50	45/50	44/50	43/50	43/50
		92.0	90.0	90.0	90.0	88.0	86.0	86.0
2 mg/m3	50	34/50	34/50	32/50	31/50	31/50	31/50	31/50
		68.0	68.0	64.0	62.0	62.0	62.0	62.0
8 mg/m3	50	45/50	45/50	45/50	45/50	45/50	44/50	44/50
		90.0	90.0	90.0	90.0	90.0	88.0	88.0
Number of survival/ Number of effective animals								
Survival rate(%)								

TABLE B3

SURVIVAL ANIMAL NUMBERS : MALE

(SATELLITE 52w)

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : B1 52

SEX : MALE

Group Name	Animals At start	Administration (Weeks)													
		0	1	2	3	4	5	6	7	8	9	10	11	12	13
S-Control	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-0.5 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-2 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-8 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : B1 52

SEX : MALE

Group Name	Animals At start	Administration (Weeks)													
		14	15	16	17	18	19	20	21	22	23	24	25	26	27
S-Control	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-0.5 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-2 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-8 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
		Number of survival/ Number of effective animals Survival rate(%)													



STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : B1 52

SEX : MALE

Group Name	Animals At start	Administration (Weeks)													
		28	29	30	31	32	33	34	35	36	37	38	39	40	41
S-Control	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-0.5 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-2 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-8 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : B1 52

SEX : MALE

Group Name	Animals At start	Administration (Weeks)											
		42	43	44	45	46	47	48	49	50	51	52	
S-Control	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-0.5 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-2 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-8 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	9/10 90.0	9/10 90.0	9/10 90.0	9/10 90.0
		Number of survival/ Number of effective animals Survival rate(%)											

TABLE B4

SURVIVAL ANIMAL NUMBERS : FEMALE

(SATELLITE 52w)

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : B1 52

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)													
		0	1	2	3	4	5	6	7	8	9	10	11	12	13
S-Control	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-0.5 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-2 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-8 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : B1 52

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)													
		14	15	16	17	18	19	20	21	22	23	24	25	26	27
S-Control	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-0.5 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-2 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-8 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
Number of survival/ Number of effective animals															
Survival rate(%)															

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : B1 52

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)													
		28	29	30	31	32	33	34	35	36	37	38	39	40	41
S-Control	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-0.5 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-2 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-8 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : B1 52

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)										
		42	43	44	45	46	47	48	49	50	51	52
S-Control	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-0.5 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-2 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
S-8 mg/m3	10	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0	10/10 100.0
		Number of survival/ Number of effective animals Survival rate(%)										

TABLE B5

SURVIVAL ANIMAL NUMBERS : MALE

(SATELLITE 52w+26w)



STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : B2 78

SEX : MALE

Group Name	Animals At start	Administration (Weeks)													
		53	54	55	56	57	58	59	60	61	62	63	64	65	66
S-Control	7	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0
S-0.5 mg/m3	7	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0
S-2 mg/m3	7	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7
S-8 mg/m3	6	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : B2 78

SEX : MALE

Group Name	Animals At start	Administration (Weeks)											
		67	68	69	70	71	72	73	74	75	76	77	78
S-Control	7	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7
S-0.5 mg/m3	7	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0	7/ 7 100.0
S-2 mg/m3	7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7	6/ 7 85.7
S-8 mg/m3	6	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0	6/ 6 100.0
		Number of survival/ Number of effective animals Survival rate(%)											

TABLE B6

SURVIVAL ANIMAL NUMBERS : FEMALE

(SATELLITE 52w+26w)

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : B2 78

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)													
		53	54	55	56	57	58	59	60	61	62	63	64	65	66
S-Control	7	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0
S-0.5 mg/m3	7	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0
S-2 mg/m3	7	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0
S-8 mg/m3	7	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0
Number of survival/ Number of effective animals															
Survival rate(%)															

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : B2 78

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)											
		67	68	69	70	71	72	73	74	75	76	77	78
S-Control	7	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0
S-0.5 mg/m3	7	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0
S-2 mg/m3	7	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0
S-8 mg/m3	7	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0	7/7 100.0
Number of survival/ Number of effective animals													
Survival rate(%)													

TABLE B7

SURVIVAL ANIMAL NUMBERS : MALE

(SATELLITE 52w+52w)

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : B3 104

SEX : MALE

Group Name	Animals At start	Administration (Weeks)														
		79	80	81	82	83	84	85	86	87	88	89	90	91	92	
S-Control	3	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	
S-0.5 mg/m3	4	4/4 100.0	4/4 100.0	4/4 100.0	4/4 100.0	4/4 100.0	4/4 100.0	4/4 100.0	4/4 100.0	4/4 100.0	4/4 100.0	4/4 100.0	4/4 100.0	3/4 75.0	3/4 75.0	3/4 75.0
S-2 mg/m3	3	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	
S-8 mg/m3	3	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	3/3 100.0	
		Number of survival/ Number of effective animals Survival rate(%)														

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrIj[F344/DuCrj]

REPORT TYPE : B3 104

SEX : MALE

Group Name	Animals At start	Administration (Weeks)											
		93	94	95	96	97	98	99	100	101	102	103	104
S-Control	3	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	2/ 3 66.7	2/ 3 66.7	2/ 3 66.7	2/ 3 66.7	1/ 3 33.3	1/ 3 33.3	1/ 3 33.3	1/ 3 33.3	1/ 3 33.3
S-0.5 mg/m3	4	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0
S-2 mg/m3	3	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	2/ 3 66.7	2/ 3 66.7	2/ 3 66.7
S-8 mg/m3	3	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0	3/ 3 100.0
		Number of survival/ Number of effective animals Survival rate(%)											



TABLE B8

SURVIVAL ANIMAL NUMBERS : FEMALE

(SATELLITE 52w+52w)

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]

REPORT TYPE : B3 104

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)													
		79	80	81	82	83	84	85	86	87	88	89	90	91	92
S-Control	4	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	3/ 4 75.0	3/ 4 75.0	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0
S-0.5 mg/m3	4	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0
S-2 mg/m3	4	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0
S-8 mg/m3	4	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0883

SURVIVAL ANIMAL NUMBERS

ANIMAL : RAT F344/DuCrI CrIj[F344/DuCrj]

REPORT TYPE : B3 104

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)											
		93	94	95	96	97	98	99	100	101	102	103	104
S-Control	4	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0	2/ 4 50.0
S-0.5 mg/m3	4	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0
S-2 mg/m3	4	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	4/ 4 100.0	3/ 4 75.0	3/ 4 75.0
S-8 mg/m3	4	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0	3/ 4 75.0
		Number of survival/ Number of effective animals Survival rate(%)											

TABLE C1

CLINICAL OBSERVATION : MALE  
(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 1

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROUGH FUR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 2

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
ROUGH FUR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 3

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROUGH FUR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 4

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROUGH FUR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 5

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	1	1	1	1	1	2	2	2	2	2	2	2	3	3
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	1	2	2	2	2
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	1	1	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROUGH FUR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 6

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	1	1	1	1	1	1	1	2	2	2	2	2	2	2
	0.5 mg/m3	1	1	1	1	2	2	2	2	2	2	3	3	3	3
	2 mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	2	
	8 mg/m3	0	0	0	1	1	1	3	3	3	3	3	3	4	
MORIBUND SACRIFICE	Control	3	3	3	3	3	3	3	3	3	3	3	3	3	3
	0.5 mg/m3	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	2 mg/m3	2	2	3	3	3	3	3	3	3	4	4	5	5	5
	8 mg/m3	0	0	0	0	0	1	1	1	1	3	3	3	3	3
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	1	1	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	1	1	1	1	1	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROUGH FUR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	2 mg/m3	0	1	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	1	0	0
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 7

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7
		1	1	1	1	1	2	1	1	1	1	1	1	1	
DEATH	Control	2	2	2	3	4	4	4	4	4	4	5	5	5	5
	0.5 mg/m3	3	4	4	4	4	4	4	4	4	4	5	5	5	5
	2 mg/m3	2	3	3	4	4	5	5	5	5	5	5	5	5	5
	8 mg/m3	4	4	4	4	4	4	4	4	4	4	4	4	4	4
MORIBUND SACRIFICE	Control	4	4	4	4	4	4	4	4	5	5	6	6	6	6
	0.5 mg/m3	1	1	2	3	3	3	3	3	3	3	5	5	6	6
	2 mg/m3	6	6	6	7	7	7	7	7	7	7	8	8	8	8
	8 mg/m3	3	3	3	3	3	3	3	3	4	4	5	5	5	5
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	1	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	1	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROUGH FUR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	1	1	1	1	0	1	0	0	0	0	0	0	0
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 8

Clinical sign	Group Name	Administration Week-day								
		97-7	98-7	99-7	100-7	101-7	102-7	103-7	103-7	104-7
		2	1	1	1	1	1	1	2	1
DEATH	Control	5	6	6	7	7	7	8	8	8
	0.5 mg/m3	5	5	5	5	5	6	6	6	6
	2 mg/m3	5	5	5	5	5	5	5	5	5
	8 mg/m3	4	4	4	4	5	5	5	5	6
MORIBUND SACRIFICE	Control	6	7	7	7	7	7	10	10	12
	0.5 mg/m3	6	6	7	9	9	10	12	12	12
	2 mg/m3	8	11	13	15	16	18	18	18	18
	8 mg/m3	5	5	5	5	5	6	7	7	7
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	1	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	2	2	0	2
SOILED	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
ROUGH FUR	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	1	0	0	0
	0.5 mg/m3	0	1	1	1	1	0	0	0	0
	2 mg/m3	0	1	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 9

Clinical sign	Group Name	Administration Week-day													
		1-7 1	2-7 1	3-7 1	4-7 1	5-7 1	6-7 1	7-7 1	8-7 1	9-7 1	10-7 1	11-7 1	12-7 1	13-7 1	14-7 1
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL GROWTH OF TEETH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MALOCCLUSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. MANDIBULAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 10

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
ABNORMAL GROWTH OF TEETH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
MALOCCLUSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. MANDIBULAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 11

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL GROWTH OF TEETH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MALOCCLUSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. MANDIBULAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 12

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL GROWTH OF TEETH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MALOCCLUSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	1	1	1	1	1	1	2	2	2	2	2	2	2	2
	8 mg/m3	1	1	1	1	1	1	2	2	2	2	2	2	2	2
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. MANDIBULAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 13

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL GROWTH OF TEETH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MALOCCLUSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	1	1	1	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	1	1	1	1	1	1	1	1	2	2	2	2	2
	2 mg/m3	2	2	2	2	2	2	2	2	2	2	2	2	3	2
	8 mg/m3	3	3	3	3	4	4	4	2	2	2	2	2	2	2
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. MANDIBULAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	8 mg/m3	1	1	1	1	1	1	1	0	0	0	0	0	0	0
M. PERI EAR	Control	0	0	1	1	1	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	1	1	1	1	1	1	1	1	0	0	0	0	0
	2 mg/m3	1	1	1	1	1	1	1	1	1	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 14

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL GROWTH OF TEETH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MALOCCLUSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	0.5 mg/m3	2	2	2	2	2	2	2	2	1	1	1	2	3	3
	2 mg/m3	2	2	2	2	2	2	2	2	2	2	2	3	3	3
	8 mg/m3	2	2	2	2	2	2	2	3	3	3	2	2	3	3
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	1	0	0	0	0
M. MANDIBULAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 15

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7
		1	1	1	1	1	2	1	1	1	1	1	1	1	1
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	1	1	1	2	2	0	2	2	2	2	2	2	2	2
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL GROWTH OF TEETH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MALOCCLUSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	2	3	2	3	3	0	3	2	2	2	5	6	6	7
	0.5 mg/m3	3	3	3	3	4	0	4	5	5	6	4	4	4	4
	2 mg/m3	3	3	3	2	2	0	1	1	1	1	1	1	1	1
	8 mg/m3	3	4	4	4	4	0	5	5	5	6	6	7	7	7
INTERNAL MASS	Control	0	0	1	1	1	0	1	1	1	1	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. MANDIBULAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	1	1	1	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI EAR	Control	0	0	0	1	1	0	1	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 16

Clinical sign	Group Name	Administration Week-day								
		97-7 2	98-7 1	99-7 1	100-7 1	101-7 1	102-7 1	103-7 1	103-7 2	104-7 1
CATARACT	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	2	2	2	2	1	1	0	1
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
ABNORMAL GROWTH OF TEETH	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	1	1	1	1	1	1	0	1
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
MALOCCLUSION	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	1	1	1	1	1	1	0	1
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	7	7	7	7	8	6	0	7
	0.5 mg/m3	0	4	5	5	5	5	5	0	5
	2 mg/m3	0	1	1	0	1	1	1	0	1
	8 mg/m3	0	9	9	10	11	11	11	0	11
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	1	1	1	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
M. MANDIBULAR	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	1	0	0	0	0
M. EAR	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	1	1	1	1	1	1	0	1
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 17

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 18

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 19

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 20

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	1	1	1	1	1	1	1	1
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 21

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8 mg/m3	1	1	1	1	2	2	2	1	1	1	1	1	1	1
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	2	2	2	2	2
	2 mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	1	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 22

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	1	1	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	1	1	1	1	1	1	1	2	2	2	1	1	1	
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	
	8 mg/m3	1	1	1	1	1	1	1	1	1	1	1	2	2	
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	1	1	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	1	1	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	2	2	2	2	2	2	2	2	1	1	1	1	1	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	2	2	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 23

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7
		1	1	1	1	1	2	1	1	1	1	1	1	1	1
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	0.5 mg/m3	1	1	1	1	2	0	2	2	2	2	1	1	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	1	0	1	1	1	1	1	1	1	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	8 mg/m3	1	1	1	1	1	0	2	2	2	2	2	2	2	2
M. ABDOMEN	Control	1	2	1	1	0	0	0	0	0	0	2	2	2	2
	0.5 mg/m3	0	0	0	0	0	0	0	1	1	1	0	0	0	0
	2 mg/m3	1	1	1	1	1	0	0	0	0	0	0	0	0	0
	8 mg/m3	2	2	2	2	2	0	2	2	2	2	2	3	3	3
M. ANTERIOR. DORSUM	Control	1	1	1	1	1	0	1	1	1	1	1	1	1	2
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	1	1	1	1	1	0	1	1	1	1	1	1	1	1
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	1	1	1	1	0	1	1	1	1	1	1	1	1
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	1	1	1	1	1	0	1	1	1	1	1	1	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	1	1
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	1	1	1	1	1	0	1	1	1	1	1	1	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	1	0	1	0	1	1	1	1	0	0	1	0
	0.5 mg/m3	1	1	0	1	1	0	1	0	2	2	2	2	1	1
	2 mg/m3	1	1	0	0	0	0	0	0	0	0	0	0	2	2
	8 mg/m3	0	0	1	1	1	0	1	1	0	0	0	0	1	1

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 24

Clinical sign	Group Name	Administration Week-day								
		97-7 2	98-7 1	99-7 1	100-7 1	101-7 1	102-7 1	103-7 1	103-7 2	104-7 1
M. NECK	Control	0	1	1	1	1	1	1	0	1
	0.5 mg/m3	0	1	1	1	1	1	1	0	1
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	1	1	1	1	1	0	0	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	1	1	0	0	0	0	0	0
	8 mg/m3	0	2	2	2	2	3	3	0	3
M. ABDOMEN	Control	0	2	2	1	1	1	0	0	1
	0.5 mg/m3	0	0	0	0	0	1	1	0	1
	2 mg/m3	0	0	0	0	1	1	1	0	1
	8 mg/m3	0	4	4	5	5	5	5	0	5
M. ANTERIOR. DORSUM	Control	0	2	2	3	3	3	3	0	2
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	1	1	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	1	1	1	1	1	1	0	1
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	1	2	2	2	1	1	0	1
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	2	2	2	2	2	2	0	2
M. HINDLIMB	Control	0	1	1	1	1	1	1	0	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	1	1	0	1
	0.5 mg/m3	0	1	1	1	1	1	1	0	1
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	2	3	3	2	0	0
	0.5 mg/m3	0	1	0	5	4	2	2	0	2
	2 mg/m3	0	0	0	1	0	1	1	0	1
	8 mg/m3	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 25

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
JAUNDICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	50	50	50	50	50	50	50	50	50	50	50	50	50	50
	0.5 mg/m3	50	50	50	50	50	50	50	50	50	50	50	50	50	50
	2 mg/m3	50	50	50	50	50	50	50	50	50	50	50	50	50	50
	8 mg/m3	50	50	50	50	50	50	50	50	50	50	50	50	50	50

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 26

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	
JAUNDICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
NON REMARKABLE	Control	50	50	50	50	50	50	50	50	50	50	50	50	50	
	0.5 mg/m3	50	50	50	50	50	50	50	50	50	50	50	50	50	
	2 mg/m3	50	50	50	50	50	50	50	50	50	50	50	50	50	
	8 mg/m3	50	50	50	50	50	50	50	50	50	50	50	50	50	

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 27

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
JAUNDICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	50	50	50	50	50	50	50	50	50	50	50	50	50	50
	0.5 mg/m3	50	50	50	50	50	50	50	50	50	50	50	50	50	50
	2 mg/m3	50	50	50	50	50	50	50	50	50	50	50	50	50	50
	8 mg/m3	50	50	50	50	50	50	50	50	50	50	50	50	50	49

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 28

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
JAUNDICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	50	50	50	50	50	50	50	50	50	50	50	50	50	50
	0.5 mg/m3	50	50	50	50	50	50	50	50	50	50	50	50	50	50
	2 mg/m3	49	49	49	49	49	49	48	48	48	48	48	48	48	48
	8 mg/m3	49	49	49	49	49	49	48	48	48	48	48	48	48	48



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 29

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
JAUNDICE	Control	0	0	0	0	0	0	0	0	0	0	1	1	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	1	1	1	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	49	49	48	48	48	48	48	48	48	47	46	46	46	46
	0.5 mg/m3	50	49	49	49	49	49	49	49	49	47	47	47	46	46
	2 mg/m3	48	48	48	48	48	48	48	48	48	46	46	46	45	46
	8 mg/m3	47	47	47	47	46	46	46	48	48	48	48	48	48	48

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 30

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	
JAUNDICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	1	1	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	1	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	1	0	0	0	0	0	
	2 mg/m3	0	1	0	0	0	0	0	0	0	0	1	0	0	
	8 mg/m3	0	0	0	0	0	0	0	1	0	3	0	0	0	
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	1	
NON REMARKABLE	Control	46	46	46	46	46	46	46	45	44	44	44	44	43	
	0.5 mg/m3	46	46	46	46	45	45	45	43	44	44	43	43	42	
	2 mg/m3	46	45	45	45	45	45	45	45	45	45	43	41	40	
	8 mg/m3	48	48	48	47	47	46	44	42	43	41	41	41	39	

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 31

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7
		1	1	1	1	1	2	1	1	1	1	1	1	1	1
JAUNDICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	1	1	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CICATRIX	Control	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	0.5 mg/m3	0	0	1	0	0	0	1	1	2	2	0	0	0	0
	2 mg/m3	0	0	0	0	1	0	0	0	0	0	0	0	1	2
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	42	41	41	39	38	0	38	38	37	38	34	33	32	31
	0.5 mg/m3	41	40	39	37	36	0	36	35	33	33	34	34	33	33
	2 mg/m3	39	38	38	37	37	0	37	37	37	37	36	36	33	33
	8 mg/m3	40	38	38	38	38	0	37	37	37	36	35	34	34	34

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 32

Clinical sign	Group Name	Administration Week-day								
		97-7 2	98-7 1	99-7 1	100-7 1	101-7 1	102-7 1	103-7 1	103-7 2	104-7 1
JAUNDICE	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
CICATRIX	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	1	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	1	1	0	1
IRREGULAR BREATHING	Control	0	0	0	0	1	2	0	0	0
	0.5 mg/m3	0	0	0	1	1	2	1	0	1
	2 mg/m3	0	3	1	1	0	0	1	0	1
	8 mg/m3	0	0	0	0	0	2	1	0	1
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	0	30	30	27	26	25	25	0	23
	0.5 mg/m3	0	31	30	26	26	25	23	0	23
	2 mg/m3	0	30	30	29	28	25	25	0	25
	8 mg/m3	0	32	32	31	29	26	26	0	25

TABLE C2

CLINICAL OBSERVATION : FEMALE  
(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 33

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 34

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	1	1	1	1	1	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
CATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	1	1	1	1	1	1	1	1	2	2	
	2 mg/m3	0	0	0	0	0	0	0	0	1	1	1	1	1	
	8 mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	1	
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 35

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	0.5 mg/m3	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	2 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 36

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	1	1	1	1	1	1	1	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
CATARACT	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	
	0.5 mg/m3	2	2	2	2	2	2	2	2	2	3	3	3	3	
	2 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	
	8 mg/m3	1	1	1	1	1	1	1	1	1	2	2	2	2	
EXTERNAL MASS	Control	0	0	0	0	0	0	0	1	1	1	1	1	1	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 37

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.5 mg/m3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
	2 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8 mg/m3	2	2	2	2	2	2	2	2	2	2	2	2	2	2
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 38

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	1	1	1	1	2	2	2	2	2	2
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	8 mg/m3	0	0	0	0	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	1	1	1	1	1	1	1	1	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	2 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	1	1	1	1	1	1	2	2	1	1	1	1	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	1	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.5 mg/m3	3	3	3	3	3	3	3	3	3	3	4	4	4	4
	2 mg/m3	1	1	1	1	1	1	1	1	1	1	0	0	0	0
	8 mg/m3	2	2	2	2	2	2	2	2	2	2	2	2	2	2
EXTERNAL MASS	Control	1	1	1	1	1	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	1	1	1	2	2	2	2	2	2	2	2
	2 mg/m3	1	1	1	1	1	2	2	2	2	2	2	1	1	1
	8 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 39

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7
		1	1	1	1	1	2	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	0.5 mg/m3	2	2	2	2	2	2	2	2	2	2	2	2	2	3
	2 mg/m3	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	8 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	1	1	1	1	1	2	2	3	3	4	5	5	5	5
	0.5 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	2 mg/m3	1	1	1	3	3	3	3	5	7	8	9	9	10	11
	8 mg/m3	1	1	1	2	2	2	2	2	2	3	3	3	3	3
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	1	1	1	1	1	0	1	1	1	1	1	1	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	2 mg/m3	1	1	1	1	1	0	1	1	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	1	1
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	1	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	1	2	2	2	2	0	1	1	1	1	1	1	1	1
	0.5 mg/m3	4	4	4	4	4	0	4	4	4	4	4	4	4	4
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	2	2	2	2	2	0	2	2	2	2	2	2	2	2
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	1	2	2	2	2
	0.5 mg/m3	2	2	2	2	2	0	2	2	2	2	2	2	2	2
	2 mg/m3	1	1	1	0	0	0	0	0	0	0	1	1	1	1
	8 mg/m3	1	1	1	1	1	0	1	1	2	2	3	4	5	6

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 40

Clinical sign	Group Name	Administration Week-day								
		97-7	98-7	99-7	100-7	101-7	102-7	103-7	103-7	104-7
		2	1	1	1	1	1	1	2	1
DEATH	Control	1	1	1	2	2	2	2	2	2
	0.5 mg/m3	3	3	4	4	4	4	4	5	5
	2 mg/m3	3	4	4	4	5	5	5	5	5
	8 mg/m3	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	5	6	6	6	6	6	6	6	6
	0.5 mg/m3	1	1	1	1	1	2	2	2	2
	2 mg/m3	11	12	12	14	14	14	14	14	14
	8 mg/m3	3	4	4	4	4	4	5	5	5
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	1	1	1	1	1	1	0	1
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	1	1	1	1	1	1	0	1
	2 mg/m3	0	0	0	0	0	0	1	0	1
	8 mg/m3	0	1	1	1	1	1	1	0	1
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	2
	0.5 mg/m3	0	0	0	1	1	1	1	0	0
	2 mg/m3	0	0	0	1	0	0	0	0	1
	8 mg/m3	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
EYE HEMORRHAGIC DISCHA	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	1	0	1
CATARACT	Control	0	1	1	1	1	1	1	0	1
	0.5 mg/m3	0	4	4	4	4	4	4	0	4
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	2	2	2	2	2	2	0	2
EXTERNAL MASS	Control	0	2	2	3	3	3	2	0	2
	0.5 mg/m3	0	2	2	3	3	6	9	0	8
	2 mg/m3	0	1	1	1	0	0	1	0	1
	8 mg/m3	0	7	7	6	7	7	7	0	7

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 41

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 42

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 43

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 44

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 45

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 46

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	1	1	1	1	1	1	1	1	1	1	1	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	1	1	1	1	1	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	1	1	1	1	1	1	1	1	1	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	1	1	1	1	1	1	1	1	1
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 47

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7
		1	1	1	1	1	2	1	1	1	1	1	1	1	1
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	1	1	1	1	2	0	2	1	2	2	1	1	1	0
	8 mg/m3	0	0	1	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	1	1	1	1	1	0	1	1	1	1	1	1	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	1	1	2	3	3	4
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	1	1	1	1	1	0	1	1	1	1	1	1	1	1
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	0.5 mg/m3	0	1	1	1	1	0	1	1	1	1	1	1	1	1
	2 mg/m3	1	1	1	2	0	0	0	0	0	0	1	1	1	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	1	1

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 48

Clinical sign	Group Name	Administration Week-day								
		97-7	98-7	99-7	100-7	101-7	102-7	103-7	103-7	104-7
		2	1	1	1	1	1	1	2	1
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	1	1	1	1	0	1
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	1	1	1	1	1	1	0	1
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	1	1	1	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	1	1	1	1	1	1	0	1
	0.5 mg/m3	0	0	0	1	1	3	5	0	4
	2 mg/m3	0	0	0	0	0	0	1	0	1
	8 mg/m3	0	5	5	5	5	5	5	0	5
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	1	1	0	1
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	1	1	1	2	2	4	0	3
M. ANTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	1	1	0	1
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	1	1	1	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	1	1	1	1	1	1	0	1
	0.5 mg/m3	0	1	1	1	1	1	2	0	2
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	1	1	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 49

Clinical sign	Group Name	Administration Week-day													
		1-7 1	2-7 1	3-7 1	4-7 1	5-7 1	6-7 1	7-7 1	8-7 1	9-7 1	10-7 1	11-7 1	12-7 1	13-7 1	14-7 1
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
JAUNDICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 50

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
JAUNDICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 51

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
JAUNDICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0883  
ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : FEMALE

PAGE : 52

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	1	1	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
JAUNDICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	1	1	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 53

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
JAUNDICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : FEMALE

PAGE : 54

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
ANEMIA	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
JAUNDICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	1	1	0	0	1
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 55

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7
		1	1	1	1	1	2	1	1	1	1	1	1	1	1
ANEMIA	Control	0	0	0	0	0	0	1	1	0	2	1	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	2 mg/m3	1	1	1	0	0	0	2	2	1	1	0	0	0	0
	8 mg/m3	0	0	0	0	1	0	1	1	1	0	1	1	1	1
JAUNDICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	2	0	1	1	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	1	1	1	0	0	0	0	0
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	1	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	1	1	1	1	0	1	1	1	1	1	1	1	1
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	1	1	0	1	0	0	0	1
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	1	1	0	2	3	1	1	1	1	1	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 mg/m3	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 56

Clinical sign	Group Name	Administration Week-day								
		97-7 2	98-7 1	99-7 1	100-7 1	101-7 1	102-7 1	103-7 1	103-7 2	104-7 1
ANEMIA	Control	0	1	1	2	1	2	2	0	3
	0.5 mg/m3	0	1	1	2	2	1	1	0	1
	2 mg/m3	0	0	1	1	0	0	1	0	1
	8 mg/m3	0	0	0	0	0	0	0	0	0
JAUNDICE	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
ULCER	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	1	1	1	1	1	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	1	1	1	1	0	1
CICATRIX	Control	0	0	0	0	0	0	1	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	1	1	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	1	1	0	1
	0.5 mg/m3	0	0	0	0	0	0	1	0	0
	2 mg/m3	0	0	1	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0
	0.5 mg/m3	0	0	0	0	0	0	0	0	0
	2 mg/m3	0	0	0	0	0	0	0	0	0
	8 mg/m3	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 57

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	50	50	50	50	50	50	50	50	50	50	50	50	50	50
	0.5 mg/m3	50	50	50	50	50	50	50	50	50	50	50	50	50	50
	2 mg/m3	50	50	50	50	50	50	50	50	50	50	50	50	50	50
	8 mg/m3	50	50	50	50	50	50	50	50	50	50	50	50	50	50

(HAN190)

BAS 6

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 58

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	50	50	50	50	50	50	50	50	50	50	50	50	50	50
	0.5 mg/m3	50	50	50	49	49	49	49	49	48	48	48	48	48	48
	2 mg/m3	50	50	50	50	50	50	50	50	49	49	49	49	49	49
	8 mg/m3	50	50	50	50	50	50	50	50	50	50	49	49	49	49

(HAN190)

BAS 6

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 59

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	50	50	50	50	50	50	50	50	49	49	49	49	49	49
	0.5 mg/m3	48	48	48	48	48	48	48	48	48	48	48	48	48	48
	2 mg/m3	49	49	49	49	49	49	49	49	49	49	49	49	49	49
	8 mg/m3	49	49	49	49	49	49	49	49	49	49	49	49	49	49

(HAN190)

BAS 6



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 60

Clinical sign	Group Name	Administration Week-day													
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	49	49	49	49	49	49	49	48	48	48	48	48	47	47
	0.5 mg/m3	48	48	48	48	48	48	48	48	48	48	47	47	47	47
	2 mg/m3	49	49	49	49	48	48	48	48	48	48	48	48	48	48
	8 mg/m3	49	49	49	49	49	49	49	49	49	48	48	48	48	48

(HAN190)

BAS 6

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 61

Clinical sign	Group Name	Administration Week-day													
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	47	47	47	47	47	47	47	47	47	47	47	47	47	47
	0.5 mg/m3	47	47	47	47	47	47	47	47	47	47	47	47	47	47
	2 mg/m3	48	48	48	48	48	48	48	48	48	48	48	48	48	48
	8 mg/m3	48	48	48	48	48	48	48	48	48	48	48	48	48	47

(HAN190)

BAS 6

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 62

Clinical sign	Group Name	Administration Week-day													
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	47	47	47	47	47	47	47	47	46	46	46	46	46	46
	0.5 mg/m3	47	47	47	47	46	46	45	45	43	43	43	42	41	42
	2 mg/m3	48	48	48	48	48	47	47	47	47	47	46	47	45	45
	8 mg/m3	47	47	47	46	46	46	46	46	46	46	46	46	46	45

(HAN190)

BAS 6

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 63

Clinical sign	Group Name	Administration Week-day													
		85-7	86-7	87-7	88-7	89-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7
		1	1	1	1	1	2	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	47	47	47	47	47	0	46	46	46	43	42	42	40	40
	0.5 mg/m3	42	41	41	41	41	0	41	41	41	41	41	41	41	40
	2 mg/m3	44	44	43	43	42	0	40	39	39	38	37	37	36	36
	8 mg/m3	45	45	44	44	43	0	43	43	42	42	40	39	38	37

(HAN190)

BAIS 6

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : A4 104

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : FEMALE

PAGE : 64

Clinical sign	Group Name	Administration Week-day								
		97-7	98-7	99-7	100-7	101-7	102-7	103-7	103-7	104-7
		2	1	1	1	1	1	1	2	1
NON REMARKABLE	Control	0	39	39	37	38	36	36	0	34
	0.5 mg/m3	0	40	39	36	36	32	31	0	31
	2 mg/m3	0	33	32	30	31	31	28	0	28
	8 mg/m3	0	36	36	36	35	35	34	0	34

(HAN190)

BAIS 6

TABLE C3

CLINICAL OBSERVATION : MALE

(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : B1 52

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 1

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MALOCCLUSION	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. MANDIBULAR	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	S-Control	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	S-0.5 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	S-2 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	S-8 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	10

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj[F344/DuCrj]  
 REPORT TYPE : B1 52

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 2

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	
MORIBUND SACRIFICE	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
CATARACT	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	1	1	1	1	1	1	1	1	
MALOCCLUSION	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
EXTERNAL MASS	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. MANDIBULAR	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. BREAST	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
NON REMARKABLE	S-Control	10	10	10	10	10	10	10	10	10	10	10	10	10	
	S-0.5 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	
	S-2 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	
	S-8 mg/m3	10	10	10	10	10	9	9	9	9	9	9	9	9	



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : B1 52

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 3

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
MALOCCLUSION	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. MANDIBULAR	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	S-Control	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	S-0.5 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	S-2 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	S-8 mg/m3	9	9	9	9	9	9	9	9	9	9	9	9	9	9

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : B1 52

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 4

Clinical sign	Group Name	Administration Week-day									
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7
		1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	S-Control	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	1	1	1	1
CATARACT	S-Control	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	1	1	1	1	1	1	0	0	0	0
MALOCCLUSION	S-Control	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	1	1	1	1	0	0	0	0
EXTERNAL MASS	S-Control	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	1	1	1	1	1	1	1	1
	S-8 mg/m3	0	0	0	1	1	1	0	0	0	0
M. MANDIBULAR	S-Control	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	1	1	1	0	0	0	0
M. BREAST	S-Control	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	1	1	1	1	1	1	1	1
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	S-Control	10	10	10	10	10	10	10	10	10	10
	S-0.5 mg/m3	10	10	10	10	10	10	10	10	10	10
	S-2 mg/m3	10	10	9	9	9	9	9	9	9	9
	S-8 mg/m3	9	9	9	9	9	9	9	9	9	9

TABLE C4

CLINICAL OBSERVATION : FEMALE

(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : B1 52

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 5

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
CATARACT	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	S-Control	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	S-0.5 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	S-2 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	S-8 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	10

(HAN190)

BAIS 6

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : B1 52

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 6

Clinical sign	Group Name	Administration Week-day													
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
CATARACT	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	S-Control	10	10	10	10	10	10	10	10	10	10	10	10	10	9
	S-0.5 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	S-2 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	S-8 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	10

(HAN190)

BAIS 6

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : B1 52

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 7

Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
CATARACT	S-Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	S-Control	9	9	9	9	9	9	9	9	9	9	9	9	9	9
	S-0.5 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	S-2 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	S-8 mg/m3	10	10	10	10	10	10	10	10	10	10	10	10	10	10

(HAN190)

BAIS 6

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj[F344/DuCrj]  
 REPORT TYPE : B1 52

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 8

Clinical sign	Group Name	Administration Week-day									
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7
		1	1	1	1	1	1	1	1	1	1
CATARACT	S-Control	1	1	1	1	1	1	1	1	1	1
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	S-Control	9	9	9	9	9	9	9	9	9	9
	S-0.5 mg/m3	10	10	10	10	10	10	10	10	10	10
	S-2 mg/m3	10	10	10	10	10	10	10	10	10	10
	S-8 mg/m3	10	10	10	10	10	10	10	10	10	10

(HAN190)

BAS 6

TABLE C5

CLINICAL OBSERVATION : MALE

(SATELLITE 52w+26w)



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : B2 78

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 1

Clinical sign	Group Name	Administration Week-day													
		53-7	54-7	55-7	56-7	57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	
DEATH	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	0	0	0	1	1	1	1	1	1	1	1	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
SOILED	S-Control	0	0	0	0	0	0	0	0	0	1	1	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
ROUGH FUR	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
EXTERNAL MASS	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	1	1	1	1	1	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	1	
M. BREAST	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	1	1	1	1	1	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. ABDOMEN	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. ANTERIOR. DORSUM	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	1	1	1	1	
ANEMIA	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	1	1	1	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
CICATRIX	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : B2 78

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 2

Clinical sign	Group Name	Administration Week-day											
		67-7	68-7	69-7	70-7	71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7
		1	1	1	1	1	1	1	1	1	1	1	1
DEATH	S-Control	0	0	0	1	1	1	1	1	1	1	1	1
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	S-Control	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
ROUGH FUR	S-Control	1	1	1	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	S-Control	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	1	1	1	1
	S-8 mg/m3	1	1	1	2	2	1	1	1	1	1	1	1
M. BREAST	S-Control	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	1	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	S-Control	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	1	1	1
	S-8 mg/m3	0	0	0	1	1	0	0	0	0	0	0	0
M. ANTERIOR. DORSUM	S-Control	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1
ANEMIA	S-Control	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
CICATRIX	S-Control	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	1	1	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : B2 78

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 3

Clinical sign	Group Name	Administration Week-day													
		53-7	54-7	55-7	56-7	57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	
HEMORRHAGE	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	1	1	1	0	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
IRREGULAR BREATHING	S-Control	0	0	0	0	1	1	1	1	1	1	1	1	1	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
BROWN URINE	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	
NON REMARKABLE	S-Control	7	7	7	7	6	6	6	6	6	6	6	6	6	
	S-0.5 mg/m3	7	7	7	7	7	7	7	7	7	7	7	7	7	
	S-2 mg/m3	6	6	6	6	6	6	6	6	6	6	6	6	6	
	S-8 mg/m3	6	6	6	6	6	6	6	6	6	5	5	5	5	

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : B2 78

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 4

Clinical sign	Group Name	Administration Week-day											
		67-7	68-7	69-7	70-7	71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7
		1	1	1	1	1	1	1	1	1	1	1	1
HEMORRHAGE	S-Control	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	S-Control	1	1	1	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
BROWN URINE	S-Control	1	1	1	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	S-Control	6	6	6	6	6	6	6	6	6	6	6	6
	S-0.5 mg/m3	7	7	7	7	7	7	7	7	7	7	7	7
	S-2 mg/m3	6	6	6	6	6	6	6	6	5	5	5	5
	S-8 mg/m3	5	5	5	4	4	4	4	5	5	5	5	5

TABLE C6

CLINICAL OBSERVATION : FEMALE

(SATELLITE 52w+26w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : B2 78

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 5

Clinical sign	Group Name	Administration Week-day													
		53-7	54-7	55-7	56-7	57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	S-Control	7	7	7	7	7	7	7	7	7	7	7	7	7	7
	S-0.5 mg/m3	7	7	7	7	7	7	7	7	7	7	7	7	7	7
	S-2 mg/m3	7	7	7	7	7	7	7	7	7	7	7	7	7	7
	S-8 mg/m3	7	7	7	7	7	7	7	7	7	7	7	7	7	7

(HAN190)

BAS 6

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : B2 78

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : FEMALE

PAGE : 6

Clinical sign	Group Name	Administration Week-day											
		67-7	68-7	69-7	70-7	71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7
		1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	S-Control	7	7	7	7	7	7	7	7	7	7	7	7
	S-0.5 mg/m3	7	7	7	7	7	7	7	7	7	7	7	7
	S-2 mg/m3	7	7	7	7	7	7	7	7	7	7	7	7
	S-8 mg/m3	7	7	7	7	7	7	7	7	7	7	7	7

(HAN190)

BAIS 6

TABLE C7

CLINICAL OBSERVATION : MALE

(SATELLITE 52w+52w)



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : B3 103

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 1

Clinical sign	Group Name	Administration Week-day													
		79-7	80-7	81-7	82-7	83-7	84-7	85-7	86-7	87-7	88-7	89-7	89-7	90-7	91-7
		1	1	1	1	1	1	1	1	1	1	2	1	1	
DEATH	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	1	1	1	1	1	0	1	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	1	0
IRREGULAR BREATHING	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	S-Control	3	3	3	3	3	3	3	3	3	3	3	0	3	3
	S-0.5 mg/m3	4	4	4	4	4	4	4	4	4	4	4	0	3	3
	S-2 mg/m3	3	3	3	3	3	3	2	2	2	2	2	0	2	3
	S-8 mg/m3	3	3	3	3	3	3	3	3	3	3	3	0	2	3

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : B3 103

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : MALE

PAGE : 2

Clinical sign	Group Name	Administration Week-day													
		92-7	93-7	94-7	95-7	96-7	97-7	97-7	98-7	99-7	100-7	101-7	102-7	103-7	103-7
		1	1	1	1	1	1	2	1	1	1	1	1	1	2
DEATH	S-Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	S-0.5 mg/m3	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	S-Control	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	1	1	1	1	1	0
M. ABDOMEN	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	1	1	1	1	1	0
ANEMIA	S-Control	0	0	0	1	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	1	1	1	1	0	0	0	1	1	1	1	0	0	0
	S-8 mg/m3	1	1	1	1	0	0	0	0	0	1	0	1	1	0
IRREGULAR BREATHING	S-Control	0	0	1	1	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	1	1	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	S-Control	3	3	2	2	2	2	0	2	2	1	1	1	1	0
	S-0.5 mg/m3	3	3	3	3	3	3	0	3	3	3	3	3	3	0
	S-2 mg/m3	2	2	2	2	3	3	0	2	2	2	2	2	2	0
	S-8 mg/m3	2	2	2	2	3	3	0	3	2	1	2	1	1	0

TABLE C8

CLINICAL OBSERVATION : FEMALE

(SATELLITE 52w+52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : B3 103

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 3

Clinical sign	Group Name	Administration Week-day													
		79-7	80-7	81-7	82-7	83-7	84-7	85-7	86-7	87-7	88-7	89-7	89-7	90-7	91-7
		1	1	1	1	1	1	1	1	1	1	1	2	1	1
DEATH	S-Control	0	0	0	0	0	1	1	2	2	2	2	2	2	2
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	1	0	1	1
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	1	0	1	1
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1
CRUSTA	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	1

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : B3 103

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 4

Clinical sign	Group Name	Administration Week-day													
		92-7	93-7	94-7	95-7	96-7	97-7	97-7	98-7	99-7	100-7	101-7	102-7	103-7	103-7
		1	1	1	1	1	1	2	1	1	1	1	1	1	2
DEATH	S-Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	S-8 mg/m3	0	1	1	1	1	1	1	1	1	1	1	1	1	1
WASTING	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	S-Control	0	0	1	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	1	1	1	1	1	1	0	1	1	1	1	1	1	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	1	1	1	1	1	1	0	1	1	1	1	1	1	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	S-Control	0	0	1	1	0	0	0	0	0	0	0	0	1	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-8 mg/m3	1	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	1	1	0	0
	S-8 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	S-Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-0.5 mg/m3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	S-2 mg/m3	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	S-8 mg/m3	1	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : B3 103

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 5

Clinical sign	Group Name	Administration Week-day													
		79-7	80-7	81-7	82-7	83-7	84-7	85-7	86-7	87-7	88-7	89-7	89-7	90-7	91-7
		1	1	1	1	1	1	1	1	1	1	1	2	1	1
NON REMARKABLE	S-Control	4	4	4	4	4	3	3	2	2	2	2	0	2	2
	S-0.5 mg/m3	4	4	4	4	4	4	4	4	4	4	3	0	3	3
	S-2 mg/m3	4	4	4	4	4	4	4	4	4	4	4	0	4	4
	S-8 mg/m3	4	4	4	4	4	4	4	4	4	4	4	0	4	3

(HAN190)

BAS 6

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : B3 103

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 6

Clinical sign	Group Name	Administration Week-day													
		92-7	93-7	94-7	95-7	96-7	97-7	97-7	98-7	99-7	100-7	101-7	102-7	103-7	103-7
		1	1	1	1	1	1	2	1	1	1	1	1	1	2
NON REMARKABLE	S-Control	2	2	1	1	2	2	0	2	2	2	2	2	1	0
	S-0.5 mg/m3	3	3	3	3	3	3	0	3	3	3	3	3	3	0
	S-2 mg/m3	4	4	4	4	4	4	0	4	4	4	4	2	2	0
	S-8 mg/m3	3	3	3	3	3	3	0	3	3	3	3	3	3	0

(HAN190)

BAS 6

TABLE D1

BODY WEIGHT CHANGES AND  
SURVIVAL ANIMAL NUMBERS : MALE  
(CARCINOGENICITY STUDY GROUPS)



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j [F344/DuCr j]  
 UNIT : #  
 REPORT TYPE : A4 104  
 SEX : MALE

MEAN BODY WEIGHTS AND SURVIVAL

Week-Day on Study	Control			0.5 mg/m3			2 mg/m3			8 mg/m3		
	Av. Wt. (50)	No. of Surviv. <50>		Av. Wt. (50)	% of cont. <50>	No. of Surviv.	Av. Wt. (50)	% of cont. <50>	No. of Surviv.	Av. Wt. (50)	% of cont. <50>	No. of Surviv.
0-0	119 (50)	50/50		119 (50)	100	50/50	119 (50)	100	50/50	119 (50)	100	50/50
1-7	148 (50)	50/50		146 (50)	99	50/50	146 (50)	99	50/50	144 (50)	97	50/50
2-7	179 (50)	50/50		174 (50)	97	50/50	175 (50)	98	50/50	174 (50)	97	50/50
3-7	206 (50)	50/50		199 (50)	97	50/50	200 (50)	97	50/50	200 (50)	97	50/50
4-7	228 (50)	50/50		220 (50)	96	50/50	221 (50)	97	50/50	220 (50)	96	50/50
5-7	246 (50)	50/50		236 (50)	96	50/50	237 (50)	96	50/50	235 (50)	96	50/50
6-7	259 (50)	50/50		250 (50)	97	50/50	251 (50)	97	50/50	251 (50)	97	50/50
7-7	272 (50)	50/50		263 (50)	97	50/50	265 (50)	97	50/50	266 (50)	98	50/50
8-7	285 (50)	50/50		275 (50)	96	50/50	279 (50)	98	50/50	278 (50)	98	50/50
9-7	294 (50)	50/50		286 (50)	97	50/50	290 (50)	99	50/50	290 (50)	99	50/50
10-7	302 (50)	50/50		294 (50)	97	50/50	298 (50)	99	50/50	298 (50)	99	50/50
11-7	309 (50)	50/50		300 (50)	97	50/50	305 (50)	99	50/50	305 (50)	99	50/50
12-7	315 (50)	50/50		308 (50)	98	50/50	312 (50)	99	50/50	313 (50)	99	50/50
13-7	321 (50)	50/50		315 (50)	98	50/50	319 (50)	99	50/50	321 (50)	100	50/50
14-7	327 (50)	50/50		322 (50)	98	50/50	324 (50)	99	50/50	324 (50)	99	50/50
18-7	342 (50)	50/50		338 (50)	99	50/50	340 (50)	99	50/50	343 (50)	100	50/50
22-7	356 (50)	50/50		353 (50)	99	50/50	356 (50)	100	50/50	357 (50)	100	50/50
26-7	369 (50)	50/50		365 (50)	99	50/50	370 (50)	100	50/50	373 (50)	101	50/50
30-7	382 (50)	50/50		376 (50)	98	50/50	382 (50)	100	50/50	386 (50)	101	50/50
34-7	392 (50)	50/50		386 (50)	98	50/50	392 (50)	100	50/50	394 (50)	101	50/50
38-7	400 (50)	50/50		394 (50)	99	50/50	400 (50)	100	50/50	402 (50)	101	50/50
42-7	408 (50)	50/50		400 (50)	98	50/50	408 (50)	100	50/50	411 (50)	101	50/50
46-7	413 (50)	50/50		404 (50)	98	50/50	413 (50)	100	50/50	416 (50)	101	50/50
50-7	416 (50)	50/50		408 (50)	98	50/50	418 (50)	100	50/50	420 (50)	101	50/50
52-7	419 (50)	50/50		409 (50)	98	50/50	420 (50)	100	50/50	422 (50)	101	50/50
54-7	421 (50)	50/50		411 (50)	98	50/50	421 (50)	100	50/50	425 (50)	101	50/50
58-7	426 (49)	49/50		415 (50)	97	50/50	425 (50)	100	50/50	428 (50)	100	50/50
62-7	433 (48)	48/50		416 (50)	96	50/50	427 (50)	99	50/50	431 (50)	100	50/50
66-7	433 (48)	48/50		418 (49)	97	49/50	425 (49)	98	49/50	432 (50)	100	50/50
70-7	437 (46)	46/50		419 (49)	96	49/50	430 (48)	98	48/50	433 (50)	99	50/50
74-7	437 (46)	46/50		418 (49)	96	49/50	429 (47)	98	47/50	431 (49)	99	49/50
78-7	438 (45)	45/50		418 (48)	95	48/50	429 (47)	98	47/50	432 (46)	99	46/50
82-7	436 (45)	45/50		417 (46)	96	46/50	424 (45)	97	45/50	428 (44)	98	44/50
86-7	433 (44)	44/50		412 (45)	95	45/50	423 (41)	98	41/50	428 (43)	99	43/50
90-7	431 (42)	42/50		412 (43)	96	43/50	420 (38)	97	38/50	424 (43)	98	43/50
94-7	430 (39)	39/50		406 (40)	94	40/50	414 (37)	96	37/50	425 (41)	99	41/50
98-7	427 (37)	37/50		401 (39)	94	39/50	402 (33)	94	33/50	421 (41)	99	41/50
102-7	413 (36)	36/50		391 (34)	95	34/50	402 (27)	97	27/50	414 (39)	100	39/50
104-7	415 (30)	30/50		387 (32)	93	32/50	396 (27)	95	27/50	411 (37)	99	37/50

< >:No. of effective animals. ( ):No. of measured animals Av. Wt. : g

TABLE D2

BODY WEIGHT CHANGES AND  
SURVIVAL ANIMAL NUMBERS : FEMALE  
(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j [F344/DuCr j]  
 UNIT : #  
 REPORT TYPE : A4 104  
 SEX : FEMALE

MEAN BODY WEIGHTS AND SURVIVAL

Week-Day on Study	Control		0.5 mg/m3		2 mg/m3		8 mg/m3				
	Av. Wt. (50)	No. of Surviv. <50>	Av. Wt. (50)	% of cont. <50>	No. of Surviv.	Av. Wt. (50)	% of cont. <50>	No. of Surviv.	Av. Wt. (50)	% of cont. <50>	No. of Surviv.
0-0	98 (50)	50/50	98 (50)	100	50/50	98 (50)	100	50/50	98 (50)	100	50/50
1-7	112 (50)	50/50	110 (50)	98	50/50	110 (50)	98	50/50	108 (50)	96	50/50
2-7	125 (50)	50/50	122 (50)	98	50/50	121 (50)	97	50/50	121 (50)	97	50/50
3-7	135 (50)	50/50	132 (50)	98	50/50	130 (50)	96	50/50	131 (50)	97	50/50
4-7	143 (50)	50/50	140 (50)	98	50/50	138 (50)	97	50/50	140 (50)	98	50/50
5-7	150 (50)	50/50	147 (50)	98	50/50	144 (50)	96	50/50	145 (50)	97	50/50
6-7	155 (50)	50/50	153 (50)	99	50/50	151 (50)	97	50/50	152 (50)	98	50/50
7-7	160 (50)	50/50	158 (50)	99	50/50	156 (50)	98	50/50	158 (50)	99	50/50
8-7	164 (50)	50/50	164 (50)	100	50/50	159 (50)	97	50/50	162 (50)	99	50/50
9-7	168 (50)	50/50	167 (50)	99	50/50	163 (50)	97	50/50	167 (50)	99	50/50
10-7	172 (50)	50/50	171 (50)	99	50/50	167 (50)	97	50/50	171 (50)	99	50/50
11-7	174 (50)	50/50	174 (50)	100	50/50	170 (50)	98	50/50	174 (50)	100	50/50
12-7	176 (50)	50/50	177 (50)	101	50/50	173 (50)	98	50/50	176 (50)	100	50/50
13-7	179 (50)	50/50	181 (50)	101	50/50	176 (50)	98	50/50	181 (50)	101	50/50
14-7	180 (50)	50/50	181 (50)	101	50/50	177 (50)	98	50/50	180 (50)	100	50/50
18-7	184 (50)	50/50	188 (50)	102	50/50	182 (50)	99	50/50	187 (50)	102	50/50
22-7	191 (50)	50/50	194 (50)	102	50/50	187 (50)	98	50/50	193 (50)	101	50/50
26-7	197 (50)	50/50	198 (50)	101	50/50	193 (50)	98	50/50	200 (50)	102	50/50
30-7	203 (50)	50/50	202 (50)	100	50/50	199 (50)	98	50/50	205 (50)	101	50/50
34-7	209 (50)	50/50	208 (50)	100	50/50	203 (50)	97	50/50	209 (50)	100	50/50
38-7	213 (50)	50/50	212 (50)	100	50/50	207 (50)	97	50/50	213 (50)	100	50/50
42-7	219 (50)	50/50	215 (50)	98	50/50	211 (50)	96	50/50	216 (50)	99	50/50
46-7	218 (50)	50/50	219 (50)	100	50/50	215 (50)	99	50/50	220 (50)	101	50/50
50-7	222 (50)	50/50	223 (50)	100	50/50	218 (49)	98	49/50	224 (50)	101	50/50
52-7	225 (50)	50/50	224 (50)	100	50/50	220 (49)	98	49/50	226 (50)	100	50/50
54-7	228 (50)	50/50	226 (50)	99	50/50	223 (49)	98	49/50	229 (50)	100	50/50
58-7	234 (50)	50/50	231 (50)	99	50/50	226 (49)	97	49/50	233 (50)	100	50/50
62-7	240 (50)	50/50	233 (50)	97	50/50	229 (49)	95	49/50	236 (50)	98	50/50
66-7	241 (50)	50/50	238 (50)	99	50/50	234 (49)	97	49/50	241 (50)	100	50/50
70-7	249 (50)	50/50	242 (50)	97	50/50	238 (49)	96	49/50	245 (50)	98	50/50
74-7	255 (50)	50/50	246 (50)	96	50/50	242 (49)	95	49/50	249 (50)	98	50/50
78-7	260 (49)	49/50	250 (49)	96	49/50	245 (49)	94	49/50	256 (49)	98	49/50
82-7	263 (49)	49/50	254 (47)	97	47/50	247 (48)	94	48/50	258 (49)	98	49/50
86-7	270 (49)	49/50	258 (47)	96	47/50	250 (47)	93	47/50	264 (48)	98	48/50
90-7	274 (48)	48/50	261 (47)	95	47/50	251 (45)	92	45/50	268 (47)	98	47/50
94-7	276 (46)	46/50	263 (47)	95	47/50	258 (39)	93	39/50	271 (46)	98	46/50
98-7	281 (43)	43/50	265 (46)	94	46/50	261 (34)	93	34/50	274 (45)	98	45/50
102-7	283 (42)	42/50	265 (44)	94	44/50	262 (31)	93	31/50	275 (45)	97	45/50
104-7	282 (42)	42/50	263 (43)	93	43/50	258 (31)	91	31/50	273 (44)	97	44/50

< >:No. of effective animals. ( ):No. of measured animals Av. Wt. : g

TABLE D3

BODY WEIGHT CHANGES : MALE  
(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		1-7		2-7		3-7		4-7		5-7		6-7	
	0-0															
Control	119±	6	148±	8	179±	10	206±	11	228±	10	246±	10	259±	11		
0.5 mg/m3	119±	6	146±	8	174±	10	199±	11**	220±	12**	236±	12**	250±	14**		
2 mg/m3	119±	6	146±	7	175±	9	200±	11*	221±	11**	237±	12**	251±	12**		
8 mg/m3	119±	6	144±	8	174±	10	200±	11*	220±	11**	235±	13**	251±	14**		

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		9-7		10-7		11-7		12-7		13-7	
	7-7		8-7											
Control	272±	12	285±	12	294±	13	302±	13	309±	14	315±	14	321±	14
0.5 mg/m3	263±	14**	275±	15**	286±	15	294±	15	300±	15	308±	16	315±	16
2 mg/m3	265±	13*	279±	14	290±	14	298±	15	305±	15	312±	16	319±	16
8 mg/m3	266±	15	278±	15	290±	16	298±	16	305±	17	313±	17	321±	18

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		22-7		26-7		30-7		34-7		38-7	
	14-7	18-7												
Control	327± 14	342± 15	356± 17	369± 18	382± 19	392± 20	400± 21							
0.5 mg/m3	322± 16	338± 17	353± 17	365± 17	376± 18	386± 19	394± 21							
2 mg/m3	324± 16	340± 17	356± 18	370± 18	382± 19	392± 19	400± 19							
8 mg/m3	324± 18	343± 19	357± 19	373± 20	386± 21	394± 21	402± 22							

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		50-7		52-7		54-7		58-7		62-7	
	42-7		46-7											
Control	408±	21	413±	21	416±	20	419±	20	421±	22	426±	21	433±	22
0.5 mg/m3	400±	21	404±	23	408±	23	409±	24	411±	25	415±	25*	416±	26**
2 mg/m3	408±	20	413±	21	418±	21	420±	20	421±	21	425±	22	427±	21
8 mg/m3	411±	23	416±	23	420±	23	422±	23	425±	24	428±	24	431±	24

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		74-7		78-7		82-7		86-7		90-7	
	66-7		70-7											
Control	433±	23	437±	22	437±	23	438±	24	436±	23	433±	24	431±	25
0.5 mg/m3	418±	26**	419±	24**	418±	24**	418±	28**	417±	25**	412±	30**	412±	24**
2 mg/m3	425±	24	430±	21	429±	20	429±	20	424±	25	423±	24	420±	23
8 mg/m3	432±	23	433±	23	431±	25	432±	27	428±	31	428±	31	424±	36

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		102-7		104-7	
	94-7		98-7					
Control	430±	25	427±	26	413±	32	415±	26
0.5 mg/m3	406±	21**	401±	21**	391±	24**	387±	24**
2 mg/m3	414±	23*	402±	31**	402±	21	396±	31
8 mg/m3	425±	32	421±	35	414±	43	411±	46

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

TABLE D4

BODY WEIGHT CHANGES : FEMALE  
(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		1-7		2-7		3-7		4-7		5-7		6-7	
	0-0															
Control	98±	4	112±	4	125±	4	135±	6	143±	7	150±	8	155±	8		
0.5 mg/m3	98±	4	110±	5	122±	6*	132±	6**	140±	7	147±	7*	153±	8		
2 mg/m3	98±	4	110±	5	121±	5**	130±	6**	138±	7**	144±	7**	151±	7**		
8 mg/m3	98±	4	108±	4**	121±	5**	131±	7**	140±	7	145±	7**	152±	8		

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		9-7		10-7		11-7		12-7		13-7	
	7-7		8-7											
Control	160±	9	164±	10	168±	10	172±	10	174±	11	176±	10	179±	11
0.5 mg/m3	158±	8	164±	9	167±	10	171±	10	174±	9	177±	10	181±	9
2 mg/m3	156±	8	159±	9*	163±	10*	167±	10	170±	10	173±	10	176±	10
8 mg/m3	158±	9	162±	10	167±	10	171±	11	174±	10	176±	9	181±	10

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		22-7		26-7		30-7		34-7		38-7	
	14-7	18-7												
Control	180± 12	184± 11	191± 12	197± 12	203± 13	209± 13	213± 13							
0.5 mg/m3	181± 9	188± 10	194± 11	198± 12	202± 12	208± 11	212± 12							
2 mg/m3	177± 10	182± 10	187± 11	193± 11	199± 11	203± 12	207± 12							
8 mg/m3	180± 9	187± 11	193± 13	200± 13	205± 14	209± 14	213± 14							

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		50-7		52-7		54-7		58-7		62-7	
	42-7		46-7											
Control	219±	13	218±	14	222±	14	225±	14	228±	15	234±	15	240±	17
0.5 mg/m3	215±	13	219±	13	223±	15	224±	16	226±	15	231±	17	233±	18
2 mg/m3	211±	12	215±	13	218±	13	220±	13	223±	14	226±	14	229±	17*
8 mg/m3	216±	14	220±	17	224±	17	226±	18	229±	18	233±	19	236±	20

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		74-7		78-7		82-7		86-7		90-7	
	66-7		70-7											
Control	241±	20	249±	24	255±	26	260±	22	263±	22	270±	22	274±	22
0.5 mg/m3	238±	19	242±	19	246±	19	250±	20*	254±	20	258±	21*	261±	20*
2 mg/m3	234±	17	238±	17	242±	17*	245±	18**	247±	18**	250±	21**	251±	25**
8 mg/m3	241±	21	245±	21	249±	21	256±	20	258±	20	264±	20	268±	22

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		102-7		104-7	
	94-7		98-7					
Control	276±	24	281±	24	283±	24	282±	23
0.5 mg/m3	263±	25*	265±	24**	265±	25**	263±	27**
2 mg/m3	258±	19**	261±	17**	262±	21**	258±	26**
8 mg/m3	271±	21	274±	22	275±	22	273±	24

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

TABLE D5

BODY WEIGHT CHANGES : MALE

(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		2-7		3-7		4-7		5-7		6-7	
	0-0		1-7											
S-Control	122±	6	152±	7	183±	9	211±	9	234±	9	251±	10	264±	11
S-0.5 mg/m3	122±	6	149±	9	178±	10	201±	10*	223±	10*	239±	11*	252±	11
S-2 mg/m3	122±	7	150±	7	180±	8	202±	7	224±	8	239±	9*	254±	10
S-8 mg/m3	122±	6	147±	8	178±	8	203±	8	224±	7*	239±	9*	256±	10

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		9-7		10-7		11-7		12-7		13-7	
	7-7		8-7											
S-Control	277±	13	290±	11	300±	12	304±	12	311±	14	319±	15	325±	15
S-0.5 mg/m3	264±	12	276±	12	287±	11	295±	10	302±	12	310±	13	319±	14
S-2 mg/m3	267±	9	281±	10	291±	11	299±	12	306±	13	314±	13	323±	15
S-8 mg/m3	271±	11	285±	11	294±	14	302±	15	308±	15	316±	16	323±	18

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		22-7		26-7		30-7		34-7		38-7	
	14-7		18-7											
S-Control	330±	14	346±	17	358±	18	371±	18	384±	20	395±	23	404±	19
S-0.5 mg/m3	323±	13	340±	14	357±	16	369±	17	381±	19	386±	17	396±	17
S-2 mg/m3	326±	15	338±	13	352±	11	367±	13	379±	12	387±	13	393±	13
S-8 mg/m3	327±	18	345±	19	361±	20	377±	21	392±	20	400±	23	406±	24

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		50-7		52-7	
	42-7		46-7					
S-Control	410±	20	413±	20	416±	20	421±	20
S-0.5 mg/m3	403±	16	407±	18	413±	19	414±	19
S-2 mg/m3	398±	14	403±	12	410±	13	410±	14
S-8 mg/m3	414±	25	412±	35	427±	22	427±	23

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

TABLE D6

BODY WEIGHT CHANGES : FEMALE

(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		1-7		2-7		3-7		4-7		5-7		6-7	
	0-0															
S-Control	100±	3	114±	4	126±	6	136±	6	145±	7	152±	7	159±	7		
S-0.5 mg/m3	100±	4	111±	5	124±	5	133±	5	143±	6	149±	6	157±	7		
S-2 mg/m3	100±	4	112±	4	124±	5	134±	5	142±	6	149±	6	155±	7		
S-8 mg/m3	100±	4	109±	4	122±	5	131±	6	139±	6	145±	6	152±	6		

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		9-7	10-7	11-7	12-7	13-7
	7-7	8-7	8-7	9-7					
S-Control	162± 8	167± 9	170± 9	172± 9	176± 10	178± 9	182± 9		
S-0.5 mg/m3	161± 8	166± 8	171± 8	174± 9	178± 8	181± 10	184± 8		
S-2 mg/m3	161± 8	164± 8	169± 9	172± 9	175± 10	178± 9	181± 10		
S-8 mg/m3	159± 7	163± 8	168± 9	172± 9	175± 9	178± 7	182± 8		

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		22-7		26-7		30-7		34-7		38-7	
	14-7		18-7											
S-Control	183±	9	189±	7	195±	9	202±	8	205±	8	209±	8	215±	9
S-0.5 mg/m3	186±	9	191±	8	197±	10	203±	10	206±	10	210±	11	214±	12
S-2 mg/m3	182±	11	187±	12	195±	13	197±	12	206±	13	209±	12	212±	13
S-8 mg/m3	181±	8	189±	10	197±	11	204±	13	208±	11	211±	11	216±	11

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		50-7		52-7	
	42-7		46-7					
S-Control	220±	9	223±	6	222±	7	224±	8
S-0.5 mg/m3	220±	13	222±	14	227±	15	228±	16
S-2 mg/m3	218±	14	222±	18	221±	18	224±	17
S-8 mg/m3	221±	13	226±	15	228±	12	229±	12

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

TABLE D7

BODY WEIGHT CHANGES : MALE

(SATELLITE 52w+26w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B2 78  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		62-7		66-7		70-7		74-7		78-7	
	54-7		58-7											
S-Control	429±	18	426±	24	430±	35	434±	28	447±	22	445±	22	445±	21
S-0.5 mg/m3	411±	19	418±	16	423±	19	421±	17	419±	17	415±	19	416±	21
S-2 mg/m3	413±	20	414±	16	418±	18	419±	16	419±	17	418±	19	419±	20
S-8 mg/m3	421±	23	429±	22	433±	23	432±	24	433±	25	431±	25	429±	26

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

TABLE D8

BODY WEIGHT CHANGES : FEMALE

(SATELLITE 52w+26w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B2 78  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		62-7		66-7		70-7		74-7		78-7	
	54-7		58-7											
S-Control	227±	8	232±	7	235±	8	235±	12	240±	15	246±	18	249±	23
S-0.5 mg/m3	235±	19	242±	20	249±	19	252±	19	253±	18	259±	18	261±	19
S-2 mg/m3	228±	20	238±	22	238±	21	238±	23	240±	21	241±	22	245±	21
S-8 mg/m3	230±	18	235±	17	238±	14	240±	15	248±	14	253±	15	256±	13

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

TABLE D9

BODY WEIGHT CHANGES : MALE

(SATELLITE 52w+52w)



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B3 104  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		90-7		94-7		98-7		102-7	
	82-7		86-7									
S-Control	453±	28	443±	29	449±	32	439±	44	427±	11 ?	415	?
S-0.5 mg/m3	421±	27	418±	23	417±	27	414±	26	408±	24	409±	25
S-2 mg/m3	425±	17	416±	25	417±	13	412±	25	413±	24	423±	19 ?
S-8 mg/m3	429±	27	423±	34	416±	32	411±	31	415±	31	407±	40

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

? : Significant test is not applied, because No. of data in this group is less than 3.

TABLE D10

BODY WEIGHT CHANGES : FEMALE

(SATELLITE 52w+52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B3 104  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		90-7		94-7		98-7		102-7	
	82-7		86-7									
S-Control	240±	31	271±	4 ?	277±	13 ?	275±	16 ?	276±	18 ?	275±	30 ?
S-0.5 mg/m3	262±	23	268±	26	270±	26	272±	24	276±	28	280±	29
S-2 mg/m3	240±	16	246±	12	253±	16	258±	20	260±	21	254±	38
S-8 mg/m3	250±	10	257±	15	258±	21	263±	14	267±	11	269±	12

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

? : Significant test is not applied, because No. of data in this group is less than 3.

TABLE E1

FOOD CONSUMPTION CHANGES AND  
SURVIVAL ANIMAL NUMBERS : MALE  
(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : MALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week-Day on Study	Control		0.5 mg/m3		2 mg/m3		8 mg/m3				
	Av. FC	No. of Surviv. <50>	Av. FC	% of cont. <50>	No. of Surviv.	Av. FC	% of cont. <50>	No. of Surviv.	Av. FC	% of cont. <50>	No. of Surviv.
1-7	15.8 (50)	50/50	15.7 (50)	99	50/50	15.9 (50)	101	50/50	16.0 (50)	101	50/50
2-7	17.6 (50)	50/50	17.4 (50)	99	50/50	17.8 (50)	101	50/50	18.1 (50)	103	50/50
3-7	18.6 (50)	50/50	18.1 (50)	97	50/50	18.7 (50)	101	50/50	18.8 (50)	101	50/50
4-7	18.4 (50)	50/50	17.8 (50)	97	50/50	18.3 (50)	99	50/50	18.3 (50)	99	50/50
5-7	18.3 (50)	50/50	17.7 (50)	97	50/50	18.1 (50)	99	50/50	18.3 (50)	100	50/50
6-7	18.5 (50)	50/50	17.0 (50)	92	50/50	17.6 (50)	95	50/50	17.7 (50)	96	50/50
7-7	18.7 (50)	50/50	18.1 (50)	97	50/50	18.4 (50)	98	50/50	18.6 (50)	99	50/50
8-7	18.7 (50)	50/50	17.9 (50)	96	50/50	18.5 (50)	99	50/50	18.7 (50)	100	50/50
9-7	18.7 (50)	50/50	18.4 (47)	98	50/50	18.8 (50)	101	50/50	19.0 (50)	102	50/50
10-7	18.3 (50)	50/50	17.9 (50)	98	50/50	18.5 (50)	101	50/50	18.7 (50)	102	50/50
11-7	18.4 (50)	50/50	17.9 (50)	97	50/50	18.6 (50)	101	50/50	18.5 (50)	101	50/50
12-7	17.6 (50)	50/50	17.6 (50)	100	50/50	17.8 (50)	101	50/50	18.4 (50)	105	50/50
13-7	17.6 (50)	50/50	17.5 (50)	99	50/50	17.8 (50)	101	50/50	17.9 (50)	102	50/50
14-7	17.6 (50)	50/50	17.4 (50)	99	50/50	17.7 (50)	101	50/50	17.8 (50)	101	50/50
18-7	17.5 (50)	50/50	17.4 (50)	99	50/50	17.6 (50)	101	50/50	18.1 (50)	103	50/50
22-7	18.1 (50)	50/50	18.0 (50)	99	50/50	18.4 (50)	102	50/50	18.6 (50)	103	50/50
26-7	18.4 (50)	50/50	17.8 (50)	97	50/50	18.6 (50)	101	50/50	18.8 (50)	102	50/50
30-7	18.5 (50)	50/50	18.2 (50)	98	50/50	18.9 (50)	102	50/50	18.9 (50)	102	50/50
34-7	18.3 (50)	50/50	18.0 (50)	98	50/50	18.7 (50)	102	50/50	18.7 (50)	102	50/50
38-7	18.2 (50)	50/50	18.0 (50)	99	50/50	18.7 (50)	103	50/50	18.6 (50)	102	50/50
42-7	18.3 (50)	50/50	18.1 (50)	99	50/50	19.0 (50)	104	50/50	19.0 (50)	104	50/50
46-7	18.6 (50)	50/50	18.5 (50)	99	50/50	19.2 (50)	103	50/50	19.4 (50)	104	50/50
50-7	17.8 (50)	50/50	18.5 (50)	104	50/50	19.2 (50)	108	50/50	19.3 (50)	108	50/50
52-7	18.6 (50)	50/50	18.5 (50)	99	50/50	19.2 (50)	103	50/50	19.3 (50)	104	50/50
54-7	18.0 (50)	50/50	19.0 (50)	106	50/50	19.4 (50)	108	50/50	19.6 (50)	109	50/50
58-7	18.8 (49)	49/50	19.0 (50)	101	50/50	19.2 (50)	102	50/50	19.4 (50)	103	50/50
62-7	18.8 (48)	48/50	18.4 (50)	98	50/50	19.2 (50)	102	50/50	19.4 (50)	103	50/50
66-7	18.5 (48)	48/50	18.4 (49)	99	49/50	18.7 (49)	101	49/50	19.2 (50)	104	50/50
70-7	18.5 (46)	46/50	18.4 (49)	99	49/50	19.1 (48)	103	48/50	19.1 (50)	103	50/50
74-7	18.5 (46)	46/50	18.4 (49)	99	49/50	18.9 (47)	102	47/50	18.9 (49)	102	49/50
78-7	18.6 (45)	45/50	18.3 (48)	98	48/50	19.0 (47)	102	47/50	18.9 (46)	102	46/50
82-7	18.3 (45)	45/50	18.6 (46)	102	46/50	18.4 (45)	101	45/50	18.8 (44)	103	44/50
86-7	18.5 (44)	44/50	18.1 (45)	98	45/50	18.9 (41)	102	41/50	19.3 (43)	104	43/50
90-7	18.6 (42)	42/50	18.7 (43)	101	43/50	18.8 (38)	101	38/50	19.2 (43)	103	43/50
94-7	18.6 (39)	39/50	18.3 (40)	98	40/50	18.6 (37)	100	37/50	19.5 (41)	105	41/50
98-7	18.8 (37)	37/50	18.8 (38)	100	39/50	18.2 (33)	97	33/50	19.7 (41)	105	41/50
102-7	17.0 (36)	36/50	18.5 (34)	109	34/50	18.8 (27)	111	27/50	19.3 (39)	114	39/50
104-7	18.5 (30)	30/50	18.1 (32)	98	32/50	18.5 (27)	100	27/50	19.2 (37)	104	37/50

< > : No. of effective animals, ( ) : No. of measured animals Av. FC : g

**TABLE E2**

**FOOD CONSUMPTION CHANGES AND  
SURVIVAL ANIMAL NUMBERS : FEMALE  
(CARCINOGENICITY STUDY GROUPS)**

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : FEMALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week-Day on Study	Control		0.5 mg/m3		2 mg/m3		8 mg/m3				
	Av. FC	No. of Surviv. <50>	Av. FC	% of cont. <50>	No. of Surviv.	Av. FC	% of cont. <50>	No. of Surviv.	Av. FC	% of cont. <50>	No. of Surviv.
1-7	12.7 (50)	50/50	12.1 (50)	95	50/50	12.1 (50)	95	50/50	12.1 (50)	95	50/50
2-7	13.3 (50)	50/50	12.6 (50)	95	50/50	12.4 (50)	93	50/50	12.7 (50)	95	50/50
3-7	13.4 (50)	50/50	12.5 (50)	93	50/50	12.0 (50)	90	50/50	12.6 (50)	94	50/50
4-7	13.0 (50)	50/50	12.2 (50)	94	50/50	12.1 (50)	93	50/50	12.2 (50)	94	50/50
5-7	13.0 (50)	50/50	12.0 (50)	92	50/50	12.2 (50)	94	50/50	12.3 (50)	95	50/50
6-7	12.8 (50)	50/50	11.7 (50)	91	50/50	12.0 (50)	94	50/50	11.8 (50)	92	50/50
7-7	13.3 (50)	50/50	12.3 (50)	92	50/50	12.1 (50)	91	50/50	12.5 (50)	94	50/50
8-7	12.4 (50)	50/50	12.1 (50)	98	50/50	11.7 (50)	94	50/50	12.3 (50)	99	50/50
9-7	12.6 (50)	50/50	12.0 (50)	95	50/50	11.8 (50)	94	50/50	12.5 (50)	99	50/50
10-7	12.4 (50)	50/50	12.1 (50)	98	50/50	11.9 (50)	96	50/50	12.3 (50)	99	50/50
11-7	12.6 (50)	50/50	12.1 (49)	96	50/50	12.1 (50)	96	50/50	12.3 (50)	98	50/50
12-7	9.2 (50)	50/50	11.9 (50)	129	50/50	11.8 (50)	128	50/50	12.2 (50)	133	50/50
13-7	12.5 (50)	50/50	12.0 (50)	96	50/50	11.7 (50)	94	50/50	12.3 (50)	98	50/50
14-7	12.1 (49)	50/50	11.7 (50)	97	50/50	11.6 (50)	96	50/50	11.8 (50)	98	50/50
18-7	11.6 (50)	50/50	11.6 (50)	100	50/50	11.6 (50)	100	50/50	12.2 (50)	105	50/50
22-7	12.3 (49)	50/50	11.9 (50)	97	50/50	11.9 (49)	97	50/50	12.6 (50)	102	50/50
26-7	12.5 (50)	50/50	12.0 (50)	96	50/50	12.0 (50)	96	50/50	12.6 (50)	101	50/50
30-7	12.6 (50)	50/50	11.9 (50)	94	50/50	12.1 (50)	96	50/50	12.4 (50)	98	50/50
34-7	12.6 (49)	50/50	12.1 (50)	96	50/50	12.2 (50)	97	50/50	12.6 (50)	100	50/50
38-7	12.3 (50)	50/50	11.8 (50)	96	50/50	11.8 (50)	96	50/50	12.3 (50)	100	50/50
42-7	12.8 (49)	50/50	12.1 (50)	95	50/50	12.4 (50)	97	50/50	12.7 (50)	99	50/50
46-7	11.9 (50)	50/50	12.4 (50)	104	50/50	12.4 (50)	104	50/50	12.9 (50)	108	50/50
50-7	12.0 (50)	50/50	12.5 (50)	104	50/50	12.5 (49)	104	49/50	12.7 (50)	106	50/50
52-7	12.8 (50)	50/50	12.5 (50)	98	50/50	12.7 (49)	99	49/50	13.0 (50)	102	50/50
54-7	13.2 (50)	50/50	12.8 (50)	97	50/50	13.0 (49)	98	49/50	13.4 (50)	102	50/50
58-7	13.2 (50)	50/50	13.0 (50)	98	50/50	13.0 (49)	98	49/50	13.3 (50)	101	50/50
62-7	13.6 (50)	50/50	12.8 (50)	94	50/50	12.9 (49)	95	49/50	13.3 (50)	98	50/50
66-7	13.2 (50)	50/50	13.0 (50)	98	50/50	13.1 (49)	99	49/50	13.4 (50)	102	50/50
70-7	13.4 (50)	50/50	13.0 (50)	97	50/50	13.3 (49)	99	49/50	13.6 (50)	101	50/50
74-7	13.9 (50)	50/50	13.1 (50)	94	50/50	13.2 (49)	95	49/50	13.2 (50)	95	50/50
78-7	13.6 (49)	49/50	13.1 (49)	96	49/50	13.1 (49)	96	49/50	13.9 (49)	102	49/50
82-7	13.7 (49)	49/50	13.4 (47)	98	47/50	13.2 (48)	96	48/50	13.8 (49)	101	49/50
86-7	14.4 (49)	49/50	13.7 (47)	95	47/50	13.3 (47)	92	47/50	14.0 (48)	97	48/50
90-7	14.0 (48)	48/50	13.7 (47)	98	47/50	12.9 (45)	92	45/50	14.2 (47)	101	47/50
94-7	14.0 (46)	46/50	13.7 (47)	98	47/50	13.8 (39)	99	39/50	14.6 (46)	104	46/50
98-7	14.5 (43)	43/50	13.8 (46)	95	46/50	13.7 (34)	94	34/50	14.8 (45)	102	45/50
102-7	14.3 (42)	42/50	13.9 (44)	97	44/50	13.7 (31)	96	31/50	14.6 (45)	102	45/50
104-7	14.5 (42)	42/50	13.4 (43)	92	43/50	13.3 (31)	92	31/50	14.2 (44)	98	44/50

< > : No. of effective animals, ( ) : No. of measured animals Av. FC. : g

TABLE E3

FOOD CONSUMPTION CHANGES : MALE  
(CARCINOGENICITY STUDY GROUPS)



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)							
	1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)	
Control	15.8± 1.2	17.6± 1.4	18.6± 1.4	18.4± 1.2	18.3± 1.0	18.5± 1.3	18.7± 1.4	
0.5 mg/m3	15.7± 1.1	17.4± 1.5	18.1± 1.4	17.8± 1.2*	17.7± 1.1*	17.0± 1.1**	18.1± 1.0	
2 mg/m3	15.9± 1.0	17.8± 1.4	18.7± 1.6	18.3± 1.3	18.1± 1.0	17.6± 1.1**	18.4± 1.3	
8 mg/m3	16.0± 1.2	18.1± 1.5	18.8± 1.5	18.3± 1.1	18.3± 1.2	17.7± 1.2**	18.6± 1.3	

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	18.7± 1.5	18.7± 1.4	18.3± 1.5	18.4± 1.5	17.6± 1.3	17.6± 1.4	17.6± 1.2
0.5 mg/m3	17.9± 1.2*	18.4± 1.2	17.9± 1.1	17.9± 1.0	17.6± 1.1	17.5± 1.0	17.4± 1.0
2 mg/m3	18.5± 1.4	18.8± 1.3	18.5± 1.3	18.6± 1.4	17.8± 1.2	17.8± 1.2	17.7± 1.1
8 mg/m3	18.7± 1.6	19.0± 1.4	18.7± 1.4	18.5± 1.3	18.4± 1.4**	17.9± 1.1	17.8± 1.1

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)					
	18-7(7)	22-7(7)	26-7(7)	30-7(7)	34-7(7)	38-7(7)	42-7(7)	
Control	17.5± 1.3	18.1± 1.4	18.4± 1.2	18.5± 1.3	18.3± 1.1	18.2± 1.2	18.3± 1.0	
0.5 mg/m3	17.4± 1.0	18.0± 0.8	17.8± 1.1*	18.2± 1.2	18.0± 1.1	18.0± 1.1	18.1± 1.0	
2 mg/m3	17.6± 1.2	18.4± 1.1	18.6± 1.2	18.9± 1.0	18.7± 1.1	18.7± 1.1	19.0± 1.1**	
8 mg/m3	18.1± 1.3	18.6± 1.0*	18.8± 1.2	18.9± 1.2	18.7± 1.2	18.6± 1.2	19.0± 1.2**	

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	46-7(7)	50-7(7)	52-7(7)	54-7(7)	58-7(7)	62-7(7)	66-7(7)
Control	18.6± 1.1	17.8± 0.9	18.6± 1.1	18.0± 1.1	18.8± 1.0	18.8± 1.0	18.5± 1.3
0.5 mg/m3	18.5± 1.3	18.5± 1.3**	18.5± 1.2	19.0± 1.3**	19.0± 1.2	18.4± 1.2	18.4± 1.3
2 mg/m3	19.2± 1.0*	19.2± 1.0**	19.2± 1.1*	19.4± 1.2**	19.2± 1.0	19.2± 1.1	18.7± 2.6
8 mg/m3	19.4± 1.2**	19.3± 1.1**	19.3± 1.2*	19.6± 1.4**	19.4± 1.1	19.4± 1.3*	19.2± 1.3*

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)				
	70-7(7)	74-7(7)	78-7(7)	82-7(7)	86-7(7)	90-7(7)	94-7(7)
Control	18.5± 0.9	18.5± 0.9	18.6± 1.0	18.3± 1.4	18.5± 1.5	18.6± 2.0	18.6± 1.2
0.5 mg/m3	18.4± 1.1	18.4± 1.3	18.3± 2.0	18.6± 1.2	18.1± 3.3	18.7± 1.3	18.3± 1.7
2 mg/m3	19.1± 1.0*	18.9± 0.7	19.0± 1.0	18.4± 2.7	18.9± 1.1	18.8± 1.2	18.6± 1.3
8 mg/m3	19.1± 1.2*	18.9± 1.4	18.9± 1.8	18.8± 1.6	19.3± 1.4	19.2± 1.5	19.5± 1.4**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)		
	98-7(7)	102-7(7)	104-7(7)
Control	18.8± 1.2	17.0± 4.8	18.5± 1.8
0.5 mg/m3	18.8± 2.0	18.5± 2.6	18.1± 2.6
2 mg/m3	18.2± 2.8	18.8± 1.7*	18.5± 2.7
8 mg/m3	19.7± 1.5*	19.3± 2.1**	19.2± 1.8

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

**TABLE E4**

**FOOD CONSUMPTION CHANGES : FEMALE  
(CARCINOGENICITY STUDY GROUPS)**

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)					
	1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)	
Control	12.7± 1.0	13.3± 1.1	13.4± 1.4	13.0± 1.4	13.0± 1.2	12.8± 1.3	13.3± 2.3	
0.5 mg/m3	12.1± 0.8**	12.6± 0.8**	12.5± 0.9**	12.2± 1.0**	12.0± 0.8**	11.7± 0.8**	12.3± 0.8	
2 mg/m3	12.1± 0.7*	12.4± 0.7**	12.0± 0.8**	12.1± 0.8**	12.2± 0.7**	12.0± 0.9**	12.1± 1.0**	
8 mg/m3	12.1± 0.7**	12.7± 0.9**	12.6± 0.9**	12.2± 0.8**	12.3± 0.8**	11.8± 0.7**	12.5± 0.9	

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)					
	8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)	
Control	12.4± 1.4	12.6± 1.5	12.4± 1.5	12.6± 2.0	9.2± 1.0	12.5± 1.9	12.1± 1.7	
0.5 mg/m3	12.1± 1.0	12.0± 0.9	12.1± 1.3	12.1± 0.8	11.9± 0.8**	12.0± 0.8	11.7± 0.8	
2 mg/m3	11.7± 0.8*	11.8± 1.0*	11.9± 1.0	12.1± 1.0	11.8± 1.0**	11.7± 0.8	11.6± 0.7	
8 mg/m3	12.3± 0.9	12.5± 1.1	12.3± 0.9	12.3± 0.7	12.2± 0.6**	12.3± 0.7	11.8± 0.7	

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)					
	18-7(7)	22-7(7)	26-7(7)	30-7(7)	34-7(7)	38-7(7)	42-7(7)	
Control	11.6± 1.3	12.3± 1.2	12.5± 1.4	12.6± 1.5	12.6± 1.5	12.3± 1.5	12.8± 1.5	
0.5 mg/m3	11.6± 1.2	11.9± 0.9	12.0± 1.3	11.9± 1.0	12.1± 0.9	11.8± 0.8	12.1± 1.0	
2 mg/m3	11.6± 0.9	11.9± 0.8	12.0± 0.9	12.1± 0.9	12.2± 1.1	11.8± 0.8	12.4± 1.1	
8 mg/m3	12.2± 1.2*	12.6± 1.2	12.6± 1.1	12.4± 1.2	12.6± 1.4	12.3± 0.8	12.7± 1.0	

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)											
	46-7(7)		50-7(7)		52-7(7)		54-7(7)		58-7(7)		62-7(7)		66-7(7)	
Control	11.9±	1.1	12.0±	1.2	12.8±	1.5	13.2±	1.7	13.2±	1.2	13.6±	1.5	13.2±	1.3
0.5 mg/m3	12.4±	1.1	12.5±	1.1	12.5±	1.1	12.8±	1.0	13.0±	1.0	12.8±	0.9**	13.0±	1.2
2 mg/m3	12.4±	1.0	12.5±	0.8*	12.7±	1.0	13.0±	1.1	13.0±	0.9	12.9±	1.0*	13.1±	0.9
8 mg/m3	12.9±	1.3**	12.7±	0.9**	13.0±	1.5	13.4±	1.3	13.3±	0.9	13.3±	1.1	13.4±	1.1

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)											
	70-7(7)		74-7(7)		78-7(7)		82-7(7)		86-7(7)		90-7(7)		94-7(7)	
Control	13.4±	1.4	13.9±	1.6	13.6±	1.2	13.7±	1.2	14.4±	1.1	14.0±	1.3	14.0±	1.7
0.5 mg/m3	13.0±	1.1	13.1±	0.9**	13.1±	1.2	13.4±	1.0	13.7±	0.9**	13.7±	0.9	13.7±	1.5
2 mg/m3	13.3±	1.0	13.2±	0.9*	13.1±	1.0	13.2±	1.1	13.3±	1.7**	12.9±	1.7**	13.8±	1.0
8 mg/m3	13.6±	1.2	13.2±	1.4	13.9±	1.1	13.8±	1.3	14.0±	1.4	14.2±	1.4	14.6±	1.6

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : A4 104  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)		
	98-7(7)	102-7(7)	104-7(7)
Control	14.5± 1.5	14.3± 1.4	14.5± 1.1
0.5 mg/m3	13.8± 1.3	13.9± 1.2	13.4± 1.5**
2 mg/m3	13.7± 1.4*	13.7± 1.1	13.3± 1.9**
8 mg/m3	14.8± 1.7	14.6± 2.1	14.2± 2.4

Significant difference : \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

TABLE E5

FOOD CONSUMPTION CHANGES : MALE

(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)					
	1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)	
S-Control	16.2± 1.0	18.4± 1.7	19.5± 1.9	18.9± 1.3	18.4± 1.2	18.7± 1.3	19.0± 1.3	
S-0.5 mg/m3	16.3± 1.3	18.0± 1.4	18.5± 1.3	17.9± 0.8	18.0± 0.9	17.3± 1.2	18.7± 1.6	
S-2 mg/m3	16.4± 1.7	19.0± 2.4	19.3± 2.3	18.7± 1.6	18.4± 1.6	18.1± 1.7	18.6± 1.8	
S-8 mg/m3	16.0± 1.1	18.3± 0.8	18.9± 1.2	18.3± 0.8	18.0± 0.7	17.9± 1.0	18.8± 1.4	

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
S-Control	18.9± 1.2	18.7± 1.2	18.1± 1.3	18.0± 1.3	17.4± 1.3	17.8± 1.4	17.8± 1.0
S-0.5 mg/m3	18.0± 1.2	18.6± 1.3	18.3± 0.9	18.4± 1.1	18.0± 1.2	17.8± 1.2	17.5± 1.1
S-2 mg/m3	18.8± 1.7	18.8± 1.5	18.4± 1.4	18.4± 1.4	18.3± 1.5	17.9± 1.3	17.7± 1.3
S-8 mg/m3	18.9± 1.4	19.2± 1.3	18.7± 1.1	18.7± 1.0	18.2± 1.1	17.5± 0.9	17.7± 0.9

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)					
	18-7(7)	22-7(7)	26-7(7)	30-7(7)	34-7(7)	38-7(7)	42-7(7)	
S-Control	17.2± 1.3	18.1± 1.5	18.4± 1.1	18.7± 1.0	18.6± 1.0	18.4± 0.8	18.1± 0.7	
S-0.5 mg/m3	17.6± 1.1	18.2± 1.0	17.9± 0.8	18.6± 0.9	18.2± 0.7	18.2± 0.9	18.5± 0.8	
S-2 mg/m3	17.2± 1.0	17.9± 1.0	18.4± 0.9	18.5± 1.4	18.6± 1.2	18.3± 0.6	18.3± 1.0	
S-8 mg/m3	18.0± 0.8	18.4± 1.1	18.8± 1.3	19.2± 1.1	18.9± 1.3	18.6± 1.2	19.2± 1.3	

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)		
	46-7(7)	50-7(7)	52-7(7)
S-Control	18.4± 1.0	17.8± 0.7	18.9± 1.3
S-0.5 mg/m3	19.0± 0.9	19.0± 0.6*	18.8± 0.6
S-2 mg/m3	19.0± 1.0	19.0± 1.0*	18.9± 1.1
S-8 mg/m3	18.7± 2.3	19.9± 1.3**	19.8± 1.2

Significant difference : \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

TABLE E6

FOOD CONSUMPTION CHANGES : FEMALE

(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)					
	1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)	
S-Control	13.0± 1.8	13.3± 1.9	13.6± 1.9	13.1± 1.0	13.4± 1.8	12.9± 1.0	13.4± 1.2	
S-0.5 mg/m3	12.3± 0.9	12.7± 0.9	12.5± 0.9	12.5± 0.9	12.3± 0.7	12.0± 0.9*	12.5± 1.0	
S-2 mg/m3	12.4± 0.6	12.8± 0.9	13.0± 0.9	12.4± 0.9	12.6± 1.4	11.9± 0.8*	12.6± 1.1	
S-8 mg/m3	12.2± 0.7	12.7± 0.9	12.5± 0.7	11.9± 0.5**	12.0± 0.6	11.7± 0.5**	12.2± 0.6	

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)					
	8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)	
S-Control	12.8± 1.3	13.1± 2.3	12.8± 1.9	12.5± 1.1	9.5± 0.7	13.8± 4.9	12.7± 1.7	
S-0.5 mg/m3	12.2± 0.9	12.3± 0.8	12.3± 0.6	12.1± 0.8	12.4± 1.0**	11.9± 0.8	12.2± 1.0	
S-2 mg/m3	11.9± 1.0	12.4± 1.1	12.2± 1.0	12.4± 1.1	12.6± 1.2**	12.4± 1.0	12.6± 1.1	
S-8 mg/m3	12.0± 0.7	12.5± 1.6	12.3± 1.3	12.5± 1.1	12.3± 1.1**	12.2± 0.6	12.1± 1.2	

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)											
	18-7(7)		22-7(7)		26-7(7)		30-7(7)		34-7(7)		38-7(7)		42-7(7)	
S-Control	12.5±	1.1	12.4±	1.2	13.7±	1.7	12.6±	1.0	13.1±	2.9	13.2±	1.6	13.1±	1.3
S-0.5 mg/m3	11.8±	0.8	11.9±	0.6	12.5±	1.1	11.8±	1.1	12.0±	0.8	12.0±	0.9	13.2±	1.2
S-2 mg/m3	12.0±	0.9	12.5±	1.1	12.2±	0.6	13.0±	1.3	12.4±	0.9	12.3±	1.0	13.2±	1.3
S-8 mg/m3	12.5±	1.2	13.1±	1.3	13.0±	1.4	12.1±	0.9	12.3±	0.9	12.2±	1.0	13.3±	2.6

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B1 52  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)		
	46-7 (7)	50-7 (7)	52-7 (7)
S-Control	12.4± 1.1	11.6± 0.5	12.7± 0.5
S-0.5 mg/m3	12.6± 0.9	13.0± 1.0**	12.9± 0.9
S-2 mg/m3	12.9± 1.6	12.4± 0.9	12.9± 0.9
S-8 mg/m3	13.4± 2.0	12.5± 0.8	13.2± 0.8

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$                       Test of Dunnett

TABLE E7

FOOD CONSUMPTION CHANGES : MALE

(SATELLITE 52w+26w)



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B2 78  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)					
	54-7(7)	58-7(7)	62-7(7)	66-7(7)	70-7(7)	74-7(7)	78-7(7)	
S-Control	18.5± 1.0	18.2± 2.9	18.0± 3.1	19.4± 1.2	19.1± 0.8	18.9± 0.9	19.1± 1.2	
S-0.5 mg/m3	18.4± 1.0	19.0± 0.6	18.5± 0.6	18.6± 1.0	18.4± 1.2	18.5± 1.4	18.5± 0.7	
S-2 mg/m3	18.3± 0.9	19.0± 1.1	18.7± 1.2	18.4± 0.7	18.5± 1.2	18.5± 1.4	18.5± 1.5	
S-8 mg/m3	18.4± 1.1	18.8± 0.9	18.7± 1.1	18.9± 1.4	18.6± 1.2	18.5± 1.2	18.8± 1.8	

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

TABLE E8

FOOD CONSUMPTION CHANGES : FEMALE

(SATELLITE 52w+26w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B2 78  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)					
	54-7(7)	58-7(7)	62-7(7)	66-7(7)	70-7(7)	74-7(7)	78-7(7)	
S-Control	14.1± 1.5	14.0± 1.3	13.6± 0.7	13.4± 1.5	12.7± 1.4	13.2± 1.2	13.0± 1.9	
S-0.5 mg/m3	13.1± 1.5	13.8± 1.0	13.5± 1.0	13.0± 1.0	13.1± 1.1	13.7± 0.9	13.0± 1.0	
S-2 mg/m3	13.0± 1.7	13.8± 1.1	12.6± 0.9	12.6± 1.0	13.0± 0.7	12.5± 1.0	12.7± 1.0	
S-8 mg/m3	12.6± 1.3	13.3± 1.0	13.1± 0.8	12.8± 0.7	13.6± 0.7	13.4± 1.2	13.4± 0.8	

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

TABLE E9

FOOD CONSUMPTION CHANGES : MALE

(SATELLITE 52w+52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 UNIT : g  
 REPORT TYPE : B3 104  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day(effective)		90-7(7)		94-7(7)		98-7(7)		102-7(7)		
	82-7(7)		86-7(7)										
S-Control	20.0±	1.1	19.6±	1.0	19.7±	1.9	19.7±	3.9	19.3±	0.2	?	19.4	?
S-0.5 mg/m3	18.7±	0.9	17.9±	0.9	18.7±	1.2	18.7±	0.5	18.4±	1.2		19.7±	0.7
S-2 mg/m3	18.9±	0.6	18.5±	0.6	19.8±	2.2	20.0±	0.7	19.5±	0.7		19.5±	0.9
S-8 mg/m3	17.5±	1.7	19.0±	2.0	19.0±	1.0	19.2±	1.8	20.0±	1.2		18.4±	1.4

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

? : Significant test is not applied, because No. of data in this group is less than 3.

TABLE E10

FOOD CONSUMPTION CHANGES : FEMALE

(SATELLITE 52w+52w)

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
UNIT : g  
REPORT TYPE : B3 104  
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
ALL ANIMALS

PAGE : 2

Group Name	Administration		week-day(effective)		90-7(7)		94-7(7)		98-7(7)		102-7(7)	
	82-7(7)		86-7(7)									
S-Control	12.8±	1.4	14.7±	1.1 ?	14.2±	0.7 ?	13.3±	0.1 ?	14.1±	2.6 ?	14.5±	2.5 ?
S-0.5 mg/m3	13.5±	0.7	13.8±	0.8	13.3±	1.2	13.9±	0.8	14.2±	1.0	14.7±	1.5
S-2 mg/m3	12.7±	1.5	12.7±	0.6	13.6±	0.7	13.6±	1.6	13.9±	1.5	12.0±	3.1
S-8 mg/m3	12.6±	0.5	13.3±	1.4	12.7±	1.9	13.1±	1.1	13.8±	1.7	13.8±	1.6

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

? : Significant test is not applied, because No. of data in this group is less than 3.

TABLE F1

URINARYSIS : MALE

(CARCINOGENICITY STUDY GROUPS)



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 MEASURE. TIME : 1  
 SEX : MALE

URINALYSIS

REPORT TYPE : A4

Group Name	NO. of Animals	pH_____							CHI	Protein_____					CHI	Glucose_____					CHI	Ketone body					CHI	Bilirubin				CHI		
		5.0	6.0	6.5	7.0	7.5	8.0	8.5		-	±	+	2+	3+		4+	-	±	+	2+		3+	4+	-	±	+		2+	3+	4+	-		+	2+
Control	27	0	3	3	3	6	6	6		0	1	5	13	8	0		27	0	0	0	0	0		17	8	2	0	0	0		26	0	0	1
0.5 mg/m3	32	0	0	2	6	6	9	9		2	3	6	13	8	0		32	0	0	0	0	0		25	6	1	0	0	0		32	0	0	0
2 mg/m3	23	0	0	0	2	6	4	11		0	2	4	8	9	0		23	0	0	0	0	0		22	0	1	0	0	0	*	23	0	0	0
8 mg/m3	37	0	0	1	2	8	12	14		0	3	5	13	16	0		37	0	0	0	0	0		36	1	0	0	0	0	**	37	0	0	0

Significant difference : \* : P ≤ 0.05      \*\* : P ≤ 0.01

Test of CHI SQUARE

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 MEASURE. TIME : 1  
 SEX : MALE

URINALYSIS

REPORT TYPE : A4

Group Name	NO. of Animals	Occult blood					CHI	Urobilinogen					CHI
		-	±	+	2+	3+		±	+	2+	3+	4+	
Control	27	26	1	0	0	0		26	1	0	0	0	
0.5 mg/m3	32	32	0	0	0	0		32	0	0	0	0	
2 mg/m3	23	23	0	0	0	0		23	0	0	0	0	
8 mg/m3	37	37	0	0	0	0		37	0	0	0	0	

Significant difference : \* : P ≤ 0.05    \*\* : P ≤ 0.01

Test of CHI SQUARE

**TABLE F2**

**URINARYSIS : FEMALE**

**(CARCINOGENICITY STUDY GROUPS)**

STUDY NO. : 0883

URINALYSIS

ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]

MEASURE TIME : 1

SEX : FEMALE

REPORT TYPE : A4

Group Name	NO. of Animals	pH_____							CHI	Protein_____					CHI	Glucose_____					CHI	Ketone body					CHI	Bilirubin				CHI		
		5.0	6.0	6.5	7.0	7.5	8.0	8.5		-	±	+	2+	3+		4+	-	±	+	2+		3+	4+	-	±	+		2+	3+	4+	-		+	2+
Control	36	0	0	1	2	6	4	23		6	4	13	11	2	0		36	0	0	0	0	0		24	8	4	0	0	0		36	0	0	0
0.5 mg/m3	43	0	0	0	1	3	9	30		12	10	11	8	2	0		43	0	0	0	0	0		21	21	1	0	0	0	*	43	0	0	0
2 mg/m3	30	0	0	0	1	2	12	15		10	3	9	5	2	1		30	0	0	0	0	0		22	5	3	0	0	0		29	1	0	0
8 mg/m3	44	0	2	0	3	6	13	20		8	10	9	6	11	0	*	44	0	0	0	0	0		29	13	2	0	0	0		44	0	0	0

Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01

Test of CHI SQUARE

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 MEASURE TIME : 1  
 SEX : FEMALE REPORT TYPE : A4

URINALYSIS

Group Name	NO. of Animals	Occult blood					CHI	Urobilinogen					CHI
		-	±	+	2+	3+		±	+	2+	3+	4+	
Control	36	34	0	1	0	1		36	0	0	0	0	
0.5 mg/m3	43	42	0	0	0	1		43	0	0	0	0	
2 mg/m3	30	25	0	1	2	2		30	0	0	0	0	
8 mg/m3	44	40	0	2	1	1		44	0	0	0	0	

Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01

Test of CHI SQUARE

TABLE G1

HEMATOLOGY : MALE

(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 MEASURE TIME : 1  
 SEX : MALE

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS (105W)

REPORT TYPE : A4

Group Name	NO. of Animals	RED BLOOD CELL 10 <sup>6</sup> /μl		HEMOGLOBIN g/dl		HEMATOCRIT %		MCV fl		MCH pg		MCHC g/dl		PLATELET 10 <sup>3</sup> /μl	
Control	27	8.07±	1.25	13.5±	2.0	39.7±	5.2	49.5±	3.2	16.8±	1.1	33.8±	1.0	839±	97
0.5 mg/m <sup>3</sup>	31	7.65±	1.38	11.9±	2.2*	36.0±	5.8*	47.3±	4.0**	15.6±	1.6**	32.9±	1.5*	964±	210**
2 mg/m <sup>3</sup>	25	8.37±	0.91	13.8±	1.5	40.8±	3.9	48.9±	2.1	16.5±	0.8	33.8±	0.8	837±	162
8 mg/m <sup>3</sup>	37	7.92±	1.51	13.2±	2.4	39.0±	6.5	49.7±	4.4	16.8±	1.5	33.8±	1.0	836±	179

Significant difference ; \* : P ≤ 0.05

\*\* : P ≤ 0.01

Test of Dunnett

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
MEASURE. TIME : 1  
SEX : MALE

HEMATOLOGY (SUMMARY)  
ALL ANIMALS (105W)

REPORT TYPE : A4

PAGE : 2

---

Group Name	NO. of Animals	RETICULOCYTE %	
Control	27	6.4±	4.7
0.5 mg/m3	31	7.7±	5.6
2 mg/m3	25	4.9±	2.3
8 mg/m3	37	6.6±	4.8

---

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL070)

BAIS6



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 MEASURE TIME : 1  
 SEX : MALE

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS (105W)

REPORT TYPE : A4

Group Name	NO. of Animals	WBC		Differential		WBC (%)		MONO	EOSINO	BASO			
		$10^3/\mu\ell$		NEUTRO		LYMPHO							
Control	27	4.46±	1.46	54.6±	8.5	31.6±	6.9	12.3±	6.6	1.4±	0.5	0.1±	0.1
0.5 mg/m <sup>3</sup>	31	4.20±	1.05	58.8±	7.6	28.9±	5.9	11.0±	2.8	1.2±	0.4	0.1±	0.1
2 mg/m <sup>3</sup>	25	4.33±	1.01	54.2±	9.0	32.2±	6.8	11.9±	4.4	1.6±	0.6	0.2±	0.1
8 mg/m <sup>3</sup>	37	5.01±	2.38	52.3±	12.1	33.9±	11.0	11.9±	3.0	1.7±	1.1	0.2±	0.1

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

TABLE G2

HEMATOLOGY : FEMALE

(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 MEASURE TIME : 1  
 SEX : FEMALE REPORT TYPE : A4

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS (105W)

Group Name	NO. of Animals	RED BLOOD CELL 10 <sup>6</sup> /μl		HEMOGLOBIN g/dl		HEMATOCRIT %		MCV fl		MCH pg		MCHC g/dl		PLATELET 10 <sup>3</sup> /μl	
Control	41	7.96±	1.17	14.6±	2.0	41.1±	4.6	52.2±	4.3	18.4±	1.5	35.4±	1.4	665±	155
0.5 mg/m3	39	8.06±	1.07	14.6±	1.7	41.3±	4.2	51.6±	3.5	18.2±	0.9	35.3±	0.9	701±	111
2 mg/m3	27	8.01±	0.60	14.6±	1.0	41.1±	2.5	51.4±	2.0	18.3±	0.6	35.5±	0.5	692±	91
8 mg/m3	41	8.07±	1.04	14.8±	1.6	41.8±	3.9	52.4±	4.7	18.5±	1.2	35.3±	0.9	671±	117

Significant difference ; \* : P ≤ 0.05

\*\* : P ≤ 0.01

Test of Dunnett

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
MEASURE TIME : 1  
SEX : FEMALE REPORT TYPE : A4

HEMATOLOGY (SUMMARY)  
ALL ANIMALS (105W)

PAGE : 5

---

Group Name	NO. of Animals	RETICULOCYTE %	
Control	41	4.6±	4.1
0.5 mg/m3	39	4.2±	3.4
2 mg/m3	27	3.6±	1.4
8 mg/m3	41	4.2±	4.4

---

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL070)

BAIS6

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 MEASURE TIME : 1  
 SEX : FEMALE REPORT TYPE : A4

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS (105W)

Group Name	NO. of Animals	WBC		Differential		WBC (%)		MONO	EOSINO	BASO			
		10 <sup>3</sup> /μl		NEUTRO		LYMPHO							
Control	41	2.24±	1.72	49.5±	11.1	36.5±	10.2	12.1±	7.9	1.8±	0.8	0.1±	0.3
0.5 mg/m3	39	2.94±	2.32	47.6±	12.4	36.6±	8.8	13.6±	9.0	1.7±	0.8	0.5±	1.3
2 mg/m3	27	2.62±	2.16	45.9±	9.9	38.7±	8.0	13.6±	10.4	1.6±	0.5	0.2±	0.3
8 mg/m3	41	2.45±	1.60	50.9±	10.1	35.1±	8.1	11.9±	6.6	1.9±	0.7	0.2±	0.3

Significant difference ; \* : P ≤ 0.05

\*\* : P ≤ 0.01

Test of Dunnett

TABLE H1

BIOCHEMISTRY : MALE

(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS (105W)

REPORT TYPE : A4

PAGE : 1

Group Name	NO. of Animals	TOTAL PROTEIN g / √		ALBUMIN g / √		A/G RATIO		T-BILIRUBIN mg / √		GLUCOSE mg / √		T-CHOLESTEROL mg / √		TRIGLYCERIDE mg / √	
Control	30	6.5±	0.2	2.8±	0.2	0.8±	0.1	0.13±	0.14	166±	31	165±	32	77±	34
0.5 mg/m3	32	6.4±	0.3	2.7±	0.2	0.7±	0.1	0.08±	0.06*	176±	25	150±	36	65±	34
2 mg/m3	27	6.4±	0.4	2.8±	0.3	0.8±	0.1	0.34±	1.34	179±	28	167±	28	74±	38
8 mg/m3	37	6.4±	0.4	2.8±	0.2	0.8±	0.1	0.12±	0.12	171±	27	170±	54	84±	61

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS (105W)

REPORT TYPE : A4

Group Name	NO. of Animals	PHOSPHOLIPID		AST		ALT		LDH		ALP		G-GTP		CK	
		mg/✓		U/L		U/L		U/L		U/L	U/L		U/L		
Control	30	238±	37	119±	139	42±	34	182±	123	341±	111	10.7±	5.6	123±	27
0.5 mg/m3	32	221±	48	84±	27	32±	9	151±	40	351±	133	9.2±	7.5	128±	19
2 mg/m3	27	244±	57	106±	100	37±	21	166±	59	307±	118	7.7±	3.3	148±	142
8 mg/m3	37	242±	72	101±	55	38±	22	150±	27	309±	93	10.7±	7.0	135±	53

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS (105W)

REPORT TYPE : A4

Group Name	NO. of Animals	UREA NITROGEN		CREATININE		SODIUM		POTASSIUM		CHLORIDE		CALCIUM		INORGANIC PHOSPHORUS	
		mg/∇		mg/∇		mEq/ℓ		mEq/ℓ		mEq/ℓ		mg/∇		mg/∇	
Control	30	16.9±	2.1	0.37±	0.04	142±	1	3.7±	0.3	106±	2	10.2±	0.3	3.8±	0.7
0.5 mg/m3	32	17.7±	2.8	0.38±	0.04	142±	1	3.8±	0.3	108±	2**	10.1±	0.3	3.6±	0.6
2 mg/m3	27	18.7±	4.0	0.37±	0.04	142±	1	3.7±	0.3	107±	1	10.2±	0.2	3.8±	0.6
8 mg/m3	37	17.8±	2.9	0.38±	0.07	142±	1	3.7±	0.3	108±	2*	10.3±	0.3	3.8±	0.6

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

**TABLE H2**

**BIOCHEMISTRY : FEMALE  
(CARCINOGENICITY STUDY GROUPS)**

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]  
 MEASURE. TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS (105W)

REPORT TYPE : A4

Group Name	NO. of Animals	TOTAL PROTEIN g/dl		ALBUMIN g/dl		A/G RATIO		T-BILIRUBIN mg/dl		GLUCOSE mg/dl		T-CHOLESTEROL mg/dl		TRIGLYCERIDE mg/dl	
Control	42	6.7±	0.3	3.4±	0.3	1.0±	0.2	0.08±	0.11	163±	25	140±	34	78±	59
0.5 mg/m3	42	6.8±	0.5	3.3±	0.4	1.0±	0.1*	0.07±	0.08	161±	22	132±	22	49±	17**
2 mg/m3	31	6.9±	0.5	3.4±	0.3	1.0±	0.1*	0.23±	0.94	157±	26	144±	33	57±	38**
8 mg/m3	44	6.9±	0.4	3.5±	0.3	1.0±	0.1	0.06±	0.05	161±	21	142±	32	50±	23**

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj[F344/DuCrj]  
 MEASURE TIME : 1  
 SEX : FEMALE REPORT TYPE : A4

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS (105W)

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl		AST U/L		ALT U/L		LDH U/L		ALP U/L		G-GTP U/L		CK U/L	
Control	42	248±	51	158±	119	61±	42	186±	78	224±	117	3.4±	2.4	160±	326
0.5 mg/m3	42	233±	37	130±	83	51±	28	181±	64	216±	90	2.7±	2.0	129±	45*
2 mg/m3	31	255±	66	174±	216	54±	22	246±	291	219±	96	3.1±	2.6	133±	45**
8 mg/m3	44	251±	57	145±	96	52±	19	212±	109	191±	50	2.2±	1.2	120±	24

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]  
 MEASURE TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS (105W)

REPORT TYPE : A4

PAGE : 6

Group Name	NO. of Animals	UREA NITROGEN mg/dℓ		CREATININE mg/dℓ		SODIUM mEq/ℓ		POTASSIUM mEq/ℓ		CHLORIDE mEq/ℓ		CALCIUM mg/dℓ		INORGANIC PHOSPHORUS mg/dℓ	
Control	42	17.2±	3.2	0.31±	0.03	141±	1	3.6±	0.5	104±	2	10.4±	0.2	3.8±	0.6
0.5 mg/m3	42	17.9±	4.6	0.33±	0.05**	142±	2	3.4±	0.4	107±	2**	10.3±	0.3	3.3±	0.8**
2 mg/m3	31	17.7±	4.5	0.33±	0.04*	142±	2	3.4±	0.3	105±	2	10.4±	0.3	3.8±	0.9
8 mg/m3	44	16.9±	2.3	0.32±	0.03	141±	2	3.4±	0.3	105±	2	10.4±	0.4	3.6±	0.7

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

TABLE I1

GROSS FINDINGS : MALE  
(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : A4  
SEX : MALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control			
			50 (%)	0.5 mg/m3 (%)	2 mg/m3 (%)	8 mg/m3 (%)
skin/app	nodule		3 ( 6)	2 ( 4)	2 ( 4)	1 ( 2)
subcutis	jaundice		5 ( 10)	3 ( 6)	5 ( 10)	0 ( 0)
	mass		8 ( 16)	4 ( 8)	5 ( 10)	10 ( 20)
lung	red		0 ( 0)	1 ( 2)	1 ( 2)	2 ( 4)
	white zone		1 ( 2)	41 ( 82)	50 (100)	50 (100)
	red zone		0 ( 0)	1 ( 2)	1 ( 2)	0 ( 0)
	black zone		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
	nodule		3 ( 6)	4 ( 8)	4 ( 8)	6 ( 12)
	adhesion		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
	voluminous		0 ( 0)	1 ( 2)	0 ( 0)	2 ( 4)
lymph node	enlarged		2 ( 4)	6 ( 12)	4 ( 8)	1 ( 2)
	white		0 ( 0)	0 ( 0)	2 ( 4)	20 ( 40)
	red		1 ( 2)	0 ( 0)	0 ( 0)	1 ( 2)
thymus	enlarged		1 ( 2)	2 ( 4)	1 ( 2)	0 ( 0)
spleen	enlarged		17 ( 34)	17 ( 34)	15 ( 30)	9 ( 18)
	white zone		0 ( 0)	1 ( 2)	2 ( 4)	1 ( 2)
	nodule		1 ( 2)	0 ( 0)	1 ( 2)	1 ( 2)
	deformed		1 ( 2)	0 ( 0)	0 ( 0)	1 ( 2)
heart	white zone		3 ( 6)	1 ( 2)	0 ( 0)	1 ( 2)
	hypertrophy		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
tongue	nodule		1 ( 2)	1 ( 2)	0 ( 0)	0 ( 0)
stomach	adhesion		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : A4  
SEX : MALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control			
			50 (%)	50 (%)	2 mg/m3 (%)	8 mg/m3 (%)
stomach	gas		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
	forestomach:ulcer		3 ( 6)	0 ( 0)	2 ( 4)	1 ( 2)
	forestomach:erosion		0 ( 0)	1 ( 2)	1 ( 2)	0 ( 0)
	forestomach:nodule		0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)
	forestomach:thick		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
	glandular stomach:ulcer		0 ( 0)	0 ( 0)	1 ( 2)	1 ( 2)
	glandular stomach:erosion		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	glandular stomach:nodule		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
	glandular stomach:black zone		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
glandular stomach:thick		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	
duodenum	nodule		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
small intes	red zone		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
cecum	nodule		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
liver	enlarged		9 ( 18)	8 ( 16)	3 ( 6)	6 ( 12)
	white zone		0 ( 0)	0 ( 0)	1 ( 2)	2 ( 4)
	nodule		2 ( 4)	0 ( 0)	2 ( 4)	1 ( 2)
	rough		9 ( 18)	10 ( 20)	5 ( 10)	2 ( 4)
	granular		1 ( 2)	0 ( 0)	1 ( 2)	0 ( 0)
	herniation		4 ( 8)	5 ( 10)	8 ( 16)	5 ( 10)
pancreas	nodule		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
kidney	white zone		2 ( 4)	0 ( 0)	2 ( 4)	1 ( 2)
	brown zone		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)



STUDY NO. : 0883  
ANIMAL : RAT F344/DuCrI CrI j [F344/DuCr j]  
REPORT TYPE : A4  
SEX : MALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control			
			50 (%)	50 (%)	2 mg/m3 (%)	8 mg/m3 (%)
kidney	nodule		0 ( 0)	0 ( 0)	2 ( 4)	1 ( 2)
	granular		1 ( 2)	1 ( 2)	0 ( 0)	6 ( 12)
urin bladd	calculus		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
	thick		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
	urine:marked retention		2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
pituitary	enlarged		6 ( 12)	4 ( 8)	4 ( 8)	8 ( 16)
	red		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
	red zone		4 ( 8)	3 ( 6)	4 ( 8)	2 ( 4)
	nodule		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
	cyst		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
thyroid	enlarged		0 ( 0)	1 ( 2)	1 ( 2)	1 ( 2)
	nodule		2 ( 4)	3 ( 6)	4 ( 8)	6 ( 12)
adrenal	enlarged		1 ( 2)	0 ( 0)	1 ( 2)	1 ( 2)
	nodule		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
testis	nodule		34 ( 68)	39 ( 78)	38 ( 76)	36 ( 72)
brain	enlarged		0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)
	red zone		0 ( 0)	2 ( 4)	1 ( 2)	1 ( 2)
	brown zone		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
spinal cord	red zone		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
eye	white		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
Zymbal gl	nodule		1 ( 2)	2 ( 4)	3 ( 6)	0 ( 0)
muscle	nodule		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : A4  
SEX : MALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control			
			50 (%)	50 (%)	2 mg/m3 (%)	8 mg/m3 (%)
bone	nodule		0 ( 0)	0 ( 0)	1 ( 2)	1 ( 2)
pleura	nodule		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
mediastinum	mass		1 ( 2)	0 ( 0)	0 ( 0)	2 ( 4)
peritoneum	nodule		3 ( 6)	1 ( 2)	2 ( 4)	2 ( 4)
	adhesion		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	thick		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
abdominal c	ascites		1 ( 2)	2 ( 4)	3 ( 6)	4 ( 8)
thoracic ca	pleural fluid		6 ( 12)	7 ( 14)	5 ( 10)	5 ( 10)
other	hindlimb:nodule		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
	lower jaw:nodule		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
	bulbourethral gland:nodule		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
whole body	anemic		0 ( 0)	1 ( 2)	2 ( 4)	0 ( 0)

**TABLE I2**

**GROSS FINDINGS : FEMALE  
(CARCINOGENICITY STUDY GROUPS)**

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : A4  
SEX : FEMALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control			
			50 (%)	50 (%)	2 mg/m3 (%)	8 mg/m3 (%)
skin/app	nodule		0 ( 0)	1 ( 2)	1 ( 2)	0 ( 0)
	scab		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
subcutis	red zone		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
	jaundice		2 ( 4)	1 ( 2)	4 ( 8)	1 ( 2)
	mass		5 ( 10)	9 ( 18)	3 ( 6)	9 ( 18)
	abscess		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
	lung	white zone		2 ( 4)	47 ( 94)	50 (100)
lung	red zone		0 ( 0)	0 ( 0)	1 ( 2)	1 ( 2)
	brown zone		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	nodule		0 ( 0)	2 ( 4)	3 ( 6)	1 ( 2)
	lymph node	enlarged		3 ( 6)	0 ( 0)	2 ( 4)
lymph node	white		0 ( 0)	0 ( 0)	1 ( 2)	14 ( 28)
	red		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
	thymus	enlarged		0 ( 0)	0 ( 0)	1 ( 2)
spleen	enlarged		9 ( 18)	5 ( 10)	10 ( 20)	5 ( 10)
	white zone		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	nodule		0 ( 0)	0 ( 0)	1 ( 2)	1 ( 2)
oral cavity	food		1 ( 2)	1 ( 2)	0 ( 0)	0 ( 0)
tongue	nodule		1 ( 2)	0 ( 0)	0 ( 0)	1 ( 2)
stomach	forestomach:ulcer		1 ( 2)	0 ( 0)	1 ( 2)	0 ( 0)
	glandular stomach:ulcer		1 ( 2)	0 ( 0)	1 ( 2)	1 ( 2)
	glandular stomach:black zone		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : A4  
SEX : FEMALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control			
			50 (%)	0.5 mg/m3 (%)	2 mg/m3 (%)	8 mg/m3 (%)
stomach	glandular stomach:red zone		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
	glandular stomach:thick		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
large intes	nodule		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
liver	enlarged		1 ( 2)	0 ( 0)	4 ( 8)	0 ( 0)
	white zone		1 ( 2)	0 ( 0)	2 ( 4)	0 ( 0)
	red zone		0 ( 0)	0 ( 0)	1 ( 2)	1 ( 2)
	nodule		1 ( 2)	1 ( 2)	1 ( 2)	2 ( 4)
	rough		5 ( 10)	4 ( 8)	5 ( 10)	2 ( 4)
	nodular		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
	herniation		6 ( 12)	12 ( 24)	5 ( 10)	7 ( 14)
	kidney	white zone		0 ( 0)	0 ( 0)	0 ( 0)
	brown zone		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	granular		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
urin bladd	nodule		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	urine:marked retention		0 ( 0)	1 ( 2)	0 ( 0)	1 ( 2)
pituitary	enlarged		8 ( 16)	10 ( 20)	11 ( 22)	12 ( 24)
	red zone		2 ( 4)	9 ( 18)	10 ( 20)	3 ( 6)
	nodule		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
thyroid	white zone		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
	nodule		0 ( 0)	5 ( 10)	2 ( 4)	0 ( 0)
adrenal	enlarged		2 ( 4)	1 ( 2)	0 ( 0)	0 ( 0)
ovary	cyst		2 ( 4)	2 ( 4)	1 ( 2)	1 ( 2)

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : A4  
SEX : FEMALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	Control			
			50 (%)	50 (%)	2 mg/m3 (%)	8 mg/m3 (%)
uterus	nodule		6 ( 12)	8 ( 16)	3 ( 6)	6 ( 12)
	cyst		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	adhesion		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
	dilated lumen		0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)
mammary gl	nodule		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
brain	red zone		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
	black zone		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
spinal cord	black zone		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
eye	white		2 ( 4)	4 ( 8)	1 ( 2)	2 ( 4)
Harder gl	red		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
Zymbal gl	nodule		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
muscle	nodule		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
bone	fracture		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
pleura	nodule		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
mediastinum	mass		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
peritoneum	nodule		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
	thick		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)
retroperit	nodule		0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
abdominal c	ascites		0 ( 0)	0 ( 0)	1 ( 2)	1 ( 2)
thoracic ca	hemorrhage		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)
	pleural fluid		1 ( 2)	0 ( 0)	2 ( 4)	1 ( 2)
other	fluid:red		0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : A4  
SEX : FEMALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0-105W)

---

Organ	Findings	Group Name NO. of Animals	Control			
			50 (%)	0.5 mg/m3 50 (%)	2 mg/m3 50 (%)	8 mg/m3 50 (%)
whole body	anemic		0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)

---

TABLE I3

GROSS FINDINGS : MALE

(SATELLITE 52w)



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A1  
 SEX : MALE

GROSS FINDINGS (SUMMARY)  
 ALL ANIMALS (0- 53W)

Organ	Findings	Group Name NO. of Animals	S-Control 3 (%)	S-0.5 mg/m3 3 (%)	S-2 mg/m3 3 (%)	S-8 mg/m3 4 (%)
lung	white zone		0 ( 0)	2 ( 67)	3 (100)	4 (100)
lymph node	white		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)
liver	herniation		1 ( 33)	0 ( 0)	0 ( 0)	1 ( 25)
eye	white		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)
other	nose:nodule		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)

TABLE I4

GROSS FINDINGS : FEMALE

(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A1  
 SEX : FEMALE

GROSS FINDINGS (SUMMARY)  
 ALL ANIMALS (0- 53W)

Organ	Findings	Group Name NO. of Animals	S-Control 3 (%)	S-0.5 mg/m3 3 (%)	S-2 mg/m3 3 (%)	S-8 mg/m3 3 (%)
lung	white zone		0 ( 0)	3 (100)	3 (100)	3 (100)
lymph node	white		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)
liver	herniation		1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)
pituitary	red zone		1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)
eye	white		1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)

TABLE I5

GROSS FINDINGS : MALE

(SATELLITE 52w+26w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A2  
 SEX : MALE

GROSS FINDINGS (SUMMARY)  
 ALL ANIMALS (0- 79W)

Organ	Findings	Group Name NO. of Animals	S-Control	S-0.5 mg/m3	S-2 mg/m3	S-8 mg/m3
			4 (%)	3 (%)	4 (%)	3 (%)
skin/app	nodule		0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)
subcutis	mass		0 ( 0)	0 ( 0)	1 ( 25)	1 ( 33)
lung	white zone		0 ( 0)	0 ( 0)	4 (100)	3 (100)
lymph node	enlarged		1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)
	white		0 ( 0)	0 ( 0)	0 ( 0)	2 ( 67)
spleen	enlarged		1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)
liver	herniation		0 ( 0)	0 ( 0)	2 ( 50)	0 ( 0)
testis	nodule		0 ( 0)	1 ( 33)	0 ( 0)	1 ( 33)
pleura	nodule		1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)
peritoneum	nodule		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)
thoracic ca	pleural fluid		0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)

TABLE I6

GROSS FINDINGS : FEMALE

(SATELLITE 52w+26w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A2  
 SEX : FEMALE

GROSS FINDINGS (SUMMARY)  
 ALL ANIMALS (0- 79W)

Organ	Findings	Group Name NO. of Animals	S-Control 3 (%)	S-0.5 mg/m3 3 (%)	S-2 mg/m3 3 (%)	S-8 mg/m3 3 (%)
lung	white zone		0 ( 0)	0 ( 0)	3 (100)	3 (100)
	nodule		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)
liver	herniation		0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)
pituitary	red zone		1 ( 33)	0 ( 0)	0 ( 0)	1 ( 33)

TABLE I7

GROSS FINDINGS : MALE

(SATELLITE 52w+52w)



STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : A3  
SEX : MALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0-104W)

Organ	Findings	Group Name NO. of Animals	S-Control	S-0.5 mg/m3	S-2 mg/m3	S-8 mg/m3
			3 (%)	4 (%)	3 (%)	3 (%)
subcutis	jaundice		1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)
	mass		1 ( 33)	0 ( 0)	0 ( 0)	1 ( 33)
lung	white zone		0 ( 0)	2 ( 50)	3 (100)	3 (100)
lymph node	enlarged		0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)
spleen	enlarged		1 ( 33)	1 ( 25)	1 ( 33)	1 ( 33)
tongue	nodule		1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)
liver	enlarged		1 ( 33)	1 ( 25)	1 ( 33)	0 ( 0)
	rough		1 ( 33)	1 ( 25)	1 ( 33)	1 ( 33)
	herniation		0 ( 0)	1 ( 25)	1 ( 33)	0 ( 0)
kidney	enlarged		0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)
pituitary	enlarged		1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)
thyroid	nodule		1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)
testis	nodule		2 ( 67)	3 ( 75)	2 ( 67)	2 ( 67)
thoracic ca	pleural fluid		0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)
whole body	anemic		0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)

TABLE I8

GROSS FINDINGS : FEMALE

(SATELLITE 52w+52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : FEMALE

GROSS FINDINGS (SUMMARY)  
 ALL ANIMALS (0-104W)

Organ	Findings	Group Name NO. of Animals	S-Control	S-0.5 mg/m3	S-2 mg/m3	S-8 mg/m3
			4 (%)	4 (%)	4 (%)	4 (%)
skin/app	scab		0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)
subcutis	mass		0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)
lung	white zone		0 ( 0)	3 ( 75)	4 (100)	4 (100)
	nodule		0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)
	voluminous		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)
spleen	enlarged		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)
oral cavity	food		1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)
liver	rough		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)
	herniation		1 ( 25)	0 ( 0)	0 ( 0)	1 ( 25)
pituitary	enlarged		0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)
	red zone		1 ( 25)	0 ( 0)	2 ( 50)	0 ( 0)
uterus	nodule		2 ( 50)	1 ( 25)	0 ( 0)	0 ( 0)
thoracic ca	pleural fluid		0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)

TABLE J1

ORGAN WEIGHT, ABSOLUTE : MALE  
(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight		ADRENALS		TESTES		HEART		LUNGS		KIDNEYS	
Control	30	390±	26	0.073±	0.012	3.847±	2.007	1.182±	0.100	1.415±	0.378	2.591±	0.166
0.5 mg/m3	32	361±	25**	0.070±	0.010	3.486±	2.143	1.172±	0.072	1.367±	0.251	2.568±	0.260
2 mg/m3	27	371±	29	0.077±	0.040	3.880±	1.488	1.156±	0.074	1.397±	0.326	2.553±	0.150
8 mg/m3	37	387±	47	0.080±	0.049	3.561±	1.167	1.164±	0.113	1.523±	0.194**	2.616±	0.252

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$     Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
Control	30	1.474±	1.286	10.769±	1.225	2.075±	0.040
0.5 mg/m3	32	1.307±	1.186	10.573±	1.803	2.068±	0.036
2 mg/m3	27	1.237±	0.770	10.365±	0.955	2.082±	0.030
8 mg/m3	37	1.459±	0.921	11.061±	1.799	2.076±	0.052

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

**TABLE J2**

**ORGAN WEIGHT, ABSOLUTE : FEMALE  
(CARCINOGENICITY STUDY GROUPS)**

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight		ADRENALS		OVARIES		HEART		LUNGS		KIDNEYS	
Control	42	262±	23	0.093±	0.114	0.164±	0.187	0.846±	0.065	0.982±	0.186	1.704±	0.135
0.5 mg/m3	43	244±	26**	0.069±	0.019**	0.142±	0.085	0.825±	0.067	0.935±	0.157	1.676±	0.134
2 mg/m3	31	240±	25**	0.067±	0.009*	0.123±	0.015	0.826±	0.054	0.992±	0.503	1.672±	0.126
8 mg/m3	44	257±	24	0.069±	0.010	0.127±	0.041	0.850±	0.063	1.107±	0.149**	1.696±	0.146

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett



STUDY NO. : 0883  
ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
REPORT TYPE : A4  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
SURVIVAL ANIMALS (105W)

PAGE : 4

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
Control	42	1.147±	2.664	6.775±	1.989	1.890±	0.041
0.5 mg/m3	43	0.878±	1.277	6.324±	1.181	1.883±	0.037
2 mg/m3	31	0.861±	1.438	6.373±	1.120	1.879±	0.036
8 mg/m3	44	0.928±	1.453	6.442±	1.099	1.885±	0.035

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

(HCL040)

BAIS 6

TABLE J3

ORGAN WEIGHT, ABSOLUTE : MALE

(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 53W)

Group Name	NO. of Animals	Body Weight		ADRENALS		TESTES		HEART		LUNGS		KIDNEYS	
S-Control	3	381±	5	0.053±	0.002	3.091±	0.138	1.006±	0.059	1.129±	0.034	2.034±	0.033
S-0.5 mg/m3	3	400±	20	0.055±	0.006	2.392±	0.609	1.078±	0.030	1.178±	0.038	2.252±	0.113
S-2 mg/m3	3	393±	13	0.054±	0.002	3.209±	0.087	1.068±	0.008	1.141±	0.063	2.245±	0.135
S-8 mg/m3	3	412±	23	0.052±	0.007	2.943±	0.436	1.142±	0.073	1.221±	0.072	2.269±	0.130

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 53W)

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
S-Control	3	0.709±	0.048	9.662±	0.509	2.036±	0.043
S-0.5 mg/m3	3	0.783±	0.087	10.647±	0.454	2.014±	0.043
S-2 mg/m3	3	0.745±	0.054	9.964±	0.364	1.993±	0.072
S-8 mg/m3	3	0.773±	0.048	10.641±	1.521	2.020±	0.022

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

TABLE J4

ORGAN WEIGHT, ABSOLUTE : FEMALE

(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A1  
 SEX : FEMALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 53W)

Group Name	NO. of Animals	Body Weight		ADRENALS		OVARIES		HEART		LUNGS		KIDNEYS	
S-Control	3	214±	4	0.063±	0.009	0.128±	0.027	0.685±	0.028	0.839±	0.023	1.392±	0.071
S-0.5 mg/m3	3	202±	6	0.061±	0.002	0.105±	0.005	0.678±	0.032	0.794±	0.025	1.375±	0.024
S-2 mg/m3	3	206±	21	0.057±	0.005	0.122±	0.016	0.659±	0.052	0.807±	0.032	1.381±	0.118
S-8 mg/m3	3	215±	13	0.062±	0.012	0.103±	0.018	0.742±	0.032	0.911±	0.034*	1.441±	0.043

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A1  
 SEX : FEMALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 53W)

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
S-Control	3	0.416±	0.011	4.985±	0.082	1.846±	0.027
S-0.5 mg/m3	3	0.399±	0.028	4.749±	0.191	1.821±	0.023
S-2 mg/m3	3	0.400±	0.050	4.814±	0.642	1.864±	0.022
S-8 mg/m3	3	0.435±	0.020	5.370±	0.117	1.870±	0.038

Significant difference : \* : P ≤ 0.05      \*\* : P ≤ 0.01      Test of Dunnett

TABLE J5

ORGAN WEIGHT, ABSOLUTE : MALE

(SATELLITE 52w+26w)



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A2  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 79W)

Group Name	NO. of Animals	Body Weight		ADRENALS		TESTES		HEART		LUNGS		KIDNEYS	
S-Control	3	413±	7	0.068±	0.006	2.681±	0.375	1.186±	0.038	1.355±	0.180	2.724±	0.216
S-0.5 mg/m3	3	375±	6	0.068±	0.006	2.789±	0.644	1.173±	0.036	1.301±	0.059	2.474±	0.011
S-2 mg/m3	3	385±	17	0.066±	0.002	2.915±	0.231	1.120±	0.033	1.361±	0.048	2.642±	0.110
S-8 mg/m3	3	391±	28	0.073±	0.003	2.582±	0.210	1.155±	0.038	1.330±	0.055	2.733±	0.251

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A2  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 79W)

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
S-Control	3	1.344±	0.897	11.396±	0.206	1.984±	0.028
S-0.5 mg/m3	3	0.746±	0.102	9.434±	0.498*	1.993±	0.055
S-2 mg/m3	3	0.850±	0.088	10.663±	1.029	2.024±	0.014
S-8 mg/m3	3	0.826±	0.111	11.203±	0.823	2.006±	0.047

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

TABLE J6

ORGAN WEIGHT, ABSOLUTE : FEMALE

(SATELLITE 52w+26w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A2  
 SEX : FEMALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 79W)

Group Name	NO. of Animals	Body Weight		ADRENALS		OVARIES		HEART		LUNGS		KIDNEYS	
S-Control	3	245±	6	0.079±	0.008	0.114±	0.021	0.785±	0.041	0.873±	0.050	1.622±	0.068
S-0.5 mg/m3	3	249±	15	0.073±	0.009	0.129±	0.010	0.808±	0.053	0.942±	0.038	1.664±	0.022
S-2 mg/m3	3	241±	25	0.079±	0.010	0.116±	0.010	0.782±	0.054	0.931±	0.044	1.708±	0.162
S-8 mg/m3	3	245±	12	0.082±	0.004	0.125±	0.006	0.778±	0.085	0.933±	0.098	1.629±	0.164

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
REPORT TYPE : A2  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
SURVIVAL ANIMALS ( 79W)

PAGE : 4

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
S-Control	3	0.432±	0.049	5.616±	0.329	1.801±	0.014
S-0.5 mg/m3	3	0.521±	0.071	5.697±	0.428	1.793±	0.067
S-2 mg/m3	3	0.600±	0.229	5.955±	0.943	1.802±	0.054
S-8 mg/m3	3	0.525±	0.168	5.663±	0.339	1.815±	0.079

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

(HCL040)

BAIS 6

TABLE J7

ORGAN WEIGHT, ABSOLUTE : MALE

(SATELLITE 52w+52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS (104W)

Group Name	NO. of Animals	Body Weight	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
S-Control	1	414	-	-	-	1.468	2.905
S-0.5 mg/m3	3	401± 35	-	-	-	1.337± 0.040	2.474± 0.114
S-2 mg/m3	2	412± 27 ?	-	-	-	1.264± 0.001 ?	2.533± 0.005 ?
S-8 mg/m3	3	404± 44	-	-	-	1.565± 0.288	2.785± 0.196

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

? : Significant test is not applied, because No. of data in this group is less than 3.

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS (104W)

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
S-Control	1	0.889		14.368		2.068	
S-0.5 mg/m3	3	0.962±	0.184	12.205±	0.996	2.043±	0.018
S-2 mg/m3	2	1.041±	0.079 ?	12.375±	0.749 ?	2.090±	0.001 ?
S-8 mg/m3	3	2.415±	2.104	14.583±	1.506	2.043±	0.027

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

? : Significant test is not applied, because No. of data in this group is less than 3.



TABLE J8

ORGAN WEIGHT, ABSOLUTE : FEMALE

(SATELLITE 52w+52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : FEMALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS (104W)

Group Name	NO. of Animals	Body Weight	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
S-Control	2	272± 35	-	-	-	0.964± 0.046	1.741± 0.050
S-0.5 mg/m3	4	278± 31	-	-	-	0.891± 0.012	1.856± 0.252
S-2 mg/m3	3	270± 17	-	-	-	0.867± 0.064	1.770± 0.102
S-8 mg/m3	3	270± 12	-	-	-	0.898± 0.042	1.771± 0.018

Significant difference : \* : P ≤ 0.05    \*\* : P ≤ 0.01    Test of Dunnett

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
REPORT TYPE : A3  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
SURVIVAL ANIMALS (104W)

PAGE : 4

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
S-Control	2	1.030±	0.235	9.016±	2.036	1.846±	0.008
S-0.5 mg/m3	4	0.618±	0.102**	8.738±	0.843	1.867±	0.070
S-2 mg/m3	3	0.504±	0.019**	7.502±	0.781	1.900±	0.059
S-8 mg/m3	3	0.637±	0.107*	8.352±	0.790	1.876±	0.028

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

(HCL040)

BAIS 6

TABLE K1

ORGAN WEIGHT, RELATIVE : MALE  
(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE  
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
 SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	30	390± 26	0.019± 0.003	0.996± 0.537	0.304± 0.028	0.364± 0.110	0.666± 0.044
0.5 mg/m3	32	361± 25**	0.019± 0.003	0.960± 0.568	0.326± 0.029*	0.381± 0.088*	0.715± 0.094*
2 mg/m3	27	371± 29	0.021± 0.011	1.046± 0.406	0.314± 0.042	0.387± 0.153	0.692± 0.064
8 mg/m3	37	387± 47	0.021± 0.013	0.938± 0.326	0.303± 0.032	0.395± 0.068**	0.684± 0.089

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : A4  
SEX : MALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	30	0.387 ± 0.359	2.770 ± 0.346	0.534 ± 0.034
0.5 mg/m3	32	0.367 ± 0.353	2.939 ± 0.553	0.576 ± 0.042**
2 mg/m3	27	0.349 ± 0.284	2.808 ± 0.316	0.565 ± 0.050*
8 mg/m3	37	0.384 ± 0.247	2.866 ± 0.373	0.545 ± 0.074

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

TABLE K2

ORGAN WEIGHT, RELATIVE : FEMALE  
(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE  
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
 SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	42	262 ± 23	0.036 ± 0.044	0.061 ± 0.058	0.324 ± 0.030	0.382 ± 0.087	0.653 ± 0.069
0.5 mg/m3	43	244 ± 26**	0.029 ± 0.009	0.058 ± 0.036	0.341 ± 0.045*	0.387 ± 0.077	0.696 ± 0.111*
2 mg/m3	31	240 ± 25**	0.029 ± 0.007	0.051 ± 0.006	0.347 ± 0.044**	0.430 ± 0.281	0.705 ± 0.112**
8 mg/m3	44	257 ± 24	0.027 ± 0.004	0.050 ± 0.020	0.333 ± 0.029	0.434 ± 0.079**	0.664 ± 0.063

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett



STUDY NO. : 0883  
ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
REPORT TYPE : A4  
SEX : FEMALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	42	0.458 ± 1.114	2.602 ± 0.814	0.726 ± 0.066
0.5 mg/m3	43	0.354 ± 0.479	2.609 ± 0.498	0.782 ± 0.106**
2 mg/m3	31	0.391 ± 0.752	2.680 ± 0.580	0.792 ± 0.107**
8 mg/m3	44	0.383 ± 0.657	2.519 ± 0.408	0.741 ± 0.067

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

TABLE K3

ORGAN WEIGHT, RELATIVE : MALE

(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
 SURVIVAL ANIMALS ( 53W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
S-Control	3	381± 5	0.014± 0.001	0.811± 0.035	0.264± 0.014	0.296± 0.009	0.533± 0.006
S-0.5 mg/m3	3	400± 20	0.014± 0.002	0.603± 0.176	0.270± 0.006	0.295± 0.005	0.564± 0.038
S-2 mg/m3	3	393± 13	0.014± 0.001	0.818± 0.048	0.272± 0.007	0.291± 0.025	0.572± 0.024
S-8 mg/m3	3	412± 23	0.013± 0.001	0.720± 0.142	0.277± 0.012	0.297± 0.010	0.551± 0.017

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
REPORT TYPE : A1  
SEX : MALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 53W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
S-Control	3	0.186 ± 0.011	2.533 ± 0.101	0.534 ± 0.013
S-0.5 mg/m3	3	0.195 ± 0.017	2.662 ± 0.023	0.505 ± 0.033
S-2 mg/m3	3	0.190 ± 0.019	2.539 ± 0.113	0.508 ± 0.034
S-8 mg/m3	3	0.188 ± 0.014	2.575 ± 0.226	0.491 ± 0.023

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

TABLE K4

ORGAN WEIGHT, RELATIVE : FEMALE

(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A1  
 SEX : FEMALE  
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
 SURVIVAL ANIMALS ( 53W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
S-Control	3	214± 4	0.030± 0.005	0.060± 0.014	0.320± 0.018	0.392± 0.017	0.650± 0.038
S-0.5 mg/m3	3	202± 6	0.030± 0.002	0.052± 0.003	0.335± 0.010	0.394± 0.023	0.681± 0.029
S-2 mg/m3	3	206± 21	0.028± 0.001	0.060± 0.006	0.321± 0.007	0.394± 0.031	0.673± 0.039
S-8 mg/m3	3	215± 13	0.029± 0.005	0.048± 0.006	0.346± 0.019	0.424± 0.012	0.672± 0.043

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 53W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
S-Control	3	0.194 ± 0.009	2.327 ± 0.081	0.862 ± 0.027
S-0.5 mg/m3	3	0.198 ± 0.012	2.351 ± 0.065	0.902 ± 0.025
S-2 mg/m3	3	0.195 ± 0.014	2.337 ± 0.117	0.912 ± 0.082
S-8 mg/m3	3	0.203 ± 0.020	2.505 ± 0.180	0.872 ± 0.058

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

TABLE K5

ORGAN WEIGHT, RELATIVE : MALE

(SATELLITE 52w+26w)



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A2  
 SEX : MALE  
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
 SURVIVAL ANIMALS ( 79W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
S-Control	3	413± 7	0.016± 0.002	0.651± 0.101	0.287± 0.008	0.328± 0.038	0.660± 0.044
S-0.5 mg/m3	3	375± 6	0.018± 0.002	0.746± 0.181	0.313± 0.006*	0.347± 0.015	0.660± 0.012
S-2 mg/m3	3	385± 17	0.017± 0.001	0.759± 0.070	0.291± 0.008	0.354± 0.007	0.687± 0.003
S-8 mg/m3	3	391± 28	0.019± 0.002	0.660± 0.021	0.296± 0.011	0.341± 0.020	0.704± 0.114

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
REPORT TYPE : A2  
SEX : MALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 79W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
S-Control	3	0.324 ± 0.211	2.761 ± 0.042	0.481 ± 0.010
S-0.5 mg/m3	3	0.199 ± 0.028	2.517 ± 0.155	0.531 ± 0.009*
S-2 mg/m3	3	0.221 ± 0.019	2.768 ± 0.150	0.527 ± 0.020*
S-8 mg/m3	3	0.211 ± 0.017	2.877 ± 0.330	0.514 ± 0.025

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

TABLE K6

ORGAN WEIGHT, RELATIVE : FEMALE

(SATELLITE 52w+26w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A2  
 SEX : FEMALE  
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
 SURVIVAL ANIMALS ( 79W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
S-Control	3	245 ± 6	0.032 ± 0.003	0.047 ± 0.007	0.321 ± 0.010	0.357 ± 0.014	0.663 ± 0.028
S-0.5 mg/m3	3	249 ± 15	0.029 ± 0.004	0.052 ± 0.004	0.325 ± 0.008	0.379 ± 0.020	0.671 ± 0.046
S-2 mg/m3	3	241 ± 25	0.033 ± 0.005	0.048 ± 0.005	0.326 ± 0.021	0.388 ± 0.025	0.709 ± 0.020
S-8 mg/m3	3	245 ± 12	0.033 ± 0.001	0.051 ± 0.000	0.317 ± 0.021	0.380 ± 0.022	0.663 ± 0.035

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
REPORT TYPE : A2  
SEX : FEMALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 79W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
S-Control	3	0.176 ± 0.017	2.294 ± 0.090	0.736 ± 0.022
S-0.5 mg/m3	3	0.210 ± 0.030	2.290 ± 0.046	0.722 ± 0.023
S-2 mg/m3	3	0.245 ± 0.065	2.462 ± 0.129	0.751 ± 0.053
S-8 mg/m3	3	0.212 ± 0.059	2.308 ± 0.033	0.740 ± 0.022

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

TABLE K7

ORGAN WEIGHT, RELATIVE : MALE

(SATELLITE 52w+52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : MALE  
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
 SURVIVAL ANIMALS (104W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
S-Control	1	414	-	-	-	0.355	0.702
S-0.5 mg/m3	3	401± 35	-	-	-	0.335± 0.024	0.619± 0.037
S-2 mg/m3	2	412± 27 ?	-	-	-	0.308± 0.021 ?	0.616± 0.040 ?
S-8 mg/m3	3	404± 44	-	-	-	0.394± 0.107	0.692± 0.061

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

? : Significant test is not applied, because No. of data in this group is less than 3.

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : MALE  
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
 SURVIVAL ANIMALS (104W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
S-Control	1	0.215	3.471	0.500
S-0.5 mg/m3	3	0.239 ± 0.027	3.045 ± 0.047	0.512 ± 0.047
S-2 mg/m3	2	0.253 ± 0.003 ?	3.004 ± 0.014 ?	0.509 ± 0.033 ?
S-8 mg/m3	3	0.627 ± 0.591	3.633 ± 0.543	0.509 ± 0.050

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

? : Significant test is not applied, because No. of data in this group is less than 3.



TABLE K8

ORGAN WEIGHT, RELATIVE : FEMALE

(SATELLITE 52w+52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : FEMALE  
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
 SURVIVAL ANIMALS (104W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
S-Control	2	272± 35	-	-	-	0.357± 0.029	0.645± 0.064
S-0.5 mg/m3	4	278± 31	-	-	-	0.323± 0.033	0.677± 0.153
S-2 mg/m3	3	270± 17	-	-	-	0.322± 0.027	0.656± 0.028
S-8 mg/m3	3	270± 12	-	-	-	0.333± 0.026	0.656± 0.024

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCrI CrI j[F344/DuCrj]  
REPORT TYPE : A3  
SEX : FEMALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS (104W)

PAGE : 4

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
S-Control	2	0.377 ± 0.038	3.300 ± 0.329	0.685 ± 0.085
S-0.5 mg/m3	4	0.223 ± 0.041**	3.167 ± 0.466	0.678 ± 0.092
S-2 mg/m3	3	0.187 ± 0.013**	2.774 ± 0.116	0.705 ± 0.023
S-8 mg/m3	3	0.236 ± 0.048**	3.102 ± 0.436	0.695 ± 0.035

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

(HCL042)

BAIS 6

TABLE L1

HISTOPATHOLOGICAL FINDINGS :  
NEOPLASTIC LESIONS : MALE  
(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
[Integumentary system/appandage]						
skin/app	squamous cell papilloma		<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 0 ( 0%)
	keratoacanthoma		3 ( 6%)	1 ( 2%)	1 ( 2%)	0 ( 0%)
	basal cell adenoma		0 ( 0%)	1 ( 2%)	0 ( 0%)	0 ( 0%)
subcutis	fibroma		<50> 6 ( 12%)	<50> 1 ( 2%)	<50> 2 ( 4%)	<50> 7 ( 14%)
	lipoma		0 ( 0%)	0 ( 0%)	1 ( 2%)	2 ( 4%)
	schwannoma		1 ( 2%)	0 ( 0%)	0 ( 0%)	0 ( 0%)
	histiocytic sarcoma		1 ( 2%)	0 ( 0%)	0 ( 0%)	0 ( 0%)
[Respiratory system]						
lung	bronchiolar-alveolar adenoma		<50> 4 ( 8%)	<50> 5 ( 10%)	<50> 7 ( 14%)	<50> 2 ( 4%)
	bronchiolar-alveolar carcinoma		0 ( 0%)	0 ( 0%)	0 ( 0%)	2 ( 4%)
[Hematopoietic system]						
lymph node	histiocytic sarcoma		<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)
	malignant lymphoma		0 ( 0%)	0 ( 0%)	0 ( 0%)	1 ( 2%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : A4  
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
[Hematopoietic system]						
spleen	hemangioma		<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 1 ( 2%)
	mononuclear cell leukemia		16 ( 32%)	15 ( 30%)	13 ( 26%)	6 ( 12%)
[Digestive system]						
oral cavity	squamous cell carcinoma		<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 1 ( 2%)
	tongue		<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 0 ( 0%)
small intes	squamous cell carcinoma		0 ( 0%)	1 ( 2%)	0 ( 0%)	0 ( 0%)
	fibrosarcoma		<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)
large intes	fibrosarcoma		<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 0 ( 0%)
	liver		<50> 1 ( 2%)	<50> 1 ( 2%)	<50> 2 ( 4%)	<50> 1 ( 2%)
pancreas	hepatocellular adenoma		<50> 4 ( 8%)	<50> 5 ( 10%)	<50> 3 ( 6%)	<50> 5 ( 10%)
	islet cell adenocarcinoma		2 ( 4%)	1 ( 2%)	0 ( 0%)	1 ( 2%)
[Endocrine system]						
pituitary	adenoma		<50> 11 ( 22%)	<50> 3 ( 6%)	<50> 6 ( 12%)	<50> 10 ( 20%)

< a > a : Number of animals examined at the site  
b ( c ) b : Number of animals with neoplasm c : b / a \* 100

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
[Endocrine system]						
pituitary	adenocarcinoma		<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 1 ( 2%)
	thyroid		<50>	<50>	<50>	<50>
	C-cell adenoma		7 ( 14%)	7 ( 14%)	8 ( 16%)	10 ( 20%)
	follicular adenoma		1 ( 2%)	2 ( 4%)	0 ( 0%)	0 ( 0%)
	C-cell carcinoma		1 ( 2%)	1 ( 2%)	1 ( 2%)	1 ( 2%)
	follicular adenocarcinoma		0 ( 0%)	0 ( 0%)	0 ( 0%)	1 ( 2%)
adrenal	pheochromocytoma		<50> 0 ( 0%)	<50> 3 ( 6%)	<50> 2 ( 4%)	<50> 2 ( 4%)
	pheochromocytoma:malignant		1 ( 2%)	0 ( 0%)	1 ( 2%)	1 ( 2%)
[Reproductive system]						
testis	interstitial cell tumor		<50> 37 ( 74%)	<50> 39 ( 78%)	<50> 36 ( 72%)	<50> 39 ( 78%)
	mammary gl		<50>	<50>	<50>	<50>
	fibroadenoma		1 ( 2%)	0 ( 0%)	0 ( 0%)	1 ( 2%)
	prep/cli gl		<50>	<50>	<50>	<50>
	adenoma		0 ( 0%)	1 ( 2%)	1 ( 2%)	0 ( 0%)
	[Nervous system]					
brain	glioma		<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 3 ( 6%)	<50> 0 ( 0%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ_____	Findings_____	Group Name No. of animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
{Special sense organs/appendage}						
Zymbal gl	Zymbal gland tumor:benign		<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 1 ( 2%)	<50> 0 ( 0%)
	Zymbal gland tumor:malignant		1 ( 2%)	1 ( 2%)	2 ( 4%)	0 ( 0%)
{Musculoskeletal system}						
bone	osteoma		<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)
vertebra	chordoma:malignant		<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 0 ( 0%)
{Body cavities}						
peritoneum	fibroma		<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 0 ( 0%)
	fibrosarcoma		0 ( 0%)	0 ( 0%)	0 ( 0%)	1 ( 2%)
	mesothelioma		2 ( 4%)	1 ( 2%)	2 ( 4%)	1 ( 2%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100



**TABLE L2**

**HISTOPATHOLOGICAL FINDINGS :  
NEOPLASTIC LESIONS : FEMALE  
(CARCINOGENICITY STUDY GROUPS)**

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
{Integumentary system/appandage}						
subcutis	fibroma		<50> 1 ( 2%)	<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 1 ( 2%)
{Respiratory system}						
lung	bronchiolar-alveolar adenoma		<50> 1 ( 2%)	<50> 2 ( 4%)	<50> 3 ( 6%)	<50> 4 ( 8%)
	adenosquamous carcinoma		0 ( 0%)	0 ( 0%)	1 ( 2%)	0 ( 0%)
	bronchiolar-alveolar carcinoma		0 ( 0%)	0 ( 0%)	1 ( 2%)	0 ( 0%)
{Hematopoietic system}						
lymph node	malignant lymphoma		<50> 2 ( 4%)	<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 0 ( 0%)
spleen	mononuclear cell leukemia		<50> 8 ( 16%)	<50> 5 ( 10%)	<50> 10 ( 20%)	<50> 4 ( 8%)
{Digestive system}						
tongue	squamous cell papilloma		<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 1 ( 2%)
stomach	squamous cell papilloma		<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 1 ( 2%)
large intes	adenocarcinoma		<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 0 ( 0%)
liver	hepatocellular adenoma		<50> 3 ( 6%)	<50> 3 ( 6%)	<50> 1 ( 2%)	<50> 0 ( 0%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
[Digestive system]						
liver	histiocytic sarcoma		<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)
pancreas	islet cell adenoma		<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 2 ( 4%)
[Urinary system]						
urin bladd	transitional cell carcinoma		<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 0 ( 0%)
[Endocrine system]						
pituitary	adenoma		<50> 10 ( 20%)	<50> 12 ( 24%)	<50> 15 ( 30%)	<49> 11 ( 22%)
	adenocarcinoma		0 ( 0%)	2 ( 4%)	0 ( 0%)	2 ( 4%)
thyroid	C-cell adenoma		<50> 4 ( 8%)	<50> 5 ( 10%)	<50> 4 ( 8%)	<50> 8 ( 16%)
	follicular adenoma		0 ( 0%)	1 ( 2%)	1 ( 2%)	0 ( 0%)
	C-cell carcinoma		0 ( 0%)	0 ( 0%)	0 ( 0%)	1 ( 2%)
adrenal	pheochromocytoma:malignant		<50> 2 ( 4%)	<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 0 ( 0%)
[Reproductive system]						
ovary	sertoli cell tumor		<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 0 ( 0%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j[F344/DuCr j]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
{Reproductive system}						
uterus	adenoma		<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 2 ( 4%)	<50> 0 ( 0%)
	hemangioma		0 ( 0%)	1 ( 2%)	0 ( 0%)	0 ( 0%)
	endometrial stromal polyp		5 ( 10%)	8 ( 16%)	9 ( 18%)	5 ( 10%)
	adenocarcinoma		0 ( 0%)	1 ( 2%)	0 ( 0%)	2 ( 4%)
	leiomyosarcoma		0 ( 0%)	0 ( 0%)	0 ( 0%)	1 ( 2%)
	endometrial stromal sarcoma		1 ( 2%)	1 ( 2%)	0 ( 0%)	1 ( 2%)
vagina	squamous cell papilloma		<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 0 ( 0%)
mammary gl	adenoma		<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 1 ( 2%)	<50> 0 ( 0%)
	fibroadenoma		5 ( 10%)	8 ( 16%)	0 ( 0%)	7 ( 14%)
	adenocarcinoma		0 ( 0%)	0 ( 0%)	1 ( 2%)	2 ( 4%)
prep/cli gl	adenoma		<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 1 ( 2%)
{Nervous system}						
brain	glioma		<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 1 ( 2%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
{Special sense organs/appendage}						
Zymbal gl	Zymbal gland tumor:benign		<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 0 ( 0%)
{Musculoskeletal system}						
muscle	hemangiosarcoma		<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 0 ( 0%)
bone	osteosarcoma		<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

TABLE L3

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : MALE

(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 53W)

Organ	Findings	Group Name No. of animals on Study	S-Control 3	S-0.5 mg/m3 3	S-2 mg/m3 3	S-8 mg/m3 4
[Integumentary system/appandage]						
subcutis	sarcoma:NOS		<03> 0 ( 0%)	<03> 0 ( 0%)	<03> 0 ( 0%)	<04> 1 ( 25%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

TABLE L4

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : MALE

(SATELLITE 52w+26w)



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A2  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 79W)

Organ	Findings	Group Name No. of animals on Study	S-Control 4	S-0.5 mg/m3 3	S-2 mg/m3 4	S-8 mg/m3 3
[Integumentary system/appandage]						
skin/app	keratoacanthoma		<04> 0 ( 0%)	<03> 0 ( 0%)	<04> 1 ( 25%)	<03> 0 ( 0%)
subcutis	fibroma		<04> 0 ( 0%)	<03> 0 ( 0%)	<04> 1 ( 25%)	<03> 1 ( 33%)
[Hematopoietic system]						
spleen	mononuclear cell leukemia		<04> 1 ( 25%)	<03> 0 ( 0%)	<04> 0 ( 0%)	<03> 0 ( 0%)
[Body cavities]						
peritoneum	mesothelioma		<04> 0 ( 0%)	<03> 0 ( 0%)	<04> 0 ( 0%)	<03> 1 ( 33%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

TABLE L5

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : FEMALE

(SATELLITE 52w+26w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A2  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 79W)

Organ	Findings	Group Name No. of animals on Study	S-Control 3	S-0.5 mg/m3 3	S-2 mg/m3 3	S-8 mg/m3 3
{Respiratory system}						
lung	bronchiolar-alveolar adenoma		<03> 0 ( 0%)	<03> 0 ( 0%)	<03> 0 ( 0%)	<03> 1 ( 33%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

TABLE L6

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : MALE

(SATELLITE 52w+52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-104W)

Organ	Findings	Group Name No. of animals on Study	S-Control 3	S-0.5 mg/m3 4	S-2 mg/m3 3	S-8 mg/m3 3
[Integumentary system/appandage]						
subcutis	fibroma		<03> 0 ( 0%)	<04> 0 ( 0%)	<03> 0 ( 0%)	<03> 1 ( 33%)
[Respiratory system]						
lung	bronchiolar-alveolar adenoma		<03> 0 ( 0%)	<04> 0 ( 0%)	<03> 1 ( 33%)	<03> 0 ( 0%)
[Hematopoietic system]						
spleen	mononuclear cell leukemia		<03> 1 ( 33%)	<04> 1 ( 25%)	<03> 1 ( 33%)	<03> 1 ( 33%)
[Endocrine system]						
pituitary	adenoma		<03> 1 ( 33%)	<04> 0 ( 0%)	<03> 0 ( 0%)	<03> 0 ( 0%)
thyroid	C-cell adenoma		<03> 1 ( 33%)	<04> 0 ( 0%)	<03> 0 ( 0%)	<03> 0 ( 0%)
[Reproductive system]						
mammary gl	fibroadenoma		<03> 1 ( 33%)	<04> 0 ( 0%)	<03> 0 ( 0%)	<03> 0 ( 0%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

TABLE L7

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : FEMALE

(SATELLITE 52w+52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-104W)

Organ	Findings	Group Name No. of animals on Study	S-Control 4	S-0.5 mg/m3 4	S-2 mg/m3 4	S-8 mg/m3 4
{Respiratory system}						
lung	bronchiolar-alveolar adenoma		<04> 0 ( 0%)	<04> 1 ( 25%)	<04> 0 ( 0%)	<04> 0 ( 0%)
{Hematopoietic system}						
spleen	mononuclear cell leukemia		<04> 0 ( 0%)	<04> 0 ( 0%)	<04> 1 ( 25%)	<04> 1 ( 25%)
{Endocrine system}						
pituitary	adenoma		<04> 0 ( 0%)	<04> 1 ( 25%)	<04> 0 ( 0%)	<04> 0 ( 0%)
{Reproductive system}						
uterus	endometrial stromal polyp		<04> 1 ( 25%)	<04> 1 ( 25%)	<04> 0 ( 0%)	<04> 0 ( 0%)
	endometrial adenocarcinoma		<04> 1 ( 25%)	<04> 0 ( 0%)	<04> 0 ( 0%)	<04> 0 ( 0%)
mammary gl	fibroadenoma		<04> 0 ( 0%)	<04> 1 ( 25%)	<04> 0 ( 0%)	<04> 0 ( 0%)
prep/cli gl	adenoma		<04> 0 ( 0%)	<04> 0 ( 0%)	<04> 1 ( 25%)	<04> 0 ( 0%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

TABLE M1

NEOPLASTIC LESIONS-INCIDENCE AND  
STATISTICAL ANALYSIS : MALE  
(CARCINOGENICITY STUDY GROUPS)



STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : skin/appendage TUMOR : squamous cell papilloma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	0.00	2.78	0.00	0.00
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4729			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5042			
Fisher Exact test(e)		P = 0.5000	P = N. C.	P = N. C.
SITE : skin/appendage TUMOR : keratoacanthoma				
Tumor rate				
Overall rates(a)	3/50( 6.0)	1/50( 2.0)	1/50( 2.0)	0/50( 0.0)
Adjusted rates(b)	10.00	3.12	3.12	0.00
Terminal rates(c)	3/30( 10.0)	1/32( 3.1)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9586			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.1313			
Fisher Exact test(e)		P = 0.3086	P = 0.3086	P = 0.1212
SITE : skin/appendage TUMOR : basal cell adenoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	0.00	3.12	0.00	0.00
Terminal rates(c)	0/30( 0.0)	1/32( 3.1)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4927			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5042			
Fisher Exact test(e)		P = 0.5000	P = N. C.	P = N. C.

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : skin/appendage TUMOR : squamous cell papilloma, keratoacanthoma, basal cell adenoma				
Tumor rate				
Overall rates(a)	3/50( 6.0)	3/50( 6.0)	1/50( 2.0)	0/50( 0.0)
Adjusted rates(b)	10.00	8.33	3.12	0.00
Terminal rates(c)	3/30( 10.0)	2/32( 6.3)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9826			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0727			
Fisher Exact test(e)		P = 0.6611	P = 0.3086	P = 0.1212
SITE : subcutis TUMOR : fibroma				
Tumor rate				
Overall rates(a)	6/50( 12.0)	1/50( 2.0)	2/50( 4.0)	7/50( 14.0)
Adjusted rates(b)	14.71	3.12	5.00	18.92
Terminal rates(c)	3/30( 10.0)	1/32( 3.1)	0/27( 0.0)	7/37( 18.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.0597			
Combined analysis(d)	P = 0.0969			
Cochran-Armitage test(e)	P = 0.1306			
Fisher Exact test(e)		P = 0.0559	P = 0.1343	P = 0.5000
SITE : subcutis TUMOR : lipoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)	2/50( 4.0)
Adjusted rates(b)	0.00	0.00	3.70	5.41
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	1/27( 3.7)	2/37( 5.4)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.0725			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0648			
Fisher Exact test(e)		P = N. C.	P = 0.5000	P = 0.2475

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : subcutis TUMOR : schwannoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	2.78	0.00	0.00	0.00
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 1.0000 ?			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.4093			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.5000
SITE : subcutis TUMOR : histiocytic sarcoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 1.0000 ?			
Cochran-Armitage test(e)	P = 0.4093			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.5000
SITE : lung TUMOR : bronchiolar-alveolar adenoma				
Tumor rate				
Overall rates(a)	4/50( 8.0)	5/50( 10.0)	7/50( 14.0)	2/50( 4.0)
Adjusted rates(b)	13.33	15.62	16.67	4.35
Terminal rates(c)	4/30( 13.3)	5/32( 15.6)	3/27( 11.1)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.8786			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.2532			
Fisher Exact test(e)		P = 0.5000	P = 0.2623	P = 0.3389

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : lung				
TUMOR : bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)	2/50( 4.0)
Adjusted rates(b)	0.00	0.00	0.00	2.70
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	0/27( 0.0)	1/37( 2.7)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1551			
Prevalence method(d)	P = 0.2004			
Combined analysis(d)	P = 0.0194* ?			
Cochran-Armitage test(e)	P = 0.0166*			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.2475
SITE : lung				
TUMOR : bronchiolar-alveolar adenoma,bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	4/50( 8.0)	5/50( 10.0)	7/50( 14.0)	4/50( 8.0)
Adjusted rates(b)	13.33	15.62	16.67	6.67
Terminal rates(c)	4/30( 13.3)	5/32( 15.6)	3/27( 11.1)	1/37( 2.7)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1551			
Prevalence method(d)	P = 0.7502			
Combined analysis(d)	P = 0.5972			
Cochran-Armitage test(e)	P = 0.7675			
Fisher Exact test(e)		P = 0.5000	P = 0.2623	P = 0.6425
SITE : lymph node				
TUMOR : histiocytic sarcoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3599			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.3599			
Cochran-Armitage test(e)	P = 0.8443			
Fisher Exact test(e)		P = N. C.	P = 0.5000	P = N. C.

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : lymph node TUMOR : malignant lymphoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1544			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.1544			
Cochran-Armitage test(e)	P = 0.0911			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000
SITE : spleen TUMOR : hemangioma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	0.00	0.00	0.00	2.70
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	0/27( 0.0)	1/37( 2.7)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.2004			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0911			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000
SITE : spleen TUMOR : mononuclear cell leukemia				
Tumor rate				
Overall rates(a)	16/50( 32.0)	15/50( 30.0)	13/50( 26.0)	6/50( 12.0)
Adjusted rates(b)	13.33	6.25	7.41	8.11
Terminal rates(c)	4/30( 13.3)	2/32( 6.3)	2/27( 7.4)	3/37( 8.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.9978			
Prevalence method(d)	P = 0.5934			
Combined analysis(d)	P = 0.9953			
Cochran-Armitage test(e)	P = 0.0109*			
Fisher Exact test(e)		P = 0.5000	P = 0.3299	P = 0.0142*

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : oral cavity				
TUMOR : squamous cell carcinoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1947			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.1947			
Cochran-Armitage test(e)	P = 0.0911			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000
SITE : tongue				
TUMOR : squamous cell papilloma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	2.56	0.00	0.00	0.00
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 1.0000 ?			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.4093			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.5000
SITE : tongue				
TUMOR : squamous cell carcinoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.4882			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.4882			
Cochran-Armitage test(e)	P = 0.5042			
Fisher Exact test(e)		P = 0.5000	P = N. C.	P = N. C.

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : tongue				
TUMOR : squamous cell papilloma, squamous cell carcinoma				
Tumor rate				
Overall rates(a)	1/50 ( 2.0)	1/50 ( 2.0)	0/50 ( 0.0)	0/50 ( 0.0)
Adjusted rates(b)	2.56	0.00	0.00	0.00
Terminal rates(c)	0/30 ( 0.0)	0/32 ( 0.0)	0/27 ( 0.0)	0/37 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.4882			
Prevalence method(d)	P = 1.0000 ?			
Combined analysis(d)	P = 0.8605			
Cochran-Armitage test(e)	P = 0.2899			
Fisher Exact test(e)		P = 0.7525	P = 0.5000	P = 0.5000
SITE : small intestine				
TUMOR : fibrosarcoma				
Tumor rate				
Overall rates(a)	0/50 ( 0.0)	0/50 ( 0.0)	1/50 ( 2.0)	0/50 ( 0.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/30 ( 0.0)	0/32 ( 0.0)	0/27 ( 0.0)	0/37 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3615			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.3615			
Cochran-Armitage test(e)	P = 0.8443			
Fisher Exact test(e)		P = N. C.	P = 0.5000	P = N. C.
SITE : large intestine				
TUMOR : fibrosarcoma				
Tumor rate				
Overall rates(a)	0/50 ( 0.0)	1/50 ( 2.0)	0/50 ( 0.0)	0/50 ( 0.0)
Adjusted rates(b)	0.00	3.12	0.00	0.00
Terminal rates(c)	0/30 ( 0.0)	1/32 ( 3.1)	0/27 ( 0.0)	0/37 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4927			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5042			
Fisher Exact test(e)		P = 0.5000	P = N. C.	P = N. C.

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : liver				
TUMOR : hepatocellular adenoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	1/50( 2.0)	2/50( 4.0)	1/50( 2.0)
Adjusted rates(b)	3.33	3.12	7.41	2.70
Terminal rates(c)	1/30( 3.3)	1/32( 3.1)	2/27( 7.4)	1/37( 2.7)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.5786			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.9293			
Fisher Exact test(e)		P = 0.7525	P = 0.5000	P = 0.7525
SITE : pancreas				
TUMOR : islet cell adenoma				
Tumor rate				
Overall rates(a)	4/50( 8.0)	5/50( 10.0)	3/50( 6.0)	5/50( 10.0)
Adjusted rates(b)	13.33	13.16	8.11	11.36
Terminal rates(c)	4/30( 13.3)	4/32( 12.5)	2/27( 7.4)	4/37( 10.8)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4197			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.7580			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.5000
SITE : pancreas				
TUMOR : islet cell adenocarcinoma				
Tumor rate				
Overall rates(a)	2/50( 4.0)	1/50( 2.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	6.67	3.12	0.00	2.70
Terminal rates(c)	2/30( 6.7)	1/32( 3.1)	0/27( 0.0)	1/37( 2.7)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.6467			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.7514			
Fisher Exact test(e)		P = 0.5000	P = 0.2475	P = 0.5000



STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : pancreas				
TUMOR : islet cell adenoma, islet cell adenocarcinoma				
Tumor rate				
Overall rates(a)	6/50( 12.0)	6/50( 12.0)	3/50( 6.0)	6/50( 12.0)
Adjusted rates(b)	20.00	15.79	8.11	13.64
Terminal rates(c)	6/30( 20.0)	5/32( 15.6)	2/27( 7.4)	5/37( 13.5)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.5154			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.8921			
Fisher Exact test(e)		P = 0.6202	P = 0.2435	P = 0.6202
SITE : pituitary gland				
TUMOR : adenoma				
Tumor rate				
Overall rates(a)	11/50( 22.0)	3/50( 6.0)	6/50( 12.0)	10/50( 20.0)
Adjusted rates(b)	23.08	3.12	13.51	18.92
Terminal rates(c)	5/30( 16.7)	1/32( 3.1)	3/27( 11.1)	7/37( 18.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.2712			
Prevalence method(d)	P = 0.2924			
Combined analysis(d)	P = 0.2199			
Cochran-Armitage test(e)	P = 0.3597			
Fisher Exact test(e)		P = 0.0204*	P = 0.1434	P = 0.5000
SITE : pituitary gland				
TUMOR : adenocarcinoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	0.00	3.12	0.00	0.00
Terminal rates(c)	0/30( 0.0)	1/32( 3.1)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1613			
Prevalence method(d)	P = 0.4927			
Combined analysis(d)	P = 0.2641			
Cochran-Armitage test(e)	P = 0.4690			
Fisher Exact test(e)		P = 0.5000	P = N. C.	P = 0.5000

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : pituitary gland TUMOR : adenoma, adenocarcinoma				
Tumor rate				
Overall rates(a)	11/50( 22.0)	4/50( 8.0)	6/50( 12.0)	11/50( 22.0)
Adjusted rates(b)	23.08	6.25	13.51	18.92
Terminal rates(c)	5/30( 16.7)	2/32( 6.3)	3/27( 11.1)	7/37( 18.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1409			
Prevalence method(d)	P = 0.3486			
Combined analysis(d)	P = 0.1773			
Cochran-Armitage test(e)	P = 0.2763			
Fisher Exact test(e)		P = 0.0453*	P = 0.1434	P = 0.5952
SITE : thyroid TUMOR : C-cell adenoma				
Tumor rate				
Overall rates(a)	7/50( 14.0)	7/50( 14.0)	8/50( 16.0)	10/50( 20.0)
Adjusted rates(b)	23.33	18.42	18.52	21.43
Terminal rates(c)	7/30( 23.3)	5/32( 15.6)	5/27( 18.5)	7/37( 18.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1686			
Prevalence method(d)	P = 0.2840			
Combined analysis(d)	P = 0.1906			
Cochran-Armitage test(e)	P = 0.3486			
Fisher Exact test(e)		P = 0.6129	P = 0.5000	P = 0.2977
SITE : thyroid TUMOR : follicular adenoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	2/50( 4.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	2.94	5.26	0.00	0.00
Terminal rates(c)	0/30( 0.0)	1/32( 3.1)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9187			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.2098			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.5000

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : thyroid				
TUMOR : C-cell carcinoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	1/50( 2.0)	1/50( 2.0)	1/50( 2.0)
Adjusted rates(b)	3.33	3.12	0.00	2.70
Terminal rates(c)	1/30( 3.3)	1/32( 3.1)	0/27( 0.0)	1/37( 2.7)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3576			
Prevalence method(d)	P = 0.4748			
Combined analysis(d)	P = 0.5231			
Cochran-Armitage test(e)	P = 1.0000			
Fisher Exact test(e)		P = 0.7525	P = 0.7525	P = 0.7525
SITE : thyroid				
TUMOR : follicular adenocarcinoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1579			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.1579			
Cochran-Armitage test(e)	P = 0.0911			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000
SITE : thyroid				
TUMOR : C-cell adenoma,C-cell carcinoma				
Tumor rate				
Overall rates(a)	8/50( 16.0)	8/50( 16.0)	9/50( 18.0)	11/50( 22.0)
Adjusted rates(b)	26.67	21.05	18.52	23.81
Terminal rates(c)	8/30( 26.7)	6/32( 18.8)	5/27( 18.5)	8/37( 21.6)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1872			
Prevalence method(d)	P = 0.2955			
Combined analysis(d)	P = 0.2194			
Cochran-Armitage test(e)	P = 0.3711			
Fisher Exact test(e)		P = 0.6071	P = 0.5000	P = 0.3055

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : thyroid				
TUMOR : follicular adenoma, follicular adenocarcinoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	2/50( 4.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	2.94	5.26	0.00	0.00
Terminal rates(c)	0/30( 0.0)	1/32( 3.1)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1579			
Prevalence method(d)	P = 0.9187			
Combined analysis(d)	P = 0.5806			
Cochran-Armitage test(e)	P = 0.8122			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.7525
SITE : adrenal gland				
TUMOR : pheochromocytoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	3/50( 6.0)	2/50( 4.0)	2/50( 4.0)
Adjusted rates(b)	0.00	7.89	7.41	5.41
Terminal rates(c)	0/30( 0.0)	2/32( 6.3)	2/27( 7.4)	2/37( 5.4)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.3940			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.7062			
Fisher Exact test(e)		P = 0.1212	P = 0.2475	P = 0.2475
SITE : adrenal gland				
TUMOR : pheochromocytoma:malignant				
Tumor rate				
Overall rates(a)	1/50( 2.0)	0/50( 0.0)	1/50( 2.0)	1/50( 2.0)
Adjusted rates(b)	0.00	0.00	3.70	2.70
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	1/27( 3.7)	1/37( 2.7)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.2104			
Combined analysis(d)	P = 0.3640			
Cochran-Armitage test(e)	P = 0.6983			
Fisher Exact test(e)		P = 0.5000	P = 0.7525	P = 0.7525

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : adrenal gland TUMOR : pheochromocytoma, pheochromocytoma:malignant				
Tumor rate				
Overall rates(a)	1/50( 2.0)	3/50( 6.0)	3/50( 6.0)	2/50( 4.0)
Adjusted rates(b)	0.00	7.89	11.11	5.41
Terminal rates(c)	0/30( 0.0)	2/32( 6.3)	3/27( 11.1)	2/37( 5.4)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.4373			
Combined analysis(d)	P = 0.5439			
Cochran-Armitage test(e)	P = 0.9893			
Fisher Exact test(e)		P = 0.3086	P = 0.3086	P = 0.5000
SITE : testis TUMOR : interstitial cell tumor				
Tumor rate				
Overall rates(a)	37/50( 74.0)	39/50( 78.0)	36/50( 72.0)	39/50( 78.0)
Adjusted rates(b)	84.85	88.24	93.75	95.00
Terminal rates(c)	25/30( 83.3)	28/32( 87.5)	25/27( 92.6)	35/37( 94.6)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4768			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.7134			
Fisher Exact test(e)		P = 0.4076	P = 0.5000	P = 0.4076
SITE : mammary gland TUMOR : fibroadenoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	3.33	0.00	0.00	2.70
Terminal rates(c)	1/30( 3.3)	0/32( 0.0)	0/27( 0.0)	1/37( 2.7)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.3109			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5400			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.7525

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : preputial/clitoral gland TUMOR : adenoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	1/50( 2.0)	0/50( 0.0)
Adjusted rates(b)	0.00	3.12	2.56	0.00
Terminal rates(c)	0/30( 0.0)	1/32( 3.1)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.6532			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5400			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = N.C.
SITE : brain TUMOR : glioma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	0/50( 0.0)	3/50( 6.0)	0/50( 0.0)
Adjusted rates(b)	3.33	0.00	0.00	0.00
Terminal rates(c)	1/30( 3.3)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.5827			
Prevalence method(d)	P = 1.0000 ?			
Combined analysis(d)	P = 0.7473			
Cochran-Armitage test(e)	P = 0.4761			
Fisher Exact test(e)		P = 0.5000	P = 0.3086	P = 0.5000
SITE : Zymbal gland TUMOR : Zymbal gland tumor:benign				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	1/50( 2.0)	0/50( 0.0)
Adjusted rates(b)	0.00	3.12	3.03	0.00
Terminal rates(c)	0/30( 0.0)	1/32( 3.1)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.6748			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5400			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = N.C.

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : Zymbal gland				
TUMOR : Zymbal gland tumor:malignant				
Tumor rate				
Overall rates(a)	1/50( 2.0)	1/50( 2.0)	2/50( 4.0)	0/50( 0.0)
Adjusted rates(b)	0.00	0.00	3.70	0.00
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	1/27( 3.7)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8254			
Prevalence method(d)	P = 0.3733			
Combined analysis(d)	P = 0.8266			
Cochran-Armitage test(e)	P = 0.3420			
Fisher Exact test(e)		P = 0.7525	P = 0.5000	P = 0.5000
SITE : Zymbal gland				
TUMOR : Zymbal gland tumor:benign,Zymbal gland tumor:malignant				
Tumor rate				
Overall rates(a)	1/50( 2.0)	2/50( 4.0)	3/50( 6.0)	0/50( 0.0)
Adjusted rates(b)	0.00	3.12	6.06	0.00
Terminal rates(c)	0/30( 0.0)	1/32( 3.1)	1/27( 3.7)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8254			
Prevalence method(d)	P = 0.7087			
Combined analysis(d)	P = 0.8813			
Cochran-Armitage test(e)	P = 0.2554			
Fisher Exact test(e)		P = 0.5000	P = 0.3086	P = 0.5000
SITE : bone				
TUMOR : osteoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)
Adjusted rates(b)	0.00	0.00	3.45	0.00
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.3615			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.8443			
Fisher Exact test(e)		P = N. C.	P = 0.5000	P = N. C.

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : vertebra TUMOR : chordoma:malignant				
Tumor rate				
Overall rates(a)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	3.33	0.00	0.00	0.00
Terminal rates(c)	1/30( 3.3)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 1.0000 ?			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.4093			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.5000
SITE : peritoneum TUMOR : fibroma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	0.00	2.78	0.00	0.00
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4729			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5042			
Fisher Exact test(e)		P = 0.5000	P = N. C.	P = N. C.
SITE : peritoneum TUMOR : fibrosarcoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/30( 0.0)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.2051			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.2051			
Cochran-Armitage test(e)	P = 0.0911			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000



STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
	SITE : peritoneum			
	TUMOR : mesothelioma			
Tumor rate				
Overall rates (a)	2/50 ( 4.0)	1/50 ( 2.0)	2/50 ( 4.0)	1/50 ( 2.0)
Adjusted rates (b)	4.44	2.22	0.00	2.70
Terminal rates (c)	1/30 ( 3.3)	0/32 ( 0.0)	0/27 ( 0.0)	1/37 ( 2.7)
Statistical analysis				
Peto test				
Standard method (d)	P = 0.5142			
Prevalence method (d)	P = 0.5629			
Combined analysis (d)	P = 0.6147			
Cochran-Armitage test (e)	P = 0.6727			
Fisher Exact test (e)		P = 0.5000	P = 0.6913	P = 0.5000

(HPT360)

BAIS6

- (a): Number of tumor-bearing animals/number of animals examined at the site.  
 (b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.  
 (c): Observed tumor incidence at terminal kill.  
 (d): Beneath the control incidence are the P-values associated with the trend test.  
 Standard method : Death analysis  
 Prevalence method : Incidental tumor test  
 Combined analysis : Death analysis + Incidental tumor test  
 (e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.  
 ? : The conditional probabilities of the largest and smallest possible outcomes cannot be estimated or this P-value is beyond the estimated P-value.  
 ----- : There is no data which should be statistical analysis.  
 Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$   
 N.C. : Statistical value cannot be calculated and was not significant.

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : skin/appendage TUMOR : keratoacanthoma				
Tumor rate				
Overall rates(a)	3/50( 6.0)	1/50( 2.0)	1/50( 2.0)	0/50( 0.0)
Adjusted rates(b)	10.00	3.12	3.12	0.00
Terminal rates(c)	3/30( 10.0)	1/32( 3.1)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9586			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.1313			
Fisher Exact test(e)		P = 0.3086	P = 0.3086	P = 0.1212
SITE : skin/appendage TUMOR : squamous cell papilloma, keratoacanthoma, basal cell adenoma				
Tumor rate				
Overall rates(a)	3/50( 6.0)	3/50( 6.0)	1/50( 2.0)	0/50( 0.0)
Adjusted rates(b)	10.00	8.33	3.12	0.00
Terminal rates(c)	3/30( 10.0)	2/32( 6.3)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9826			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0727			
Fisher Exact test(e)		P = 0.6611	P = 0.3086	P = 0.1212
SITE : subcutis TUMOR : fibroma				
Tumor rate				
Overall rates(a)	6/50( 12.0)	1/50( 2.0)	2/50( 4.0)	7/50( 14.0)
Adjusted rates(b)	14.71	3.12	5.00	18.92
Terminal rates(c)	3/30( 10.0)	1/32( 3.1)	0/27( 0.0)	7/37( 18.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.0597			
Combined analysis(d)	P = 0.0969			
Cochran-Armitage test(e)	P = 0.1306			
Fisher Exact test(e)		P = 0.0559	P = 0.1343	P = 0.5000

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : lung				
TUMOR : bronchiolar-alveolar adenoma				
Tumor rate				
Overall rates(a)	4/50( 8.0)	5/50( 10.0)	7/50( 14.0)	2/50( 4.0)
Adjusted rates(b)	13.33	15.62	16.67	4.35
Terminal rates(c)	4/30( 13.3)	5/32( 15.6)	3/27( 11.1)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.8786			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.2532			
Fisher Exact test(e)		P = 0.5000	P = 0.2623	P = 0.3389
SITE : lung				
TUMOR : bronchiolar-alveolar adenoma,bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	4/50( 8.0)	5/50( 10.0)	7/50( 14.0)	4/50( 8.0)
Adjusted rates(b)	13.33	15.62	16.67	6.67
Terminal rates(c)	4/30( 13.3)	5/32( 15.6)	3/27( 11.1)	1/37( 2.7)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1551			
Prevalence method(d)	P = 0.7502			
Combined analysis(d)	P = 0.5972			
Cochran-Armitage test(e)	P = 0.7675			
Fisher Exact test(e)		P = 0.5000	P = 0.2623	P = 0.6425
SITE : spleen				
TUMOR : mononuclear cell leukemia				
Tumor rate				
Overall rates(a)	16/50( 32.0)	15/50( 30.0)	13/50( 26.0)	6/50( 12.0)
Adjusted rates(b)	13.33	6.25	7.41	8.11
Terminal rates(c)	4/30( 13.3)	2/32( 6.3)	2/27( 7.4)	3/37( 8.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.9978			
Prevalence method(d)	P = 0.5934			
Combined analysis(d)	P = 0.9953			
Cochran-Armitage test(e)	P = 0.0109*			
Fisher Exact test(e)		P = 0.5000	P = 0.3299	P = 0.0142*

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : pancreas				
TUMOR : islet cell adenoma				
Tumor rate				
Overall rates(a)	4/50( 8.0)	5/50( 10.0)	3/50( 6.0)	5/50( 10.0)
Adjusted rates(b)	13.33	13.16	8.11	11.36
Terminal rates(c)	4/30( 13.3)	4/32( 12.5)	2/27( 7.4)	4/37( 10.8)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4197			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.7580			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.5000
SITE : pancreas				
TUMOR : islet cell adenoma, islet cell adenocarcinoma				
Tumor rate				
Overall rates(a)	6/50( 12.0)	6/50( 12.0)	3/50( 6.0)	6/50( 12.0)
Adjusted rates(b)	20.00	15.79	8.11	13.64
Terminal rates(c)	6/30( 20.0)	5/32( 15.6)	2/27( 7.4)	5/37( 13.5)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.5154			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.8921			
Fisher Exact test(e)		P = 0.6202	P = 0.2435	P = 0.6202
SITE : pituitary gland				
TUMOR : adenoma				
Tumor rate				
Overall rates(a)	11/50( 22.0)	3/50( 6.0)	6/50( 12.0)	10/50( 20.0)
Adjusted rates(b)	23.08	3.12	13.51	18.92
Terminal rates(c)	5/30( 16.7)	1/32( 3.1)	3/27( 11.1)	7/37( 18.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.2712			
Prevalence method(d)	P = 0.2924			
Combined analysis(d)	P = 0.2199			
Cochran-Armitage test(e)	P = 0.3597			
Fisher Exact test(e)		P = 0.0204*	P = 0.1434	P = 0.5000

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : pituitary gland TUMOR : adenoma, adenocarcinoma				
Tumor rate				
Overall rates(a)	11/50 ( 22.0)	4/50 ( 8.0)	6/50 ( 12.0)	11/50 ( 22.0)
Adjusted rates(b)	23.08	6.25	13.51	18.92
Terminal rates(c)	5/30 ( 16.7)	2/32 ( 6.3)	3/27 ( 11.1)	7/37 ( 18.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1409			
Prevalence method(d)	P = 0.3486			
Combined analysis(d)	P = 0.1773			
Cochran-Armitage test(e)	P = 0.2763			
Fisher Exact test(e)		P = 0.0453*	P = 0.1434	P = 0.5952
SITE : thyroid TUMOR : C-cell adenoma				
Tumor rate				
Overall rates(a)	7/50 ( 14.0)	7/50 ( 14.0)	8/50 ( 16.0)	10/50 ( 20.0)
Adjusted rates(b)	23.33	18.42	18.52	21.43
Terminal rates(c)	7/30 ( 23.3)	5/32 ( 15.6)	5/27 ( 18.5)	7/37 ( 18.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1686			
Prevalence method(d)	P = 0.2840			
Combined analysis(d)	P = 0.1906			
Cochran-Armitage test(e)	P = 0.3486			
Fisher Exact test(e)		P = 0.6129	P = 0.5000	P = 0.2977
SITE : thyroid TUMOR : C-cell adenoma, C-cell carcinoma				
Tumor rate				
Overall rates(a)	8/50 ( 16.0)	8/50 ( 16.0)	9/50 ( 18.0)	11/50 ( 22.0)
Adjusted rates(b)	26.67	21.05	18.52	23.81
Terminal rates(c)	8/30 ( 26.7)	6/32 ( 18.8)	5/27 ( 18.5)	8/37 ( 21.6)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1872			
Prevalence method(d)	P = 0.2955			
Combined analysis(d)	P = 0.2194			
Cochran-Armitage test(e)	P = 0.3711			
Fisher Exact test(e)		P = 0.6071	P = 0.5000	P = 0.3055

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : adrenal gland				
TUMOR : pheochromocytoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	3/50( 6.0)	2/50( 4.0)	2/50( 4.0)
Adjusted rates(b)	0.00	7.89	7.41	5.41
Terminal rates(c)	0/30( 0.0)	2/32( 6.3)	2/27( 7.4)	2/37( 5.4)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.3940			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.7062			
Fisher Exact test(e)		P = 0.1212	P = 0.2475	P = 0.2475
SITE : adrenal gland				
TUMOR : pheochromocytoma,pheochromocytoma:malignant				
Tumor rate				
Overall rates(a)	1/50( 2.0)	3/50( 6.0)	3/50( 6.0)	2/50( 4.0)
Adjusted rates(b)	0.00	7.89	11.11	5.41
Terminal rates(c)	0/30( 0.0)	2/32( 6.3)	3/27( 11.1)	2/37( 5.4)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.4373			
Combined analysis(d)	P = 0.5439			
Cochran-Armitage test(e)	P = 0.9893			
Fisher Exact test(e)		P = 0.3086	P = 0.3086	P = 0.5000
SITE : testis				
TUMOR : interstitial cell tumor				
Tumor rate				
Overall rates(a)	37/50( 74.0)	39/50( 78.0)	36/50( 72.0)	39/50( 78.0)
Adjusted rates(b)	84.85	88.24	93.75	95.00
Terminal rates(c)	25/30( 83.3)	28/32( 87.5)	25/27( 92.6)	35/37( 94.6)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4768			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.7134			
Fisher Exact test(e)		P = 0.4076	P = 0.5000	P = 0.4076

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : brain				
TUMOR : glioma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	0/50( 0.0)	3/50( 6.0)	0/50( 0.0)
Adjusted rates(b)	3.33	0.00	0.00	0.00
Terminal rates(c)	1/30( 3.3)	0/32( 0.0)	0/27( 0.0)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.5827			
Prevalence method(d)	P = 1.0000 ?			
Combined analysis(d)	P = 0.7473			
Cochran-Armitage test(e)	P = 0.4761			
Fisher Exact test(e)		P = 0.5000	P = 0.3086	P = 0.5000
SITE : Zymbal gland				
TUMOR : Zymbal gland tumor:benign,Zymbal gland tumor:malignant				
Tumor rate				
Overall rates(a)	1/50( 2.0)	2/50( 4.0)	3/50( 6.0)	0/50( 0.0)
Adjusted rates(b)	0.00	3.12	6.06	0.00
Terminal rates(c)	0/30( 0.0)	1/32( 3.1)	1/27( 3.7)	0/37( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8254			
Prevalence method(d)	P = 0.7087			
Combined analysis(d)	P = 0.8813			
Cochran-Armitage test(e)	P = 0.2554			
Fisher Exact test(e)		P = 0.5000	P = 0.3086	P = 0.5000

(HPT360A)

BAIS6

- (a): Number of tumor-bearing animals/number of animals examined at the site.  
 (b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.  
 (c): Observed tumor incidence at terminal kill.  
 (d): Beneath the control incidence are the P-values associated with the trend test.  
 Standard method : Death analysis  
 Prevalence method : Incidental tumor test  
 Combined analysis : Death analysis + Incidental tumor test  
 (e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.  
 ? : The conditional probabilities of the largest and smallest possible outcomes can not be estimated or this P-value is beyond the estimated P-value.  
 ----- : There is no data which should be statistical analysis.  
 Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$   
 N.C.: Statistical value cannot be calculated and was not significant.

TABLE M2

NEOPLASTIC LESIONS-INCIDENCE AND  
STATISTICAL ANALYSIS : FEMALE  
(CARCINOGENICITY STUDY GROUPS)



STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : subcutis TUMOR : fibroma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	1/50( 2.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	2.38	2.22	0.00	2.27
Terminal rates(c)	1/42( 2.4)	0/43( 0.0)	0/31( 0.0)	1/44( 2.3)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4368			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.9092			
Fisher Exact test(e)		P = 0.7525	P = 0.5000	P = 0.7525
SITE : lung TUMOR : bronchiolar-alveolar adenoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	2/50( 4.0)	3/50( 6.0)	4/50( 8.0)
Adjusted rates(b)	2.38	4.65	9.68	9.09
Terminal rates(c)	1/42( 2.4)	2/43( 4.7)	3/31( 9.7)	4/44( 9.1)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1301			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.1946			
Fisher Exact test(e)		P = 0.5000	P = 0.3086	P = 0.1811
SITE : lung TUMOR : adenosquamous carcinoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/42( 0.0)	0/43( 0.0)	0/31( 0.0)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3456			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.3456			
Cochran-Armitage test(e)	P = 0.8443			
Fisher Exact test(e)		P = N. C.	P = 0.5000	P = N. C.

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : lung				
TUMOR : bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)
Adjusted rates(b)	0.00	0.00	3.23	0.00
Terminal rates(c)	0/42( 0.0)	0/43( 0.0)	1/31( 3.2)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.3484			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.8443			
Fisher Exact test(e)		P = N. C.	P = 0.5000	P = N. C.
SITE : lung				
TUMOR : bronchiolar-alveolar adenoma, bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	2/50( 4.0)	4/50( 8.0)	4/50( 8.0)
Adjusted rates(b)	2.38	4.65	12.90	9.09
Terminal rates(c)	1/42( 2.4)	2/43( 4.7)	4/31( 12.9)	4/44( 9.1)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1539			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.2383			
Fisher Exact test(e)		P = 0.5000	P = 0.1811	P = 0.1811
SITE : lung				
TUMOR : bronchiolar-alveolar adenoma, bronchiolar-alveolar carcinoma, adenosquamous carcinoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	2/50( 4.0)	5/50( 10.0)	4/50( 8.0)
Adjusted rates(b)	2.38	4.65	12.90	9.09
Terminal rates(c)	1/42( 2.4)	2/43( 4.7)	4/31( 12.9)	4/44( 9.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3456			
Prevalence method(d)	P = 0.1539			
Combined analysis(d)	P = 0.1769			
Cochran-Armitage test(e)	P = 0.2830			
Fisher Exact test(e)		P = 0.5000	P = 0.1022	P = 0.1811

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : lymph node TUMOR : malignant lymphoma				
Tumor rate				
Overall rates(a)	2/50( 4.0)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/42( 0.0)	0/43( 0.0)	0/31( 0.0)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8985			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.8985			
Cochran-Armitage test(e)	P = 0.2421			
Fisher Exact test(e)		P = 0.2475	P = 0.2475	P = 0.2475
SITE : spleen TUMOR : mononuclear cell leukemia				
Tumor rate				
Overall rates(a)	8/50( 16.0)	5/50( 10.0)	10/50( 20.0)	4/50( 8.0)
Adjusted rates(b)	11.90	6.98	9.68	6.82
Terminal rates(c)	5/42( 11.9)	3/43( 7.0)	3/31( 9.7)	3/44( 6.8)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8327			
Prevalence method(d)	P = 0.6987			
Combined analysis(d)	P = 0.8602			
Cochran-Armitage test(e)	P = 0.2881			
Fisher Exact test(e)		P = 0.2768	P = 0.3976	P = 0.1783
SITE : tongue TUMOR : squamous cell papilloma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	0.00	0.00	0.00	2.27
Terminal rates(c)	0/42( 0.0)	0/43( 0.0)	0/31( 0.0)	1/44( 2.3)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1884			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0911			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : tongue				
TUMOR : squamous cell papilloma, squamous cell carcinoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	0.00	0.00	0.00	2.27
Terminal rates(c)	0/42( 0.0)	0/43( 0.0)	0/31( 0.0)	1/44( 2.3)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1884			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0911			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000
SITE : stomach				
TUMOR : squamous cell papilloma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	0.00	0.00	0.00	2.27
Terminal rates(c)	0/42( 0.0)	0/43( 0.0)	0/31( 0.0)	1/44( 2.3)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1884			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0911			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000
SITE : large intestine				
TUMOR : adenocarcinoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	0.00	2.33	0.00	0.00
Terminal rates(c)	0/42( 0.0)	1/43( 2.3)	0/31( 0.0)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4536			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5042			
Fisher Exact test(e)		P = 0.5000	P = N. C.	P = N. C.

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : liver				
TUMOR : hepatocellular adenoma				
Tumor rate				
Overall rates(a)	3/50( 6.0)	3/50( 6.0)	1/50( 2.0)	0/50( 0.0)
Adjusted rates(b)	7.14	6.98	3.23	0.00
Terminal rates(c)	3/42( 7.1)	3/43( 7.0)	1/31( 3.2)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9783			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0727			
Fisher Exact test(e)		P = 0.6611	P = 0.3086	P = 0.1212
SITE : liver				
TUMOR : histiocytic sarcoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/42( 0.0)	0/43( 0.0)	0/31( 0.0)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3421			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.3421			
Cochran-Armitage test(e)	P = 0.8443			
Fisher Exact test(e)		P = N. C.	P = 0.5000	P = N. C.
SITE : pancreas				
TUMOR : islet cell adenoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)	2/50( 4.0)
Adjusted rates(b)	2.38	0.00	0.00	4.55
Terminal rates(c)	1/42( 2.4)	0/43( 0.0)	0/31( 0.0)	2/44( 4.5)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1074			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.1383			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.5000

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : pancreas				
TUMOR : islet cell adenoma, islet cell adenocarcinoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)	2/50( 4.0)
Adjusted rates(b)	2.38	0.00	0.00	4.55
Terminal rates(c)	1/42( 2.4)	0/43( 0.0)	0/31( 0.0)	2/44( 4.5)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1074			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.1383			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.5000
SITE : urinary bladder				
TUMOR : transitional cell carcinoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	2.38	0.00	0.00	0.00
Terminal rates(c)	1/42( 2.4)	0/43( 0.0)	0/31( 0.0)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 1.0000 ?			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.4093			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.5000
SITE : pituitary gland				
TUMOR : adenoma				
Tumor rate				
Overall rates(a)	10/50( 20.0)	12/50( 24.0)	15/50( 30.0)	11/49( 22.4)
Adjusted rates(b)	21.28	20.00	26.47	22.73
Terminal rates(c)	7/42( 16.7)	8/43( 18.6)	7/31( 22.6)	10/44( 22.7)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.6483			
Prevalence method(d)	P = 0.4528			
Combined analysis(d)	P = 0.5407			
Cochran-Armitage test(e)	P = 0.9707			
Fisher Exact test(e)		P = 0.4049	P = 0.1779	P = 0.4790

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : pituitary gland TUMOR : adenocarcinoma				
Tumor rate				
Overall rates(a)	0/50 ( 0.0)	2/50 ( 4.0)	0/50 ( 0.0)	2/49 ( 4.1)
Adjusted rates(b)	0.00	2.33	0.00	2.27
Terminal rates(c)	0/42 ( 0.0)	1/43 ( 2.3)	0/31 ( 0.0)	1/44 ( 2.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.2604			
Prevalence method(d)	P = 0.2596			
Combined analysis(d)	P = 0.1872			
Cochran-Armitage test(e)	P = 0.2931			
Fisher Exact test(e)		P = 0.2475	P = N. C.	P = 0.2424
SITE : pituitary gland TUMOR : adenoma, adenocarcinoma				
Tumor rate				
Overall rates(a)	10/50 ( 20.0)	14/50 ( 28.0)	15/50 ( 30.0)	13/49 ( 26.5)
Adjusted rates(b)	21.28	22.73	26.47	25.00
Terminal rates(c)	7/42 ( 16.7)	9/43 ( 20.9)	7/31 ( 22.6)	11/44 ( 25.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.5245			
Prevalence method(d)	P = 0.3695			
Combined analysis(d)	P = 0.4083			
Cochran-Armitage test(e)	P = 0.7641			
Fisher Exact test(e)		P = 0.2415	P = 0.1779	P = 0.2978
SITE : thyroid TUMOR : C-cell adenoma				
Tumor rate				
Overall rates(a)	4/50 ( 8.0)	5/50 ( 10.0)	4/50 ( 8.0)	8/50 ( 16.0)
Adjusted rates(b)	9.52	11.63	9.68	16.67
Terminal rates(c)	4/42 ( 9.5)	5/43 ( 11.6)	3/31 ( 9.7)	7/44 ( 15.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3405			
Prevalence method(d)	P = 0.0938			
Combined analysis(d)	P = 0.1068			
Cochran-Armitage test(e)	P = 0.1611			
Fisher Exact test(e)		P = 0.5000	P = 0.6425	P = 0.1783

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : thyroid				
TUMOR : follicular adenoma				
Tumor rate				
Overall rates(a)	0/50 ( 0.0)	1/50 ( 2.0)	1/50 ( 2.0)	0/50 ( 0.0)
Adjusted rates(b)	0.00	2.33	3.23	0.00
Terminal rates(c)	0/42 ( 0.0)	1/43 ( 2.3)	1/31 ( 3.2)	0/44 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.6626			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5400			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = N. C.
SITE : thyroid				
TUMOR : C-cell carcinoma				
Tumor rate				
Overall rates(a)	0/50 ( 0.0)	0/50 ( 0.0)	0/50 ( 0.0)	1/50 ( 2.0)
Adjusted rates(b)	0.00	0.00	0.00	2.27
Terminal rates(c)	0/42 ( 0.0)	0/43 ( 0.0)	0/31 ( 0.0)	1/44 ( 2.3)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1884			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0911			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000
SITE : thyroid				
TUMOR : C-cell adenoma, C-cell carcinoma				
Tumor rate				
Overall rates(a)	4/50 ( 8.0)	5/50 ( 10.0)	4/50 ( 8.0)	9/50 ( 18.0)
Adjusted rates(b)	9.52	11.63	9.68	18.75
Terminal rates(c)	4/42 ( 9.5)	5/43 ( 11.6)	3/31 ( 9.7)	8/44 ( 18.2)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3405			
Prevalence method(d)	P = 0.0503			
Combined analysis(d)	P = 0.0591			
Cochran-Armitage test(e)	P = 0.0795			
Fisher Exact test(e)		P = 0.5000	P = 0.6425	P = 0.1168



STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : thyroid				
TUMOR : follicular adenoma, follicular adenocarcinoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	1/50( 2.0)	0/50( 0.0)
Adjusted rates(b)	0.00	2.33	3.23	0.00
Terminal rates(c)	0/42( 0.0)	1/43( 2.3)	1/31( 3.2)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.6626			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5400			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = N.C.
SITE : adrenal gland				
TUMOR : pheochromocytoma:malignant				
Tumor rate				
Overall rates(a)	2/50( 4.0)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	4.76	0.00	0.00	0.00
Terminal rates(c)	2/42( 4.8)	0/43( 0.0)	0/31( 0.0)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.8982			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.2421			
Fisher Exact test(e)		P = 0.2475	P = 0.2475	P = 0.2475
SITE : adrenal gland				
TUMOR : pheochromocytoma, pheochromocytoma:malignant				
Tumor rate				
Overall rates(a)	2/50( 4.0)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	4.76	0.00	0.00	0.00
Terminal rates(c)	2/42( 4.8)	0/43( 0.0)	0/31( 0.0)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.8982			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.2421			
Fisher Exact test(e)		P = 0.2475	P = 0.2475	P = 0.2475

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : ovary TUMOR : sertoli cell tumor				
Tumor rate				
Overall rates(a)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	2.38	0.00	0.00	0.00
Terminal rates(c)	1/42( 2.4)	0/43( 0.0)	0/31( 0.0)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 1.0000 ?			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.4093			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.5000
SITE : uterus TUMOR : adenoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	2/50( 4.0)	0/50( 0.0)
Adjusted rates(b)	0.00	0.00	6.45	0.00
Terminal rates(c)	0/42( 0.0)	0/43( 0.0)	2/31( 6.5)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.5396			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.7806			
Fisher Exact test(e)		P = N. C.	P = 0.2475	P = N. C.
SITE : uterus TUMOR : hemangioma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	0.00	2.33	0.00	0.00
Terminal rates(c)	0/42( 0.0)	1/43( 2.3)	0/31( 0.0)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4536			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5042			
Fisher Exact test(e)		P = 0.5000	P = N. C.	P = N. C.

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : uterus TUMOR : endometrial stromal polyp				
Tumor rate				
Overall rates(a)	5/50 ( 10.0)	8/50 ( 16.0)	9/50 ( 18.0)	5/50 ( 10.0)
Adjusted rates(b)	9.52	16.67	20.00	10.64
Terminal rates(c)	4/42 ( 9.5)	7/43 ( 16.3)	4/31 ( 12.9)	4/44 ( 9.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.6965			
Prevalence method(d)	P = 0.6524			
Combined analysis(d)	P = 0.7204			
Cochran-Armitage test(e)	P = 0.5647			
Fisher Exact test(e)		P = 0.2768	P = 0.1940	P = 0.6296
SITE : uterus TUMOR : adenocarcinoma				
Tumor rate				
Overall rates(a)	0/50 ( 0.0)	1/50 ( 2.0)	0/50 ( 0.0)	2/50 ( 4.0)
Adjusted rates(b)	0.00	2.33	0.00	2.27
Terminal rates(c)	0/42 ( 0.0)	1/43 ( 2.3)	0/31 ( 0.0)	1/44 ( 2.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1594			
Prevalence method(d)	P = 0.2596			
Combined analysis(d)	P = 0.0912			
Cochran-Armitage test(e)	P = 0.1157			
Fisher Exact test(e)		P = 0.5000	P = N. C.	P = 0.2475
SITE : uterus TUMOR : leiomyosarcoma				
Tumor rate				
Overall rates(a)	0/50 ( 0.0)	0/50 ( 0.0)	0/50 ( 0.0)	1/50 ( 2.0)
Adjusted rates(b)	0.00	0.00	0.00	2.27
Terminal rates(c)	0/42 ( 0.0)	0/43 ( 0.0)	0/31 ( 0.0)	1/44 ( 2.3)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1884			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0911			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : uterus				
TUMOR : endometrial stromal sarcoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	1/50( 2.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	2.08	2.33	0.00	0.00
Terminal rates(c)	0/42( 0.0)	1/43( 2.3)	0/31( 0.0)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1610			
Prevalence method(d)	P = 0.8515			
Combined analysis(d)	P = 0.4130			
Cochran-Armitage test(e)	P = 0.9092			
Fisher Exact test(e)		P = 0.7525	P = 0.5000	P = 0.7525
SITE : vagina				
TUMOR : squamous cell papilloma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	0.00	2.33	0.00	0.00
Terminal rates(c)	0/42( 0.0)	1/43( 2.3)	0/31( 0.0)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4536			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5042			
Fisher Exact test(e)		P = 0.5000	P = N. C.	P = N. C.
SITE : mammary gland				
TUMOR : adenoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	1/50( 2.0)	0/50( 0.0)
Adjusted rates(b)	0.00	2.33	3.23	0.00
Terminal rates(c)	0/42( 0.0)	1/43( 2.3)	1/31( 3.2)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.6626			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5400			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = N. C.

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : mammary gland TUMOR : fibroadenoma				
Tumor rate				
Overall rates(a)	5/50 ( 10.0)	8/50 ( 16.0)	0/50 ( 0.0)	7/50 ( 14.0)
Adjusted rates(b)	9.52	18.18	0.00	15.91
Terminal rates(c)	4/42 ( 9.5)	7/43 ( 16.3)	0/31 ( 0.0)	7/44 ( 15.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.2616			
Combined analysis(d)	P = 0.3289			
Cochran-Armitage test(e)	P = 0.5794			
Fisher Exact test(e)		P = 0.2768	P = 0.0281*	P = 0.3798
SITE : mammary gland TUMOR : adenocarcinoma				
Tumor rate				
Overall rates(a)	0/50 ( 0.0)	0/50 ( 0.0)	1/50 ( 2.0)	2/50 ( 4.0)
Adjusted rates(b)	0.00	0.00	2.04	4.55
Terminal rates(c)	0/42 ( 0.0)	0/43 ( 0.0)	0/31 ( 0.0)	2/44 ( 4.5)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.0529			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0648			
Fisher Exact test(e)		P = N. C.	P = 0.5000	P = 0.2475
SITE : mammary gland TUMOR : adenoma, fibroadenoma				
Tumor rate				
Overall rates(a)	5/50 ( 10.0)	9/50 ( 18.0)	1/50 ( 2.0)	7/50 ( 14.0)
Adjusted rates(b)	9.52	20.45	3.23	15.91
Terminal rates(c)	4/42 ( 9.5)	8/43 ( 18.6)	1/31 ( 3.2)	7/44 ( 15.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.3393			
Combined analysis(d)	P = 0.4089			
Cochran-Armitage test(e)	P = 0.7364			
Fisher Exact test(e)		P = 0.1940	P = 0.1022	P = 0.3798

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : mammary gland TUMOR : adenoma, fibroadenoma, adenocarcinoma				
Tumor rate				
Overall rates(a)	5/50( 10.0)	9/50( 18.0)	2/50( 4.0)	8/50( 16.0)
Adjusted rates(b)	9.52	20.45	4.08	18.18
Terminal rates(c)	4/42( 9.5)	8/43( 18.6)	1/31( 3.2)	8/44( 18.2)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.2342			
Combined analysis(d)	P = 0.2937			
Cochran-Armitage test(e)	P = 0.5169			
Fisher Exact test(e)		P = 0.1940	P = 0.2180	P = 0.2768
SITE : preputial/clitoral gland TUMOR : adenoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	0.00	2.33	0.00	2.27
Terminal rates(c)	0/42( 0.0)	1/43( 2.3)	0/31( 0.0)	1/44( 2.3)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.2596			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.4690			
Fisher Exact test(e)		P = 0.5000	P = N. C.	P = 0.5000
SITE : brain TUMOR : glioma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)	1/50( 2.0)
Adjusted rates(b)	0.00	0.00	0.00	2.27
Terminal rates(c)	0/42( 0.0)	0/43( 0.0)	0/31( 0.0)	1/44( 2.3)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1884			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0911			
Fisher Exact test(e)		P = N. C.	P = N. C.	P = 0.5000

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : Zymbal gland				
TUMOR : Zymbal gland tumor:benign				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	0.00	2.33	0.00	0.00
Terminal rates(c)	0/42( 0.0)	1/43( 2.3)	0/31( 0.0)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4536			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5042			
Fisher Exact test(e)		P = 0.5000	P = N. C.	P = N. C.
SITE : Zymbal gland				
TUMOR : Zymbal gland tumor:benign,Zymbal gland tumor:malignant				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	0.00	2.33	0.00	0.00
Terminal rates(c)	0/42( 0.0)	1/43( 2.3)	0/31( 0.0)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4536			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.5042			
Fisher Exact test(e)		P = 0.5000	P = N. C.	P = N. C.
SITE : muscle				
TUMOR : hemangiosarcoma				
Tumor rate				
Overall rates(a)	0/50( 0.0)	1/50( 2.0)	0/50( 0.0)	0/50( 0.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/42( 0.0)	0/43( 0.0)	0/31( 0.0)	0/44( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.4891			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.4891			
Cochran-Armitage test(e)	P = 0.5042			
Fisher Exact test(e)		P = 0.5000	P = N. C.	P = N. C.

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : bone				
TUMOR : osteosarcoma				
Tumor rate				
Overall rates (a)	0/50 ( 0.0)	0/50 ( 0.0)	1/50 ( 2.0)	0/50 ( 0.0)
Adjusted rates (b)	0.00	0.00	0.00	0.00
Terminal rates (c)	0/42 ( 0.0)	0/43 ( 0.0)	0/31 ( 0.0)	0/44 ( 0.0)
Statistical analysis				
Peto test				
Standard method (d)	P = 0.3481			
Prevalence method (d)	P = -----			
Combined analysis (d)	P = 0.3481			
Cochran-Armitage test (e)	P = 0.8443			
Fisher Exact test (e)		P = N. C.	P = 0.5000	P = N. C.

(HPT360)

BAIS6

- (a): Number of tumor-bearing animals/number of animals examined at the site.  
 (b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.  
 (c): Observed tumor incidence at terminal kill.  
 (d): Beneath the control incidence are the P-values associated with the trend test.  
 Standard method : Death analysis  
 Prevalence method : Incidental tumor test  
 Combined analysis : Death analysis + Incidental tumor test  
 (e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.  
 ? : The conditional probabilities of the largest and smallest possible outcomes cannot be estimated or this P-value is beyond the estimated P-value.  
 ----- : There is no data which should be statistical analysis.  
 Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$   
 N. C. : Statistical value cannot be calculated and was not significant.



STUDY No. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : lung				
TUMOR : bronchiolar-alveolar adenoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	2/50( 4.0)	3/50( 6.0)	4/50( 8.0)
Adjusted rates(b)	2.38	4.65	9.68	9.09
Terminal rates(c)	1/42( 2.4)	2/43( 4.7)	3/31( 9.7)	4/44( 9.1)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1301			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.1946			
Fisher Exact test(e)		P = 0.5000	P = 0.3086	P = 0.1811
SITE : lung				
TUMOR : bronchiolar-alveolar adenoma,bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	2/50( 4.0)	4/50( 8.0)	4/50( 8.0)
Adjusted rates(b)	2.38	4.65	12.90	9.09
Terminal rates(c)	1/42( 2.4)	2/43( 4.7)	4/31( 12.9)	4/44( 9.1)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1539			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.2383			
Fisher Exact test(e)		P = 0.5000	P = 0.1811	P = 0.1811
SITE : lung				
TUMOR : bronchiolar-alveolar adenoma,bronchiolar-alveolar carcinoma,adenosquamous carcinoma				
Tumor rate				
Overall rates(a)	1/50( 2.0)	2/50( 4.0)	5/50( 10.0)	4/50( 8.0)
Adjusted rates(b)	2.38	4.65	12.90	9.09
Terminal rates(c)	1/42( 2.4)	2/43( 4.7)	4/31( 12.9)	4/44( 9.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3456			
Prevalence method(d)	P = 0.1539			
Combined analysis(d)	P = 0.1769			
Cochran-Armitage test(e)	P = 0.2830			
Fisher Exact test(e)		P = 0.5000	P = 0.1022	P = 0.1811

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : spleen TUMOR : mononuclear cell leukemia				
Tumor rate				
Overall rates(a)	8/50 ( 16.0)	5/50 ( 10.0)	10/50 ( 20.0)	4/50 ( 8.0)
Adjusted rates(b)	11.90	6.98	9.68	6.82
Terminal rates(c)	5/42 ( 11.9)	3/43 ( 7.0)	3/31 ( 9.7)	3/44 ( 6.8)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8327			
Prevalence method(d)	P = 0.6987			
Combined analysis(d)	P = 0.8602			
Cochran-Armitage test(e)	P = 0.2881			
Fisher Exact test(e)		P = 0.2768	P = 0.3976	P = 0.1783
SITE : liver TUMOR : hepatocellular adenoma				
Tumor rate				
Overall rates(a)	3/50 ( 6.0)	3/50 ( 6.0)	1/50 ( 2.0)	0/50 ( 0.0)
Adjusted rates(b)	7.14	6.98	3.23	0.00
Terminal rates(c)	3/42 ( 7.1)	3/43 ( 7.0)	1/31 ( 3.2)	0/44 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9783			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0727			
Fisher Exact test(e)		P = 0.6611	P = 0.3086	P = 0.1212
SITE : pituitary gland TUMOR : adenoma				
Tumor rate				
Overall rates(a)	10/50 ( 20.0)	12/50 ( 24.0)	15/50 ( 30.0)	11/49 ( 22.4)
Adjusted rates(b)	21.28	20.00	26.47	22.73
Terminal rates(c)	7/42 ( 16.7)	8/43 ( 18.6)	7/31 ( 22.6)	10/44 ( 22.7)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.6483			
Prevalence method(d)	P = 0.4528			
Combined analysis(d)	P = 0.5407			
Cochran-Armitage test(e)	P = 0.9707			
Fisher Exact test(e)		P = 0.4049	P = 0.1779	P = 0.4790

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : pituitary gland TUMOR : adenoma, adenocarcinoma				
Tumor rate				
Overall rates(a)	10/50 ( 20.0)	14/50 ( 28.0)	15/50 ( 30.0)	13/49 ( 26.5)
Adjusted rates(b)	21.28	22.73	26.47	25.00
Terminal rates(c)	7/42 ( 16.7)	9/43 ( 20.9)	7/31 ( 22.6)	11/44 ( 25.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.5245			
Prevalence method(d)	P = 0.3695			
Combined analysis(d)	P = 0.4083			
Cochran-Armitage test(e)	P = 0.7641			
Fisher Exact test(e)		P = 0.2415	P = 0.1779	P = 0.2978
SITE : thyroid TUMOR : C-cell adenoma				
Tumor rate				
Overall rates(a)	4/50 ( 8.0)	5/50 ( 10.0)	4/50 ( 8.0)	8/50 ( 16.0)
Adjusted rates(b)	9.52	11.63	9.68	16.67
Terminal rates(c)	4/42 ( 9.5)	5/43 ( 11.6)	3/31 ( 9.7)	7/44 ( 15.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3405			
Prevalence method(d)	P = 0.0938			
Combined analysis(d)	P = 0.1068			
Cochran-Armitage test(e)	P = 0.1611			
Fisher Exact test(e)		P = 0.5000	P = 0.6425	P = 0.1783
SITE : thyroid TUMOR : C-cell adenoma, C-cell carcinoma				
Tumor rate				
Overall rates(a)	4/50 ( 8.0)	5/50 ( 10.0)	4/50 ( 8.0)	9/50 ( 18.0)
Adjusted rates(b)	9.52	11.63	9.68	18.75
Terminal rates(c)	4/42 ( 9.5)	5/43 ( 11.6)	3/31 ( 9.7)	8/44 ( 18.2)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3405			
Prevalence method(d)	P = 0.0503			
Combined analysis(d)	P = 0.0591			
Cochran-Armitage test(e)	P = 0.0795			
Fisher Exact test(e)		P = 0.5000	P = 0.6425	P = 0.1168

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrIj [F344/DuCrj]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : uterus TUMOR : endometrial stromal polyp				
Tumor rate				
Overall rates(a)	5/50 ( 10.0)	8/50 ( 16.0)	9/50 ( 18.0)	5/50 ( 10.0)
Adjusted rates(b)	9.52	16.67	20.00	10.64
Terminal rates(c)	4/42 ( 9.5)	7/43 ( 16.3)	4/31 ( 12.9)	4/44 ( 9.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.6965			
Prevalence method(d)	P = 0.6524			
Combined analysis(d)	P = 0.7204			
Cochran-Armitage test(e)	P = 0.5647			
Fisher Exact test(e)		P = 0.2768	P = 0.1940	P = 0.6296
SITE : mammary gland TUMOR : fibroadenoma				
Tumor rate				
Overall rates(a)	5/50 ( 10.0)	8/50 ( 16.0)	0/50 ( 0.0)	7/50 ( 14.0)
Adjusted rates(b)	9.52	18.18	0.00	15.91
Terminal rates(c)	4/42 ( 9.5)	7/43 ( 16.3)	0/31 ( 0.0)	7/44 ( 15.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.2616			
Combined analysis(d)	P = 0.3289			
Cochran-Armitage test(e)	P = 0.5794			
Fisher Exact test(e)		P = 0.2768	P = 0.0281*	P = 0.3798
SITE : mammary gland TUMOR : adenoma, fibroadenoma				
Tumor rate				
Overall rates(a)	5/50 ( 10.0)	9/50 ( 18.0)	1/50 ( 2.0)	7/50 ( 14.0)
Adjusted rates(b)	9.52	20.45	3.23	15.91
Terminal rates(c)	4/42 ( 9.5)	8/43 ( 18.6)	1/31 ( 3.2)	7/44 ( 15.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.3393			
Combined analysis(d)	P = 0.4089			
Cochran-Armitage test(e)	P = 0.7364			
Fisher Exact test(e)		P = 0.1940	P = 0.1022	P = 0.3798

STUDY No. : 0883  
 ANIMAL : RAT F344/DuCrI CrI j [F344/DuCr j]  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	500 ug/m3	2000 ug/m3	8000 ug/m3
SITE : mammary gland				
TUMOR : adenoma, fibroadenoma, adenocarcinoma				
Tumor rate				
Overall rates (a)	5/50 ( 10.0)	9/50 ( 18.0)	2/50 ( 4.0)	8/50 ( 16.0)
Adjusted rates (b)	9.52	20.45	4.08	18.18
Terminal rates (c)	4/42 ( 9.5)	8/43 ( 18.6)	1/31 ( 3.2)	8/44 ( 18.2)
Statistical analysis				
Peto test				
Standard method (d)	P = 1.0000 ?			
Prevalence method (d)	P = 0.2342			
Combined analysis (d)	P = 0.2937			
Cochran-Armitage test (e)	P = 0.5169			
Fisher Exact test (e)		P = 0.1940	P = 0.2180	P = 0.2768

(HPT360A)

BAIS6

- (a): Number of tumor-bearing animals/number of animals examined at the site.  
 (b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.  
 (c): Observed tumor incidence at terminal kill.  
 (d): Beneath the control incidence are the P-values associated with the trend test.  
 Standard method : Death analysis  
 Prevalence method : Incidental tumor test  
 Combined analysis : Death analysis + Incidental tumor test  
 (e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.  
 ? : The conditional probabilities of the largest and smallest possible outcomes cannot be estimated or this P-value is beyond the estimated P-value.  
 ----- : There is no data which should be statistical analysis.  
 Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$   
 N.C. : Statistical value cannot be calculated and was not significant.

TABLE N

HISTORICAL CONTROL DATA OF SELECTED  
NEOPLASTIC LESIONS IN JAPAN BIOASSAY  
RESEARCH CENTER : F344/DuCr1Cr1j RATS

TABLE N HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS  
IN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCr1Cr1j RATS

Lung Tumors		No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min. - Max. (%)
Male	Bronchiolar-alveolar carcinoma	599	5	0.8	0 - 4
Female	Bronchiolar-alveolar adenoma	600	15	2.5	0 - 6
	Adenosquamous carcinoma		0	0.0	0 - 0

12 carcinogenicity studies examined in Japan Bioassay Research Center were used.  
Study No. : 0667, 0675, 0686, 0704, 0731, 0753, 0774, 0794, 0800, 0816, 0831, 0849

TABLE O1

HISTOPATHOLOGICAL FINDINGS :  
METASTASIS OF TUMORS : MALE  
(CARCINOGENICITY STUDY GROUPS)



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
[Integumentary system/appandage]						
subcutis	leukemic cell infiltration		<50> 0	<50> 0	<50> 0	<50> 1
[Respiratory system]						
nasal cavit	leukemic cell infiltration		<50> 6	<50> 7	<50> 0	<50> 4
larynx	leukemic cell infiltration		<50> 1	<50> 0	<50> 0	<50> 0
trachea	leukemic cell infiltration		<50> 1	<50> 1	<50> 0	<50> 0
lung	leukemic cell infiltration		<50> 14	<50> 12	<50> 13	<50> 6
	metastasis:thyroid tumor		1	0	0	0
	metastasis:peritoneum tumor		0	0	0	1
	metastasis:subcutis tumor		1	0	0	0
	metastasis:Zymbal gland tumor		1	1	0	0
	metastasis:vertebra tumor		1	0	0	0
	metastasis:oral cavity tumor		0	0	0	1
	metastasis:lymph node tumor		0	0	1	0
[Hematopoietic system]						
bone marrow	leukemic cell infiltration		<50> 9	<50> 14	<50> 11	<50> 4

< a > a : Number of animals examined at the site  
 b b : Number of animals with lesion

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
[Hematopoietic system]						
bone marrow	metastasis:subcutis tumor		<50> 1	<50> 0	<50> 0	<50> 0
	metastasis:lymph node tumor		0	0	1	0
lymph node	leukemic cell infiltration		<50> 5	<50> 8	<50> 5	<50> 2
	metastasis:peritoneum tumor		0	0	0	1
	metastasis:subcutis tumor		1	0	0	0
	metastasis:lung tumor		0	0	0	1
thymus	leukemic cell infiltration		<50> 3	<50> 3	<50> 1	<50> 1
	metastasis:lymph node tumor		0	0	1	0
spleen	leukemic cell infiltration		<50> 0	<50> 0	<50> 0	<50> 1
	metastasis:peritoneum tumor		0	0	0	1
[Circulatory system]						
heart	leukemic cell infiltration		<50> 1	<50> 2	<50> 2	<50> 0
artery/aort	metastasis:vertebra tumor		<50> 1	<50> 0	<50> 0	<50> 0
[Digestive system]						
esophagus	leukemic cell infiltration		<50> 1	<50> 0	<50> 1	<50> 0

< a > a : Number of animals examined at the site  
 b b : Number of animals with lesion

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : A4  
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
[Digestive system]						
esophagus	metastasis:subcutis tumor		<50> 1	<50> 0	<50> 0	<50> 0
stomach	leukemic cell infiltration		<50> 2	<50> 0	<50> 2	<50> 0
small intes	leukemic cell infiltration		<50> 2	<50> 0	<50> 1	<50> 0
large intes	leukemic cell infiltration		<50> 2	<50> 0	<50> 0	<50> 0
liver	leukemic cell infiltration		<50> 14	<50> 15	<50> 13	<50> 7
	metastasis:peritoneum tumor		0	0	0	1
	metastasis:subcutis tumor		1	0	0	0
pancreas	metastasis:lymph node tumor		0	0	1	0
	leukemic cell infiltration		<50> 1	<50> 1	<50> 2	<50> 2
	metastasis:peritoneum tumor		0	0	0	1
	metastasis:lymph node tumor		0	0	1	0
[Urinary system]						
kidney	leukemic cell infiltration		<50> 6	<50> 11	<50> 7	<50> 3
	metastasis:peritoneum tumor		0	0	0	1

< a > a : Number of animals examined at the site  
b : Number of animals with lesion

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
[Urinary system]						
kidney	metastasis:lymph node tumor		<50> 0	<50> 0	<50> 1	<50> 0
urin bladd	leukemic cell infiltration		<50> 0	<50> 1	<50> 1	<50> 0
[Endocrine system]						
pituitary	leukemic cell infiltration		<50> 0	<50> 2	<50> 2	<50> 0
thyroid	leukemic cell infiltration		<50> 1	<50> 3	<50> 0	<50> 0
adrenal	leukemic cell infiltration		<50> 2	<50> 0	<50> 2	<50> 3
	metastasis:peritoneum tumor		0	0	0	1
	metastasis:lymph node tumor		0	0	1	0
[Reproductive system]						
testis	leukemic cell infiltration		<50> 0	<50> 1	<50> 0	<50> 0
epididymis	leukemic cell infiltration		<50> 0	<50> 1	<50> 0	<50> 0
semin ves	leukemic cell infiltration		<50> 1	<50> 1	<50> 1	<50> 0
prostate	leukemic cell infiltration		<50> 1	<50> 0	<50> 0	<50> 0

< a > a : Number of animals examined at the site  
 b b : Number of animals with lesion

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
[Nervous system]						
brain	leukemic cell infiltration		<50> 1	<50> 4	<50> 1	<50> 2
	metastasis:pituitary tumor		0	1	0	0
spinal cord	leukemic cell infiltration		<50> 1	<50> 3	<50> 0	<50> 1
	[Special sense organs/appendage]					
Harder gl	leukemic cell infiltration		<50> 1	<50> 0	<50> 0	<50> 2
	[Musculoskeletal system]					
muscle	metastasis:subcutis tumor		<50> 1	<50> 0	<50> 0	<50> 0
	[Body cavities]					
pleura	metastasis:lung tumor		<50> 0	<50> 0	<50> 0	<50> 1
	mediastinum	leukemic cell infiltration		<50> 1	<50> 0	<50> 0
metastasis:lung tumor			0	0	0	1
adipose	leukemic cell infiltration		<50> 2	<50> 0	<50> 0	<50> 0
	metastasis:peritoneum tumor		0	0	0	1

< a > a : Number of animals examined at the site  
 b b : Number of animals with lesion

**TABLE O2**

**HISTOPATHOLOGICAL FINDINGS :  
METASTASIS OF TUMORS : FEMALE  
(CARCINOGENICITY STUDY GROUPS)**

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
REPORT TYPE : A4  
SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
[Respiratory system]						
nasal cavit	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0
trachea	metastasis:thyroid tumor		<50> 0	<50> 0	<50> 0	<50> 1
lung	leukemic cell infiltration		<50> 8	<50> 5	<50> 9	<50> 3
	metastasis:liver tumor		0	0	1	0
	metastasis:uterus tumor		0	0	0	1
	metastasis:adrenal tumor		1	0	0	0
	metastasis:thyroid tumor		0	0	0	1
	metastasis:bone tumor		0	0	1	0
[Hematopoietic system]						
bone marrow	leukemic cell infiltration		<50> 7	<50> 3	<50> 7	<50> 3
lymph node	leukemic cell infiltration		<50> 3	<50> 1	<50> 2	<50> 1
	metastasis:uterus tumor		0	0	0	1
	metastasis:thyroid tumor		0	0	0	1
thymus	leukemic cell infiltration		<50> 0	<50> 0	<50> 3	<50> 0
	metastasis:lung tumor		0	0	1	0

< a > a : Number of animals examined at the site  
b : Number of animals with lesion

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
[Hematopoietic system]						
spleen	leukemic cell infiltration		<50> 1	<50> 0	<50> 1	<50> 0
	metastasis:thyroid tumor		0	0	0	1
[Circulatory system]						
heart	leukemic cell infiltration		<50> 2	<50> 0	<50> 0	<50> 0
[Digestive system]						
tongue	leukemic cell infiltration		<50> 1	<50> 0	<50> 0	<50> 0
stomach	leukemic cell infiltration		<50> 1	<50> 0	<50> 1	<50> 0
small intes	leukemic cell infiltration		<50> 1	<50> 0	<50> 0	<50> 0
large intes	leukemic cell infiltration		<50> 1	<50> 0	<50> 0	<50> 0
liver	leukemic cell infiltration		<50> 9	<50> 4	<50> 9	<50> 4
	metastasis:thyroid tumor		0	0	0	1
pancreas	leukemic cell infiltration		<50> 1	<50> 0	<50> 1	<50> 0
	metastasis:uterus tumor		0	0	0	2

< a > a : Number of animals examined at the site  
 b b : Number of animals with lesion



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
[Urinary system]						
kidney	leukemic cell infiltration		<50> 3	<50> 0	<50> 1	<50> 0
	metastasis:uterus tumor		0	0	0	1
urin bladd	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0
	[Endocrine system]					
thyroid	leukemic cell infiltration		<50> 2	<50> 0	<50> 0	<50> 0
	[Nervous system]					
brain	leukemic cell infiltration		<50> 0	<50> 1	<50> 1	<50> 0
	metastasis:pituitary tumor		0	0	0	1
spinal cord	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0
	[Special sense organs/appendage]					
Harder gl	leukemic cell infiltration		<50> 1	<50> 0	<50> 0	<50> 0
	[Body cavities]					
pleura	metastasis:lung tumor		<50> 0	<50> 0	<50> 1	<50> 0

< a > a : Number of animals examined at the site  
 b b : Number of animals with lesion

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	0.5 mg/m3 50	2 mg/m3 50	8 mg/m3 50
[Body cavities]						
mediastinum	metastasis:lung tumor		<50> 0	<50> 0	<50> 1	<50> 0
peritoneum	metastasis:uterus tumor		<50> 0	<50> 0	<50> 0	<50> 1
retroperit	metastasis:uterus tumor		<50> 0	<50> 1	<50> 0	<50> 0

< a > a : Number of animals examined at the site  
 b b : Number of animals with lesion

TABLE 03

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMORS : MALE

(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0- 53W)

Organ	Findings	Group Name No. of Animals on Study	S-Control 3	S-0.5 mg/m3 3	S-2 mg/m3 3	S-8 mg/m3 4
[Respiratory system]						
nasal cavit	metastasis:subcutis tumor		< 3> 0	< 3> 0	< 3> 0	< 4> 1
lung	metastasis:subcutis tumor		< 3> 0	< 3> 0	< 3> 0	< 4> 1
< a >	a : Number of animals examined at the site					
b	b : Number of animals with lesion					

TABLE 04

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMORS : MALE

(SATELLITE 52w+52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0-104W)

Organ	Findings	Group Name No. of Animals on Study	S-Control 3	S-0.5 mg/m3 4	S-2 mg/m3 3	S-8 mg/m3 3
[Respiratory system]						
lung	leukemic cell infiltration		< 3> 1	< 4> 1	< 3> 1	< 3> 1
[Digestive system]						
liver	leukemic cell infiltration		< 3> 1	< 4> 1	< 3> 1	< 3> 1

< a > a : Number of animals examined at the site  
 b b : Number of animals with lesion

TABLE 05

HISTOPATHOLOGICAL FINDINGS :  
METASTASIS OF TUMORS : FEMALE  
(SATELLITE 52w+52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0-104W)

PAGE : 2

Organ	Findings	Group Name No. of Animals on Study	S-Control 4	S-0.5 mg/m3 4	S-2 mg/m3 4	S-8 mg/m3 4
[Respiratory system]						
lung	leukemic cell infiltration		< 4> 0	< 4> 0	< 4> 1	< 4> 1
[Digestive system]						
liver	leukemic cell infiltration		< 4> 0	< 4> 0	< 4> 1	< 4> 1
[Urinary system]						
kidney	leukemic cell infiltration		< 4> 0	< 4> 0	< 4> 0	< 4> 1

< a > a : Number of animals examined at the site  
 b b : Number of animals with lesion



**TABLE P1**

**HISTOPATHOLOGICAL FINDINGS :  
NON-NEOPLASTIC LESIONS : MALE  
(CARCINOGENICITY STUDY GROUPS)**

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.5 mg/m3				2 mg/m3				8 mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		50				50				50				50			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Integumentary system/appandage]																	
skin/app	epidermal cyst	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
[Respiratory system]																	
nasal cavit	thrombus	6 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)	10 ( 20)	0 ( 0)	0 ( 0)	0 ( 0)	12 ( 24)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)
	mineralization	9 ( 18)	0 ( 0)	0 ( 0)	0 ( 0)	13 ( 26)	0 ( 0)	0 ( 0)	0 ( 0)	19 ( 38)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)
	inflammatory infiltration	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	eosinophilic change:olfactory epithelium	41 ( 82)	4 ( 8)	0 ( 0)	0 ( 0)	41 ( 82)	1 ( 2)	0 ( 0)	0 ( 0)	40 ( 80)	1 ( 2)	0 ( 0)	0 ( 0)	9 ( 18)	41 ( 82)	0 ( 0)	0 ( 0)
	eosinophilic change:respiratory epithelium	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
	inflammation:foreign body	20 ( 40)	0 ( 0)	0 ( 0)	0 ( 0)	16 ( 32)	0 ( 0)	0 ( 0)	0 ( 0)	19 ( 38)	3 ( 6)	0 ( 0)	0 ( 0)	12 ( 24)	1 ( 2)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.5 mg/m3				2 mg/m3				8 mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
Grade		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Respiratory system]																	
nasal cavit	inflammation:respiratory epithelium	<50>				<50>				<50>				<50>			
		0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	respiratory metaplasia:gland	49	0	0	0	47	0	0	0	49	0	0	0	49	0	0	0
		( 98)	( 0)	( 0)	( 0)	( 94)	( 0)	( 0)	( 0)	( 98)	( 0)	( 0)	( 0)	( 98)	( 0)	( 0)	( 0)
	squamous cell metaplasia:respiratory epithelium	1	0	0	0	3	0	0	0	2	0	0	0	0	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 6)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	ulcer:respiratory epithelium	0	0	0	0	2	0	0	0	2	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
larynx	inflammatory infiltration	<50>				<50>				<50>				<50>			
		2	0	0	0	3	0	0	0	1	0	0	0	3	0	0	0
		( 4)	( 0)	( 0)	( 0)	( 6)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 6)	( 0)	( 0)	( 0)
trachea	inflammatory infiltration	<50>				<50>				<50>				<50>			
		0	0	0	0	1	0	0	0	2	0	0	0	3	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 6)	( 0)	( 0)	( 0)
lung	hemorrhage	<50>				<50>				<50>				<50>			
		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.5 mg/m3				2 mg/m3				8 mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		50				50				50				50			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Respiratory system]																	
lung																	
	edema	<50>				<50>				<50>				<50>			
		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	lymphocytic infiltration	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	granulomatous inflammation	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)
	osseous metaplasia	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)
	bronchiolar-alveolar cell hyperplasia	2	0	0	0	6	4	0	0 *	0	2	0	0	5	0	0	0
		( 4)	( 0)	( 0)	( 0)	( 12)	( 8)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 10)	( 0)	( 0)	( 0)
	thickening:pleura	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	fibrosis:alveolar wall	0	0	0	0	2	0	0	0	2	0	0	0	15	13	0	0 **
		( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 30)	( 26)	( 0)	( 0)
	accumulation:macrophage	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.5 mg/m3				2 mg/m3				8 mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
Grade		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Respiratory system}																	
lung																	
	hyperplasia:alveolar epithelium,particle-induced	0	0	0	0	30	1	0	0 **	39	5	0	0 **	1	48	0	0 **
		( 0)	( 0)	( 0)	( 0)	( 60)	( 2)	( 0)	( 0)	( 78)	( 10)	( 0)	( 0)	( 2)	( 96)	( 0)	( 0)
	deposit of particle:alveolar space,phagocytosed by alveolar macrophages	0	0	0	0	46	0	0	0 **	50	0	0	0 **	0	50	0	0 **
		( 0)	( 0)	( 0)	( 0)	( 92)	( 0)	( 0)	( 0)	(100)	( 0)	( 0)	( 0)	( 0)	(100)	( 0)	( 0)
	deposit of particle:bronchus-associated lymphoid tissue	0	0	0	0	42	0	0	0 **	49	1	0	0 **	0	50	0	0 **
		( 0)	( 0)	( 0)	( 0)	( 84)	( 0)	( 0)	( 0)	( 98)	( 2)	( 0)	( 0)	( 0)	(100)	( 0)	( 0)
{Hematopoietic system}																	
bone marrow																	
	atrophy	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	inflammatory infiltration	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)
	granulation	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)
	increased hematopoiesis	7	0	0	0	7	0	0	0	9	0	0	0	5	0	0	0
		( 14)	( 0)	( 0)	( 0)	( 14)	( 0)	( 0)	( 0)	( 18)	( 0)	( 0)	( 0)	( 10)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.5 mg/m3				2 mg/m3				8 mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
Grade		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Hematopoietic system]																	
lymph node																	
hemorrhage		<50>				<50>				<50>				<50>			
		2	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0
		( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 6)	( 0)	( 0)	( 0)
granulation		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
lymphadenitis		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
lymphoid hyperplasia		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)
deposit of particle:mediastinum		0	0	0	0	12	0	0	0 **	21	5	0	0 **	6	34	0	0 **
		( 0)	( 0)	( 0)	( 0)	( 24)	( 0)	( 0)	( 0)	( 42)	( 10)	( 0)	( 0)	( 12)	( 68)	( 0)	( 0)
deposit of brown pigment		4	0	0	0	1	0	0	0	2	0	0	0	1	0	0	0
		( 8)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)
thymus																	
ectopic tissue		<50>				<50>				<50>				<50>			
		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
hemorrhage		0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Hematopoietic system]																	
spleen																	
	congestion	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	deposit of hemosiderin	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	
	fibrosis:focal	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	1 ( 2)	
	extramedullary hematopoiesis	6 ( 12)	1 ( 2)	0 ( 0)	0 ( 0)	11 ( 22)	1 ( 2)	0 ( 0)	0 ( 0)	5 ( 10)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	10 ( 20)	1 ( 2)	
	lymphoid hyperplasia	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
[Circulatory system]																	
heart																	
	thrombus	1 ( 2)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	inflammatory cell nest	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Circulatory system]																	
heart	myocardial fibrosis	18 ( 36)	0 ( 0)	0 ( 0)	0 ( 0)	13 ( 26)	0 ( 0)	0 ( 0)	0 ( 0)	15 ( 30)	0 ( 0)	0 ( 0)	0 ( 0)	17 ( 34)	0 ( 0)	0 ( 0)	0 ( 0)
	subendocardial fibrosis	4 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	1 ( 2)	0 ( 0)	0 ( 0)
[Digestive system]																	
tongue	inflammation	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
stomach	adhesion	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	ulcer:forestomach	1 ( 2)	5 ( 10)	1 ( 2)	0 ( 0)	5 ( 10)	5 ( 10)	2 ( 4)	0 ( 0)	4 ( 8)	4 ( 8)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)
	hyperplasia:forestomach	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 6)	1 ( 2)	0 ( 0)	0 ( 0)	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Digestive system]																	
stomach	erosion:glandular stomach	4 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	6 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	1 ( 2)	0 ( 0)	0 ( 0)
	ulcer:glandular stomach	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	1 ( 2)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
small intes	hemorrhage	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	lymphocytic infiltration	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
large intes	hyperplasia	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	herniation	5 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)	8 ( 16)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)
liver	angiectasis	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.5 mg/m3				2 mg/m3				8 mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		50				50				50				50			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Digestive system]																	
liver																	
		<50>				<50>				<50>				<50>			
necrosis:central		1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
necrosis:focal		0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
fatty change		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 2)	( 0)	( 0)
fatty change:central		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
fatty change:peripheral		0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
lymphocytic infiltration		0	0	0	0	1	0	0	0	0	0	0	0	2	1	0	0
		( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 2)	( 0)	( 0)
granulation		2	0	0	0	1	0	0	0	0	0	0	0	4	1	0	0
		( 4)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 8)	( 2)	( 0)	( 0)
extramedullary hematopoiesis		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Digestive system]																	
liver	clear cell focus	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	acidophilic cell focus	10 ( 20)	2 ( 4)	2 ( 4)	0 ( 0)	9 ( 18)	4 ( 8)	3 ( 6)	0 ( 0)	7 ( 14)	5 ( 10)	1 ( 2)	0 ( 0)	13 ( 26)	4 ( 8)	1 ( 2)	0 ( 0)
	basophilic cell focus	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	spongiosis hepatis	5 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)	7 ( 14)	1 ( 2)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
	bile duct hyperplasia	36 ( 72)	0 ( 0)	0 ( 0)	0 ( 0)	37 ( 74)	0 ( 0)	0 ( 0)	0 ( 0)	36 ( 72)	0 ( 0)	0 ( 0)	0 ( 0)	39 ( 78)	0 ( 0)	0 ( 0)	0 ( 0)
	focal fatty change	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
pancreas	atrophy:focal	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	1 ( 2)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 8)	1 ( 2)	0 ( 0)	0 ( 0)
	islet cell hyperplasia	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	5 ( 10)	0 ( 0)	0 ( 0) *	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Urinary system]																	
kidney																	
	ectopic tissue	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	infarct	1 ( 2)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	hyaline droplet	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
	hyaline cast	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	8 ( 16)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)
	inflammatory infiltration	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	chronic nephropathy	29 ( 58)	8 ( 16)	1 ( 2)	0 ( 0)	32 ( 64)	4 ( 8)	1 ( 2)	0 ( 0)	20 ( 40)	7 ( 14)	1 ( 2)	0 ( 0)	30 ( 60)	6 ( 12)	3 ( 6)	0 ( 0)
	tubular necrosis	1 ( 2)	0 ( 0)	3 ( 6)	0 ( 0)	0 ( 0)	1 ( 2)	2 ( 4)	0 ( 0)	0 ( 0)	2 ( 4)	1 ( 2)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
	degeneration:tubule	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Urinary system]																	
kidney	atypical tubule hyperplasia	<50>				<50>				<50>				<50>			
		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	dilated pelvis	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
	regeneration:renal tubule	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	deposit of brown pigment:proximal tubule	5 ( 10)	1 ( 2)	0 ( 0)	0 ( 0)	5 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)	7 ( 14)	0 ( 0)	0 ( 0)	0 ( 0)	8 ( 16)	0 ( 0)	0 ( 0)	0 ( 0)
urin bladd	dilatation	<50>				<50>				<50>				<50>			
		0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	papillary and/or nodular hyperplasia	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
[Endocrine system]																	
pituitary	angiectasis	<50>				<50>				<50>				<50>			
		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.5 mg/m3				2 mg/m3				8 mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
Grade		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Endocrine system]																	
pituitary																	
	cyst	<50>				<50>				<50>				<50>			
		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	Rathke pouch	3	0	0	0	1	0	0	0	3	0	0	0	2	0	0	0
		( 6)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 6)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)
	hyperplasia:anterior lobe	9	6	2	0	8	5	0	0	6	2	2	0	8	2	1	0
		( 18)	( 12)	( 4)	( 0)	( 16)	( 10)	( 0)	( 0)	( 12)	( 4)	( 4)	( 0)	( 16)	( 4)	( 2)	( 0)
	cystic degeneration:anterior lobe	4	0	0	0	1	0	0	0	1	0	0	0	2	1	0	0
		( 8)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 4)	( 2)	( 0)	( 0)
thyroid																	
	dysplasia	<50>				<50>				<50>				<50>			
		1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	ultimobranchial body remanet	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	follicular hyperplasia	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)
	C-cell hyperplasia	8	5	0	0	12	2	0	0	8	2	2	0	11	3	0	0
		( 16)	( 10)	( 0)	( 0)	( 24)	( 4)	( 0)	( 0)	( 16)	( 4)	( 4)	( 0)	( 22)	( 6)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.5 mg/m3				2 mg/m3				8 mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		Grade				Grade				Grade				Grade			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Endocrine system]																	
thyroid	cystic thyroid follicle	<50>				<50>				<50>				<50>			
		0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
parathyroid	focal hyperplasia	<50>				<50>				<50>				<50>			
		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
adrenal	hyperplasia:cortical cell	<50>				<50>				<50>				<50>			
		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	hyperplasia:medulla	1	0	0	0	1	2	0	0	0	1	0	0	3	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 2)	( 4)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 6)	( 0)	( 0)	( 0)
	accessory cortical nodule	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	focal fatty change:cortex	0	0	0	0	2	0	0	0	1	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
[Reproductive system]																	
testis	arteritis	<50>				<50>				<50>				<50>			
		0	0	0	0	1	0	0	0	0	0	0	0	2	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.5 mg/m3				2 mg/m3				8 mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
Grade		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Reproductive system]																	
testis	interstitial cell hyperplasia	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	7 ( 14)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)
		<50>				<50>				<50>				<50>			
prostate	hyperplasia	7 ( 14)	0 ( 0)	0 ( 0)	0 ( 0)	6 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)
		<50>				<50>				<50>				<50>			
prep/cli gl	inflammation	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
		<50>				<50>				<50>				<50>			
[Special sense organs/appendage]																	
eye	cataract	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
		<50>				<50>				<50>				<50>			
	retinal atrophy	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
		<50>				<50>				<50>				<50>			
	keratitis	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
		<50>				<50>				<50>				<50>			

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.5 mg/m3				2 mg/m3				8 mg/m3				
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				
Grade		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	
[Special sense organs/appendage]																		
Harder gl	degeneration	<50>				<50>				<50>				<50>				
		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	lymphocytic infiltration	1	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	hyperplasia	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)
[Musculoskeletal system]																		
muscle	atrophy	<50>				<50>				<50>				<50>				
		0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
bone	osteosclerosis	<50>				<50>				<50>				<50>				
		0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
tendon	inflammation	<50>				<50>				<50>				<50>				
		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study Grade	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Body cavities]																		
pleura	inflammation		<50>				<50>				<50>				<50>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	mesothelial hyperplasia		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
peritoneum	mesothelial hyperplasia		<50>				<50>				<50>				<50>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

**TABLE P2**

**HISTOPATHOLOGICAL FINDINGS :  
NON-NEOPLASTIC LESIONS : FEMALE  
(CARCINOGENICITY STUDY GROUPS)**

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Integumentary system/appandage]																	
skin/app	ulcer	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
subcutis	hemorrhage	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
[Respiratory system]																	
nasal cavit	thrombus	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)
	mineralization	26 ( 52)	0 ( 0)	0 ( 0)	0 ( 0)	21 ( 42)	0 ( 0)	0 ( 0)	0 ( 0)	11 ( 22)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	19 ( 38)	0 ( 0)	0 ( 0)
	eosinophilic change:olfactory epithelium	38 ( 76)	11 ( 22)	0 ( 0)	0 ( 0)	45 ( 90)	5 ( 10)	0 ( 0)	0 ( 0)	47 ( 94)	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)	21 ( 42)	29 ( 58)	0 ( 0)
	eosinophilic change:respiratory epithelium	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Respiratory system]																	
nasal cavit	inflammation:foreign body	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	1 ( 2)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)
	respiratory metaplasia:gland	49 ( 98)	0 ( 0)	0 ( 0)	0 ( 0)	50 (100)	0 ( 0)	0 ( 0)	0 ( 0)	48 ( 96)	2 ( 4)	0 ( 0)	0 ( 0)	49 ( 98)	0 ( 0)	0 ( 0)	0 ( 0)
	squamous cell metaplasia:respiratory epithelium	18 ( 36)	0 ( 0)	0 ( 0)	0 ( 0)	21 ( 42)	0 ( 0)	0 ( 0)	0 ( 0)	22 ( 44)	0 ( 0)	0 ( 0)	0 ( 0)	20 ( 40)	0 ( 0)	0 ( 0)	0 ( 0)
larynx	inflammatory infiltration	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)
	trachea	inflammatory infiltration	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
lung	granulomatous inflammation	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	inflammatory cell infiltration:focal	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Respiratory system]																	
lung		<50>				<50>				<50>				<50>			
	bronchiolar-alveolar cell hyperplasia	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	2 (4)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)
	fibrosis:alveolar wall	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	2 (4)	0 (0)	0 (0)	11 (22)	37 (74)	0 (0)	0 (0) **
	accumulation:macrophage	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia:alveolar epithelium,particle-induced	0 (0)	0 (0)	0 (0)	0 (0)	42 (84)	0 (0)	0 (0)	0 (0) **	37 (74)	10 (20)	0 (0)	0 (0) **	0 (0)	50 (100)	0 (0)	0 (0) **
	deposit of particle:alveolar space,phagocytosed by alveolar macrophages	0 (0)	0 (0)	0 (0)	0 (0)	49 (98)	0 (0)	0 (0)	0 (0) **	48 (96)	2 (4)	0 (0)	0 (0) **	0 (0)	50 (100)	0 (0)	0 (0) **
	deposit of particle:bronchus-associated lymphoid tissue	0 (0)	0 (0)	0 (0)	0 (0)	48 (96)	0 (0)	0 (0)	0 (0) **	49 (98)	0 (0)	0 (0)	0 (0) **	0 (0)	50 (100)	0 (0)	0 (0) **
[Hematopoietic system]																	
bone marrow		<50>				<50>				<50>				<50>			
	atrophy	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50						
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)			
[Hematopoietic system]																				
bone marrow																				
	inflammatory infiltration	<50>				<50>				<50>				<50>						
		1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)				
	granulation	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)			
	increased hematopoiesis	5 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	8 ( 16)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	7 ( 14)	0 ( 0)	0 ( 0)	0 ( 0)	
lymph node																				
	hemorrhage	<50>				<50>				<50>				<50>						
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	deposit of particle:mediastinum	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	10 ( 20)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	17 ( 34)	6 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)	21 ( 42)	23 ( 46)	0 ( 0)	0 ( 0)	0 ( 0)
	deposit of brown pigment	5 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
spleen																				
	deposit of hemosiderin	<50>				<50>				<50>				<50>						
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Hematopoietic system]																	
spleen	fibrosis	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	extramedullary hematopoiesis	15 ( 30)	1 ( 2)	0 ( 0)	0 ( 0)	17 ( 34)	1 ( 2)	0 ( 0)	0 ( 0)	15 ( 30)	5 ( 10)	0 ( 0)	0 ( 0)	20 ( 40)	3 ( 6)	0 ( 0)	0 ( 0)
[Circulatory system]																	
heart	thrombus	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	inflammatory cell nest	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	myocardial fibrosis	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)
	subendocardial fibrosis	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
[Digestive system]																	
tongue	squamous cell hyperplasia	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Digestive system]																	
stomach	ulcer:forestomach	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	1 ( 2)	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	hyperplasia:forestomach	3 ( 6)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	
	erosion:glandular stomach	4 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	ulcer:glandular stomach	1 ( 2)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	
	hyperplasia:glandular stomach	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
small intes	erosion	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
liver	herniation	6 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)	12 ( 24)	0 ( 0)	0 ( 0)	0 ( 0)	6 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	7 ( 14)	0 ( 0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.5 mg/m3				2 mg/m3				8 mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
		50				50				50				50			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Digestive system]																	
liver																	
	angiectasis	<50>				<50>				<50>				<50>			
		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	necrosis:central	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)
	necrosis:focal	0	0	0	0	2	0	0	0	0	0	0	0	1	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)
	fatty change	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	lymphocytic infiltration	1	0	0	0	2	0	0	0	0	2	0	0	2	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)
	granulation	3	0	0	0	3	2	0	0	3	2	0	0	5	0	0	0
		( 6)	( 0)	( 0)	( 0)	( 6)	( 4)	( 0)	( 0)	( 6)	( 4)	( 0)	( 0)	( 10)	( 0)	( 0)	( 0)
	granulomatous inflammation	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	clear cell focus	1	0	0	0	0	0	0	0	1	1	0	0	1	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 2)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50				
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	
[Digestive system]																		
liver	acidophilic cell focus	4 ( 8)	3 ( 6)	0 ( 0)	0 ( 0)	5 ( 10)	0 ( 0)	1 ( 2)	0 ( 0)	2 ( 4)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	2 ( 4)	0 ( 0)	
	basophilic cell focus	26 ( 52)	6 ( 12)	0 ( 0)	0 ( 0)	29 ( 58)	3 ( 6)	0 ( 0)	0 ( 0)	15 ( 30)	4 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	24 ( 48)	6 ( 12)	1 ( 2)	0 ( 0)
	bile duct hyperplasia	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	cholangiofibrosis	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	focal fatty change	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
pancreas	atrophy:focal	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	islet cell hyperplasia	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
[Urinary system]																		
kidney	infarct	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Urinary system]																	
kidney																	
	hyaline cast	5 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)
	inflammatory infiltration	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	lymphocytic infiltration	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	chronic nephropathy	6 ( 12)	1 ( 2)	0 ( 0)	0 ( 0)	3 ( 6)	1 ( 2)	0 ( 0)	0 ( 0)	7 ( 14)	2 ( 4)	0 ( 0)	0 ( 0)	11 ( 22)	1 ( 2)	0 ( 0)	0 ( 0)
	tubular necrosis	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
	degeneration:tubule	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	dilated pelvis	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	regeneration:renal tubule	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.5 mg/m3				2 mg/m3				8 mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
Grade		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Urinary system]																	
kidney	deposit of brown pigment:proximal tubule	7 (14)	1 (2)	0 (0)	0 (0)	13 (26)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	2 (4)	0 (0)	5 (10)	1 (2)	0 (0)	0 (0)
		<50>				<50>				<50>				<50>			
urin bladd	dilatation	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
		<50>				<50>				<50>				<50>			
[Endocrine system]																	
pituitary	angiectasis	3 (6)	2 (4)	0 (0)	0 (0)	7 (14)	1 (2)	0 (0)	0 (0)	5 (10)	1 (2)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)
		<50>				<50>				<50>				<49>			
	Rathke pouch	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	hyperplasia:anterior lobe	10 (20)	1 (2)	1 (2)	0 (0)	8 (16)	3 (6)	3 (6)	0 (0)	4 (8)	1 (2)	2 (4)	0 (0)	5 (10)	2 (4)	1 (2)	0 (0)
	cystic degeneration:anterior lobe	13 (26)	1 (2)	0 (0)	0 (0)	13 (26)	0 (0)	0 (0)	0 (0)	15 (30)	0 (0)	0 (0)	0 (0)	11 (22)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Endocrine system]																	
thyroid																	
	degeneration:epithelium	<50>				<50>				<50>				<50>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	ultimobranchial body remanet	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	follicular hyperplasia	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	C-cell hyperplasia	11 ( 22)	1 ( 2)	0 ( 0)	0 ( 0)	11 ( 22)	1 ( 2)	0 ( 0)	0 ( 0)	12 ( 24)	1 ( 2)	0 ( 0)	0 ( 0)	14 ( 28)	0 ( 0)	0 ( 0)	0 ( 0)
	cystic thyroid follicle	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
adrenal																	
	angiectasis	<50>				<50>				<50>				<50>			
		2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 10)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)
	hemorrhage	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	hyperplasia:cortical cell	2 ( 4)	1 ( 2)	0 ( 0)	0 ( 0)	3 ( 6)	1 ( 2)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control 50				0.5 mg/m3 50				2 mg/m3 50				8 mg/m3 50				
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	
[Endocrine system]																		
adrenal	hyperplasia:medulla	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	focal fatty change:cortex	5 ( 10)	1 ( 2)	0 ( 0)	0 ( 0)	4 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	6 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	6 ( 12)	0 ( 0)	0 ( 0)
[Reproductive system]																		
ovary	cyst	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
	stromal hyperplasia	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
uterus	dilatation	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	cystic endometrial hyperplasia	0 ( 0)	2 ( 4)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 6)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A4  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-105W)

Organ	Findings	Control				0.5 mg/m3				2 mg/m3				8 mg/m3			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
Grade		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Nervous system]																	
brain	hemorrhage	<50>				<50>				<50>				<50>			
		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
[Special sense organs/appendage]																	
eye	cataract	<50>				<50>				<50>				<50>			
		1	1	0	0	3	1	0	0	0	0	1	0	0	2	0	0
		( 2)	( 2)	( 0)	( 0)	( 6)	( 2)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 4)	( 0)	( 0)
	retinal atrophy	2	2	2	0	1	0	3	0	0	1	1	0	0	0	2	0
		( 4)	( 4)	( 4)	( 0)	( 2)	( 0)	( 6)	( 0)	( 0)	( 2)	( 2)	( 0)	( 0)	( 0)	( 4)	( 0)
Harder gl	lymphocytic infiltration	<50>				<50>				<50>				<50>			
		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		( 2)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	deposit of brown pigment	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 2)	( 0)	( 0)	( 0)
[Musculoskeletal system]																	
bone	osteosclerosis	<50>				<50>				<50>				<50>			
		5	0	0	0	5	0	0	0	8	0	0	0	3	1	0	0
		( 10)	( 0)	( 0)	( 0)	( 10)	( 0)	( 0)	( 0)	( 16)	( 0)	( 0)	( 0)	( 6)	( 2)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square



TABLE P3

HISTOPATHOLOGICAL FINDINGS :  
NON-NEOPLASTIC LESIONS : MALE  
(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 53W)

Organ	Findings	Group Name No. of Animals on Study Grade	S-Control 3				S-0.5 mg/m3 3				S-2 mg/m3 3				S-8 mg/m3 4					
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)		
[Respiratory system]																				
lung			< 3>				< 3>				< 3>				< 4>					
	granulomatous inflammation		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)		
	hyperplasia:alveolar epithelium,particle-induced		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	4 (100)	0 ( 0)	0 ( 0)	0 ( 0)
	deposit of particle:alveolar space,phagocytosed by alveolar macrophages		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	4 (100)	0 ( 0)	0 ( 0)	0 ( 0)
	deposit of particle:bronchus-associated lymphoid tissue		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	4 (100)	0 ( 0)	0 ( 0)	0 ( 0)
[Hematopoietic system]																				
lymph node			< 3>				< 3>				< 3>				< 4>					
	deposit of particle:mediastinum		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)
[Digestive system]																				
liver			< 3>				< 3>				< 3>				< 4>					
	herniation		1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)
Grade	1+ : Slight	2+ : Moderate	3+ : Marked	4+ : Severe																
< a >	a : Number of animals examined at the site																			
b	b : Number of animals with lesion																			
< c >	c : b / a * 100																			

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 53W)

Organ	Findings	S-Control 3				S-0.5 mg/m3 3				S-2 mg/m3 3				S-8 mg/m3 4			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Digestive system]																	
liver	necrosis:focal	0 ( 0)	0 ( 0)	< 3> ( 0)	0 ( 0)	0 ( 0)	< 3> ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	< 3> ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)
	granulation	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	bile duct hyperplasia	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 75)	0 ( 0)
[Special sense organs/appendage]																	
eye	keratitis	0 ( 0)	0 ( 0)	< 3> ( 0)	0 ( 0)	0 ( 0)	< 3> ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	< 3> ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)
Grade	1+ : Slight	2+ : Moderate	3+ : Marked	4+ : Severe													
< a >	a : Number of animals examined at the site																
b	b : Number of animals with lesion																
( c )	c : b / a * 100																

TABLE P4

HISTOPATHOLOGICAL FINDINGS :  
NON-NEOPLASTIC LESIONS : FEMALE  
(SATELLITE 52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 53W)

Organ	Findings	S-Control 3				S-0.5 mg/m3 3				S-2 mg/m3 3				S-8 mg/m3 3			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Respiratory system]																	
lung	hyperplasia:alveolar epithelium,particle-induced	0 ( 0)	0 ( 0)	< 3> ( 0)	0 ( 0)	0 ( 0)	< 3> ( 0)	0 ( 0)	0 ( 0)	2 ( 67)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)
	deposit of particle:alveolar space,phagocytosed by alveolar macrophages	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	2 ( 67)	0 ( 0)	0 ( 0)
	deposit of particle:bronchus-associated lymphoid tissue	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)
[Hematopoietic system]																	
lymph node	deposit of particle:mediastinum	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)
[Digestive system]																	
liver	herniation	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 53W)

Organ	Findings	Group Name No. of Animals on Study Grade	S-Control 3				S-0.5 mg/m3 3				S-2 mg/m3 3				S-8 mg/m3 3			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Digestive system]																		
liver	granulation		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	
	bile duct hyperplasia		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	
[Endocrine system]																		
pituitary	angiectasis		1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
[Special sense organs/appendage]																		
eye	cataract		0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	retinal atrophy		0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100

TABLE P5

HISTOPATHOLOGICAL FINDINGS :  
NON-NEOPLASTIC LESIONS : MALE  
(SATELLITE 52w+26w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A2  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 79W)

Organ	Findings	Group Name No. of Animals on Study Grade	S-Control 4				S-0.5 mg/m3 3				S-2 mg/m3 4				S-8 mg/m3 3			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Respiratory system]																		
lung			< 4>				< 3>				< 4>				< 3>			
	bronchiolar-alveolar cell hyperplasia		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	hyperplasia:alveolar epithelium,particle-induced		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 67)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 75)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 100)	0 ( 0)
	deposit of particle:alveolar space,phagocytosed by alveolar macrophages		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	deposit of particle:bronchus-associated lymphoid tissue		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 100)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 100)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 67)	1 ( 33)
[Hematopoietic system]																		
lymph node			< 4>				< 3>				< 4>				< 3>			
	deposit of particle:mediastinum		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 67)	0 ( 0)
spleen			< 4>				< 3>				< 4>				< 3>			
	atrophy		0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A2  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 79W)

Organ	Findings	S-Control 4				S-0.5 mg/m3 3				S-2 mg/m3 4				S-8 mg/m3 3			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Hematopoietic system]																	
spleen	extramedullary hematopoiesis	0 ( 0)	0 ( 0)	< 4> ( 0)	0 ( 0)	0 ( 0)	< 3> ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
[Digestive system]																	
liver	herniation	0 ( 0)	0 ( 0)	< 4> ( 0)	0 ( 0)	0 ( 0)	< 3> ( 0)	0 ( 0)	0 ( 0)	2 ( 50)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	necrosis:central	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	acidophilic cell focus	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	1 ( 33)	
	bile duct hyperplasia	3 ( 75)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 100)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 75)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 100)	0 ( 0)	
[Urinary system]																	
kidney	chronic nephropathy	3 ( 75)	0 ( 0)	< 4> ( 0)	0 ( 0)	2 ( 67)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 75)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 100)	0 ( 0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A2  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 79W)

Organ	Findings	Group Name No. of Animals on Study Grade	S-Control 4				S-0.5 mg/m3 3				S-2 mg/m3 4				S-8 mg/m3 3			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Body cavities]																		
pleura	arteritis		< 4>				< 3>				< 4>				< 3>			
			0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
mesenterium	arteritis		< 4>				< 3>				< 4>				< 3>			
			0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	

Grade 1+ : Slight    2+ : Moderate    3+ : Marked    4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100

TABLE P6

HISTOPATHOLOGICAL FINDINGS :  
NON-NEOPLASTIC LESIONS : FEMALE  
(SATELLITE 52w+26w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A2  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 79W)

Organ	Findings	Group Name No. of Animals on Study Grade				S-Control 3				S-0.5 mg/m3 3				S-2 mg/m3 3				S-8 mg/m3 3			
		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Respiratory system]																					
lung	bronchiolar-alveolar cell hyperplasia	0 ( 0)	0 ( 0)	< 3> ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)
	hyperplasia:alveolar epithelium,particle-induced	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 67)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	2 ( 67)	0 ( 0)	0 ( 0)
	deposit of particle:bronchus-associated lymphoid tissue	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	2 ( 67)	0 ( 0)	0 ( 0)
[Digestive system]																					
liver	herniation	0 ( 0)	0 ( 0)	< 3> ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	granulation	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 67)	0 ( 0)	0 ( 0)	0 ( 0)
	basophilic cell focus	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 67)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
[Endocrine system]																					
pituitary	angiectasis	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100

TABLE P7

HISTOPATHOLOGICAL FINDINGS :  
NON-NEOPLASTIC LESIONS : MALE  
(SATELLITE 52w+52w)

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-104W)

Organ	Findings	Group Name No. of Animals on Study Grade	S-Control 3				S-0.5 mg/m3 4				S-2 mg/m3 3				S-8 mg/m3 3			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Respiratory system}																		
lung	edema		< 3>				< 4>				< 3>				< 3>			
			0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	fibrosis:alveolar wall		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 67)	0 ( 0)	0 ( 0)	
	hyperplasia:alveolar epithelium,particle-induced		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	2 ( 67)	1 ( 33)	0 ( 0)	
	deposit of particle:bronchus-associated lymphoid tissue		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	
{Hematopoietic system}																		
lymph node	lymphadenitis		< 3>				< 4>				< 3>				< 3>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
{Digestive system}																		
tongue	squamous cell hyperplasia		< 3>				< 4>				< 3>				< 3>			
			0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-104W)

Organ	Findings	Group Name No. of Animals on Study Grade	S-Control 3				S-0.5 mg/m3 4				S-2 mg/m3 3				S-8 mg/m3 3			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Digestive system]																		
liver	herniation		< 3>				< 4>				< 3>				< 3>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	clear cell focus		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)
	acidophilic cell focus		1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 50)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)
	bile duct hyperplasia		2 ( 67)	1 ( 33)	0 ( 0)	0 ( 0)	2 ( 50)	1 ( 25)	0 ( 0)	0 ( 0)	2 ( 67)	1 ( 33)	0 ( 0)	0 ( 0)	2 ( 67)	1 ( 33)	0 ( 0)	0 ( 0)
[Urinary system]																		
kidney	chronic nephropathy		< 3>				< 4>				< 3>				< 3>			
			3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 50)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)	3 (100)	0 ( 0)	0 ( 0)	0 ( 0)
	tubular necrosis		0 ( 0)	1 ( 33)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight    2+ : Moderate    3+ : Marked    4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100

TABLE P8

HISTOPATHOLOGICAL FINDINGS :  
NON-NEOPLASTIC LESIONS : FEMALE  
(SATELLITE 52w+52w)



STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-104W)

Organ	Findings	Group Name No. of Animals on Study Grade				S-Control 4				S-0.5 mg/m3 4				S-2 mg/m3 4				S-8 mg/m3 4			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)				
[Respiratory system]																					
lung	edema	2 ( 50)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)				
	bronchiolar-alveolar cell hyperplasia	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)				
	fibrosis:alveolar wall	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	2 ( 50)	0 ( 0)				
	hyperplasia:alveolar epithelium,particle-induced	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 50)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 75)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	3 ( 75)	0 ( 0)				
	deposit of particle:bronchus-associated lymphoid tissue	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 50)	0 ( 0)	0 ( 0)	0 ( 0)	4 (100)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 50)	2 ( 50)	0 ( 0)				
[Hematopoietic system]																					
spleen	extramedullary hematopoiesis	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)				
[Digestive system]																					
liver	herniation	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)				

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
 REPORT TYPE : A3  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0-104W)

Organ	Findings	S-Control 4				S-0.5 mg/m3 4				S-2 mg/m3 4				S-8 mg/m3 4				
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	
[Digestive system]																		
liver	granulation	0 ( 0)	0 ( 0)	< 4> ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	acidophilic cell focus	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 50)	0 ( 0)	0 ( 0)	0 ( 0)	
	basophilic cell focus	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 75)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
	bile duct hyperplasia	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)
[Urinary system]																		
kidney	chronic nephropathy	0 ( 0)	0 ( 0)	< 4> ( 0)	0 ( 0)	1 ( 25)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)
[Endocrine system]																		
pituitary	angiectasis	1 ( 25)	0 ( 0)	< 4> ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 25)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100

TABLE Q

AMOUNT OF TITANIUM DIOXIDE IN THE LUNG

## AMOUNT OF TITANIUM DIOXIDE IN THE LUNG

Analytical Method : The samples were analyzed by Atomic Absorption Spectrophotometer.

Instrument : Z-5010 Atomic Absorption Spectrophotometer (Hitachi, Ltd.)  
 Atomization : Graphite atomizer  
 Atomization temperature : 2800°C  
 Absorbance : 364.3 nm  
 Injection volume : 10 µL

Group Name		Concentration (mg/lung) Average ± SD			
		Satellite 52w	Satellite 52w+26w	Satellite 52w+52w	Carcinogenicity study groups
Male	0 mg/m <sup>3</sup>	0	0	0	0
	0.5 mg/m <sup>3</sup>	0.15 ± 0.03	0.06 ± 0.01	0.08 ± 0.04	0.28 ± 0.03
	2 mg/m <sup>3</sup>	0.84 ± 0.08	0.38 ± 0.09	0.35 (n=2)	1.30 ± 0.18
	8 mg/m <sup>3</sup>	4.34 ± 0.39	2.89 ± 0.40	2.82 ± 0.10	11.90 ± 0.92
Female	0 mg/m <sup>3</sup>	0	0	0	0
	0.5 mg/m <sup>3</sup>	0.11 ± 0.01	0.04 ± 0.01	0.06 ± 0.01	0.20 ± 0.05
	2 mg/m <sup>3</sup>	0.46 ± 0.05	0.27 ± 0.03	0.28 ± 0.04	1.13 ± 0.20
	8 mg/m <sup>3</sup>	3.50 ± 0.36	2.35 ± 0.35	2.26 ± 0.65	10.10 ± 0.68

**TABLE R1**

**BALF : CYTOLOGICAL ANALYSIS : MALE  
(CARCINOGENICITY STUDY GROUPS)**

STUDY NO. : 0883

ANIMAL : RAT F344/DuCr1Cr1j [F344/DuCrj]

MEASURE. TIME : 2

SEX : MALE

REPORT TYPE : A4

BALF: CYTOLOGICAL ANALYSIS (SUMMARY)

ALL ANIMALS

PAGE : 1

Group Name	NO. of Animals	TOTAL CELLS		Differential BALF Cells (%)				EOSINO		BASO		ALVEOLAR MACROPHAGE	
		$10^3 / \mu l$		NEUTRO		LYMPHO							
Control	4	0.36±	0.07	0.6±	0.4	0.3±	0.3	0.0±	0.0	0.0±	0.0	99.1±	0.5
0.5 mg/m <sup>3</sup>	5	0.34±	0.08	0.6±	0.2	0.2±	0.4	0.0±	0.0	0.0±	0.0	99.2±	0.5
2 mg/m <sup>3</sup>	2	0.39±	0.01 ?	0.9±	0.8 ?	0.1±	0.1 ?	0.0±	0.0	0.0±	0.0	99.0±	0.6 ?
8 mg/m <sup>3</sup>	6	0.50±	0.11	22.6±	20.3 **	0.7±	0.9	0.0±	0.0	0.0±	0.0	76.7±	21.2 **

Significant difference:

\* : P ≤ 0.05

\*\* : P ≤ 0.01

Test of Dunnett

? : Significant test is not applied, because No. of data in this group is less than 3.

TABLE R2

BALF : CYTOLOGICAL ANALYSIS : FEMALE  
(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883

ANIMAL : RAT F344/DuCr1Cr1j [F344/DuCrj]

MEASURE, TIME : 2

SEX : FEMALE

REPORT TYPE : A4

BALF: CYTOLOGICAL ANALYSIS (SUMMARY)

ALL ANIMALS

PAGE : 2

Group Name	NO. of Animals	TOTAL CELLS		Differential BALF Cells (%)				EOSINO		BASO		ALVEOLAR MACROPHAGE	
		$10^3 / \mu l$		NEUTRO	LYMPHO								
Control	6	0.32±	0.05	1.1±	1.5	0.1±	0.2	0.0±	0.0	0.0±	0.0	98.8±	1.4
0.5 mg/m <sup>3</sup>	5	0.34±	0.04	0.9±	0.4	0.2±	0.2	0.0±	0.0	0.0±	0.0	98.8±	0.5
2 mg/m <sup>3</sup>	5	0.36±	0.07	1.4±	0.9	0.8±	0.6*	0.0±	0.0	0.0±	0.0	97.9±	1.2
8 mg/m <sup>3</sup>	6	0.52±	0.09**	30.8±	10.7**	1.4±	1.2**	0.0±	0.0	0.0±	0.0	67.8±	10.5**

Significant difference;

\* : P ≤ 0.05

\*\* : P ≤ 0.01

Test of Dunnett



**TABLE S1**

**BALF : BIOCHEMICAL ANALYSIS : MALE  
(CARCINOGENICITY STUDY GROUPS)**

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]  
 MEASURE. TIME : 2  
 SEX : MALE

BALF: BIOCHEMICAL ANALYSIS (SUMMARY)  
 ALL ANIMALS

REPORT TYPE : A4

PAGE : 1

Group Name	NO. of Animals	ALP		G-GTP		PHOSPHOLIPID	
		U/L		U/L		mg/dl	
Control	4	77±	11	1.6±	0.1	13±	1
0.5 mg/m3	5	61±	7*	1.8±	0.3	12±	1
2 mg/m3	2	61±	2 ?	2.5±	0.9 ?	14±	1 ?
8 mg/m3	6	81±	6	2.9±	0.7**	14±	5

Significant difference : \* :  $P \leq 0.05$       \*\* :  $P \leq 0.01$       Test of Dunnett

? : Significant test is not applied, because No. of data in this group is less than 3.

**TABLE S2**

**BALF : BIOCHEMICAL ANALYSIS : FEMALE  
(CARCINOGENICITY STUDY GROUPS)**

STUDY NO. : 0883  
 ANIMAL : RAT F344/DuCrIj[F344/DuCrj]  
 MEASURE TIME : 2  
 SEX : FEMALE

BALF: BIOCHEMICAL ANALYSIS (SUMMARY)  
 ALL ANIMALS

REPORT TYPE : A4

PAGE : 2

Group Name	NO. of Animals	ALP U/L		G-GTP U/L		PHOSPHOLIPID mg/dl	
Control	6	75±	7	1.8±	0.4	11±	1
0.5 mg/m3	5	56±	13**	2.3±	0.7	10±	2
2 mg/m3	5	70±	5	2.7±	0.4*	11±	1
8 mg/m3	6	80±	7	3.2±	0.6**	12±	5

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

TABLE T1

CAUSE OF DEATH : MALE  
(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
SEX : MALE

COUSE OF DEATH (SUMMARY)  
(0-105W)

PAGE : 1

Group Name	Control	0.5 mg/m3	2 mg/m3	8 mg/m3
Number of Dead and Moribund Animal	20	18	23	13
no microscop confirm	0	1	2	0
urinary retention	2	0	0	0
tumor d:leukemia	12	13	11	4
tumor d:subcutis	2	0	0	0
tumor d:lung	0	0	0	1
tumor d:lymph node	0	0	1	0
tumor d:oral cavity	0	0	0	1
tumor d:tongue	0	1	0	0
tumor d:small intes	0	0	1	0
tumor d:pituitary	2	2	1	4
tumor d:thyroid	0	0	1	2
tumor d:adrenal	1	0	0	0
tumor d:brain	0	0	3	0
tumor d:Zymbal gl	1	1	1	0
tumor d:peritoneum	0	0	2	1

TABLE T2

CAUSE OF DEATH : FEMALE  
(CARCINOGENICITY STUDY GROUPS)

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
SEX : FEMALE

COUSE OF DEATH (SUMMARY)  
(0-105W)

Group Name	Control	0.5 mg/m3	2 mg/m3	8 mg/m3
Number of Dead and Moribund Animal	8	7	19	6
no microscop confirm	0	0	1	1
thrombosis	0	0	1	0
deglutition disorder	1	0	0	0
tumor d:leukemia	5	2	7	1
tumor d:lung	0	0	1	0
tumor d:liver	0	0	1	0
tumor d:pituitary	0	4	5	2
tumor d:thyroid	0	0	1	0
tumor d:uterus	1	0	1	2
tumor d:mammary gl	1	0	0	0
tumor d:muscle	0	1	0	0
tumor d:bone	0	0	1	0



TABLE T3

CAUSE OF DEATH : MALE

(SATELLITE 52w)

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
SEX : MALE

COUSE OF DEATH (SUMMARY)  
(0- 53W)

PAGE : 1

Group Name	S-Control	S-0.5 mg/m3	S-2 mg/m3	S-8 mg/m3
Number of Dead and Moribund Animal	0	0	0	1
tumor disubcutis	0	0	0	1

TABLE T4

CAUSE OF DEATH : MALE

(SATELLITE 52w+26w)

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
SEX : MALE

COUSE OF DEATH (SUMMARY)  
(0- 79W)

PAGE : 1

Group Name	S-Control	S-0.5 mg/m3	S-2 mg/m3	S-8 mg/m3
Number of Dead and Moribund Animal	1	0	1	0
arteritis	1	0	0	0
tumor disLboutis	0	0	1	0

TABLE T5

CAUSE OF DEATH : MALE

(SATELLITE 52w+52w)

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
SEX : MALE

COUSE OF DEATH (SUMMARY)  
(0-104W)

Group Name	S-Control	S-0.5 mg/m3	S-2 mg/m3	S-8 mg/m3
Number of Dead and Moribund Animal	2	1	1	0
tumor d:leukemia	1	1	1	0
tumor d:pituitary	1	0	0	0

(B10120)

BAIS6

TABLE T6

CAUSE OF DEATH : FEMALE

(SATELLITE 52w+52w)

STUDY NO. : 0883  
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj]  
SEX : FEMALE

COUSE OF DEATH (SUMMARY)  
(0-104W)

Group Name	S-Control	S-0.5 mg/m3	S-2 mg/m3	S-8 mg/m3
Number of Dead and Moribund Animal	2	0	1	1
no microscop confirm	1	0	0	0
deglutition disorder	1	0	0	0
tumor d: leukemia	0	0	1	1